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Abstract  
 
Introduction  
Most familial MTC is caused by a germline mutation of the RET proto-
oncogene. Rare families exist with predisposition to MTC in whom no RET 
mutation has been identified. Identification of novel candidate genes within 
such families may inform the molecular behaviour of more common, sporadic 
disease. Whole exome sequencing (WES) enables all protein coding regions 
of the genome to be sequenced in parallel; a novel paradigm for MTC gene 
discovery.  
 
Methods  
Patients with MTC were recruited through internationally developed 
collaborations. WES was completed in three generations of the index family. 
Germline and tumour DNA were analysed for conformational mutations. In 
vitro functional analysis of candidate genes was completed to unpick 
biological pathways.   
 
Results  
Over 20,000 mutations were screened. A frameshift mutation in the oestrogen 
receptor 2 gene (ESR2) has been identified with familial segregation. Further 
alterations in ESR2 have been identified in germline DNA from a patient with 
young onset sporadic disease and tumour DNA from sporadic MTC. The 
functional protein of the ESR2 gene binds to a response element in the 
upstream pathway of the RET gene, controlling transcription. In-vitro studies 
show that ESR2 mutants lead to null proteins and up-regulation of RET at 
mRNA and protein levels. Further, loss of ESR2 protein is observed in 
patients with germline ESR2 mutations. 
 
Conclusions 
This study establishes a novel method of gene predisposition identification in 
the context of MTC. As well as the potential for a genetic test, and as a 
prognostic biomarker, the on-going functional work may elucidate targets for 
novel therapies that may include pre-existing anti-oestrogens.  
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1.1 The Thyroid Gland: Anatomy, physiology and embryology  
 
This section highlights the salient anatomical, embryological and physiological 
aspects of the thyroid gland and their relation to thyroid malignancy. This 
section includes only the features relevant to this project and as such is 
neither a complete review of the topics nor an exhaustive reference. The aim 
is to highlight the challenges posed by thyroid cancer in general and the 
specific issues that make medullary thyroid cancer (MTC) more difficult to 
treat and manage both in the clinic and in the operating room. This project has 
a surgical background, as it is the challenges faced when working with often 
young patients with recurrent or residual MTC, that have driven this project. 
More and targeted research is required in this area such that outcomes from 
this disease are ultimately improved.   
 
1.1.1 The surgical anatomy of the thyroid gland limits the extent to 
which surgery can be curative.  
Surgery is the only treatment in MTC that improves survival (Kloos et al., 
2009). Surgery is both the primary treatment modality of choice and the 
choice for recurrent disease (Watkinson and Gilbert, 2012). The limitations of 
surgery are defined by the local anatomy and by the disease process. It is the 
anatomical position of the gland leads to difficulties in management, in 
particular when considering residual and recurrence disease (Watkinson and 
Gilbert, 2012). Patients with locally advanced and recurrent disease are often 
faced in the clinical setting and are potentially the most difficult to manage 
(Hardman et al., 2014). Recurrent surgery to the in the neck carries significant 
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morbidity, and surgery is only an option when disease recurs locally. There is 
little in the way of effective treatment options for distant recurrence and 
although novel therapies to date have shown some improvement in disease 
response, no improvement in life expectancy has been demonstrated (Wells 
et al., 2012). There is a need for a better understanding of the biology of MTC 
so that effect adjuncts or alternatives to surgery can be developed.  
 
Macroscopically, the thyroid gland consists of two distinct lobes, left and right 
joined by the thyroid isthmus, a narrow strip of tissue overlying the trachea 
(Gray Henry, 1974). Occasionally, a pyramidal lobe is present, representing 
an upward extension of thyroid tissue along the thyroglossal duct, containing 
a variable amount of thyroid tissue. This can represent the site of a primary 
malignancy or an area of recurrence (Rossi et al., 2014)(Moore Keith, Daslley 
Arthur, Agur Anne, 2013). The thyroid lobes sit on either side of the trachea, 
deep the strap muscles of the neck and lying medial to the vascular 
compartment containing the carotid artery and internal jugular veins on either 
side (Gray Henry, 1974). The isthmus joins the lobes together and overlies 
the trachea crossing typically at the second to fourth tracheal ring (Watkinson 
and Gilbert, 2012)(Gleeson and Clarke, 2008) (Figure 1). 
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Figure 1. Gross anatomy of the thyroid gland and its relation to the upper aero-
digestive tract and major vessels.  
 Figure 2. Staging and 10 year survival of medullary thyroid cancer (T = tumour, N = 
lymph nodal status, M = metastasis) (Modigliani et al., 1998).  
 
The depth of the gland within the neck and the fact that the majority of thyroid 
tissue is in the lower pole means that significant occult swelling can occur 
without symptoms and malignant change in the gland can go un-noticed until 
local disease is relatively advanced (Cooper et al., 2009). As an illustration, 
the proband in the index family in this project (discussed in Chapter 3) was 
identified incidentally after presenting to accident and emergency after a 
minor road traffic accident. Further, my recent review of over 300 patients with 
Stage at presentation  10 year survival 
Stage I pT1, N0, M0 100% 
Stage II pT2, N0, M0 
pT3, N0, M0 
pT4, N0, M0 
93% 
Stage III Any pT, N1, M0 71% 
Stage IV Any pT, any N, M1 21% 
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thyroid cancer presenting to University Hospital Birmingham (UHB), >90% of 
cases had primary tumours >2cm in size at presentation (T2-T4) and the 
majority of small tumours were discovered incidentally and without symptom 
(Smith et al., 2014). With an absence of symptomatic disease in early stages, 
disease stage at presentation can therefore often advanced, with 50% of MTC 
presenting stage III or above (Kloos et al., 2009). Ten-year survival for stages 
1-4 disease are 100%, 93%, 71% and 21% respectively with no trend toward 
earlier stage at presentation (Modigliani et al., 1998).  This has a significant 
impact on prognosis in MTC (Kloos et al., 2009). Further, in advanced local 
disease, involvement of the vascular compartment and upper areo-digestive 
tract, in particular carotid artery encasement, may render disease inoperable 
and as such incurable (Watkinson and Gilbert, 2012).  
 
The proximity of the thyroid gland to other structures may affect the way in 
which thyroid cancer presents. The superior poles of the lobes on either side 
receive the upper poles vessels including the superior thyroid artery and vein 
and the superior laryngeal nerve is in close proximity supplying the 
cricothyroid muscle which provides the superior poles medial relation 
(Sinnatamby, Chummy S, 2006). The inferior pole is more lobular in shape 
and receives blood from the inferior thyroid artery with venous drainage via 
the middle and inferior thyroid veins (Figure 1) (Moore Keith, Daslley Arthur, 
Agur Anne, 2013). The recurrent laryngeal nerve, a branch of the vagus 
nerve, lies deep to the gland running in the tracheoesophageal grove on the 
left and more laterally on the right and is intimately related to the inferior 
thyroid artery running over, under or between its branches (Haller, Iwanik and 
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Shen, 2012). Malignant disease that spreads beyond the thyroid capsule can 
directly invade the laryngeal nerves leading to dysphonia, or airway 
compromise (Perros, Boelaert, Colley, Evans, Rhodri M Evans, et al., 2014a). 
Further, when surgical removal of the gland for cancer treatment is warranted, 
damage to the recurrent laryngeal nerves can lead to airway compromise and 
death due to paralysis of the laryngeal musculature (Randolph et al., 2011). 
Often therefore, microscopic disease has to be left behind in order to reduce 
morbidity and preserve airway function (Perros, Boelaert, Colley, Evans, 
Rhodri M Evans, et al., 2014a). Partial tracheal resection or indeed laryngeal 
and tracheal resection may be warranted in such cases and will have 
significant impact on a patient’s quality of life (Bergamaschi et al., 1998). 
Surgery may be considered in these situations as part of a palliative 
procedure to reduce the likelihood of asphyxiation or major haemorrhage 
(Akslen et al., 1991). Surgery may, on the other hand, be limited where there 
is significant metastatic disease, with a morbidity sparing approach being 
adopted (Watkinson and Gilbert, 2012). These issues arise more commonly in 
patients with MTC as there are few other treatments we can offer for recurrent 
disease (Perros, Boelaert, Colley, Evans, Rhodri M Evans, et al., 2014a). 
Surgery is often combined with external beam radiotherapy in these situations 
but treatment is likely to be with palliative intent only, adding weight to the 
need for further therapies being developed for patients with MTC.   
 
The thyroid gland has close anatomical relations to the parathyroid glands, 
with two superior and two inferior parathyroid glands sitting in close proximity 
to the posterior surface of the thyroid lobe (Gray Henry, 1974). As the 
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parathyroid glands are involved in calcium homeostasis by the production of 
parathyroid hormone in response to low levels of serum iodonised calcium, 
inadvertent damage or removal during surgery can lead to postoperative 
hypocalcaemia and, in severe cases, tetany with cardiac dysthymia and death 
(Sturniolo et al., 2000). Parathyroid disease in the form of adenomas and 
hyperplasia may also be a features of multiple endocrine neoplasia (MEN) 
type 1 and 2 respectively, with type MEN2 having a consistent association 
with medullary thyroid cancer (Brandi et al., 2001). 
1.1.2 Thyroid cancers metastasise to loco regional lymphatics  
The lymphatic drainage of the thyroid gland has important implications for 
MTC disease presentation and spread. Primary spread of malignant disease 
of the thyroid gland, regardless of the tumour type, will be to the local 
lymphatics. Microscopically and macroscopically, nodes will be involved in 20-
50% of cases at presentation (Nam-Goong et al., 2004), with extensive neck 
nodal disease at presentation carrying a poorer prognosis (Nixon et al., 2014). 
This highlights the rich lymphatic drainage of the thyroid gland as well as early 
lymphatic involvement being a characteristic feature of thyroid cancer (Grebe 
and Hay, 1996). Furthermore, well-differentiated thyroid cancer and MTC can 
present primarily with lymphatic metastases with no clinical or radiological 
evidence of a primary lesions. In such cases, a micro-carcinoma (<10mm) is 
often discovered on subsequent histological examination (Smith et al., 2014).  
 
Lymphatic metastasis within the neck is considered in levels and tumour 
specific patterns of spread are observed within the head and neck region 
(Watkinson and Gilbert, 2012). The thyroid gland sits within level six of the 
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neck and it is to level six that thyroid cancers most often metastasise 
(Robbins et al., 2008). Level six is the anatomical region in the central neck 
between the carotids on either side and from the hyoid to clavicles (Figure 3). 
When treating patients with known thyroid cancer, an ipsilateral level six 
lymph node dissection will often be performed as part of the thyroidectomy in 
cases where no nodal disease is macroscopically apparent (N0 Neck) (Kloos 
et al., 2009).  
 
Lymph node metastasis in the central compartment are underestimated both 
clinically and radiologically (Moley and DeBenedetti, 1999). With a lack of 
adjuncts to surgery for the treatment of MTC, central compartment (level six) 
clearance is advocated in the absence of macroscopic disease, although this 
approach is not advocated in prophylactic surgery (Pelizzo et al., 2007). 
Lateral spread of disease typically affects levels IIA to level VB, although 
theoretically, any group can be involved (Figure 3). If lateral nodes are 
affected, a clearance of these levels is recommended along with central nodal 
clearance (Perros, Boelaert, Colley, Evans, Rhodri M Evans, et al., 2014b). 	
Primary surgery where possible is advocated as re-operative central node 
clearance is associated with higher rates of complications including recurrent 
laryngeal nerve palsy and hypocalcaemia (Weber et al., 2001).   
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Figure 3. Neck nodal levels with regard to the spread of malignancies within the neck. 
(Watkinson and Gilbert, 2012).   
 
In the absence of marcoscopic nodal disease involving levels II to V, (the 
‘lateral’ compartment) most would advocate a conservative approach in the 
presence of MTC with re-exploration as clinically dictated (Robbins et al., 
2008). In well-differentiated disease, such as PTC, microscopic disease is 
likely to be well treated by radioactive Iodine (131I) therapy and as such the 
pressure to surgically remove all disease in the lymphatics is diminished 
(Leboulleux et al., 2005). As a surgical disease not responsive to 131I therapy, 
in MTC, both microscopic and macroscopic disease must be removed if long-
term survival and disease free recurrence is to be achieved (Kloos et al., 
2009). To this end, and as evidenced by our own cohort, patients with MTC 
often require multiple surgical procedures (Chapter 3).  
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1.1.3 The thyroid is an endocrine gland consisting of cells with different 
function.  
The physiological differences between thyrocytes and C cells account for 
some of the disparity in treatment outcomes.  The thyroid gland is an 
endocrine organ structurally organised at a cellular level and consisting of 
cells with differing physiological function. The primary function of the thyroid 
gland is the production and release of thyroxine, vital for growth, 
differentiation and metabolism within most tissues (Oppenheimer et al., 1987). 
The primary and most abundant cell is the thyrocyte or follicular cell; cuboidal 
epithelial cells which are organised around structural units known as follicles 
(Yen, 2001). The follicle itself is located at the apical end of the thyrocyte and 
forms a storage reservoir for organified iodine and thyroglobulin. The thyroid 
gland also contains  C cells, or para-follicular cells, lymphocytes, blood 
vessels and lymphatic channels. The primary function of the thyrocyte is in the 
uptake, organification and storage of iodine required in the synthesis of 
thyroxine (Kopp, 2001). The uptake of iodine and release of thyroxine are 
controlled by thyroid stimulating hormone (TSH) which in turn is regulated by 
thyroid releasing hormone (TRH) (Vassart and Dumont, 1992). TSH and TRH 
are released from the pituitary and hypothalamus respectively under the 
control of serum thyroxine as part of a negative feedback loop (Figure 4) 
(Shupnik, Ridgway and Chin, 1989). TSH acts via the TSH receptor on the 
basal membrane of the thyrocyte which sets off an intracellular cascade 
leading to activation of thyro peroxidase and secretion of organified iodine as 
mono and di-iodothyronine at the basilar membrane where it stored in the 
thyroid follicle.  
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Figure 4. Hypothalamic-pituitary–thyroid axis. 
 
In contrast, C-cells secrete calcitonin, a 32 polypeptide hormone encoded by 
the CALCA gene and involved in calcium homestasis (Le Moullec et al., 
1984)(Copp and Cheney, 1962). Calcitonin is secreted in response to 
increased blood levels of ionised calcium and as such plays a role in calcium 
homeostasis, promoting osteoblastic activity, limiting the activity of osteoclasts 
and therefore calcium resorption from bone and increasing calcium loss in the 
kidney by decreasing resorption in the distal convoluted tubule (DCT), with a 
further reduction in intestinal calcium absorption from the gut (Guyétant et al., 
2003). Interestingly, within the context of this study, an association between 
oestrogen and calcitonin secretion has long been recognised with falling 
levels of calcitonin in post-menopausal women implicated in loss of bone 
density and osteoporosis (Stevenson, 1982). 
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Thyroid		
TSH	
T4 T3
-ve	
T4	–	T3	Liver,	muscle	
Target	tissues		
	 	 	
	 	 	 	 12	
C cells in humans are found within the thyroid and are part of the 
ultimobranchial complex in other animals (Stevenson, 1982). The role of C 
cells and calcitonin in calcium homeostasis in humans is somewhat limited; a 
fact highlighted by the lack of abnormality in calcium homeostasis seen in 
patients who have undergone total thyroidectomy. Although the effects of 
calcitonin on calcium homeostasis mirror that of PTH, it is far less potent in 
effecting blood calcium levels (Breimer, MacIntyre and Zaidi, 1988). Other 
factors including, calcium resorption and loss in the kidney clearly 
predominate. Serum calcitonin measurements form the basis of clinical tests 
for patients with suspected primary MTC as well as biochemical monitoring of 
patients following treatment. Serum calcitonin levels are an accurate marker 
of residual disease and disease recurrence in MTC. Rising serum calcitonin 
correlates well with recurrent disease with calcitonin doubling times being a 
marker of disease requiring investigation and possibly intervention (Costante 
et al., 2007).  
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Figure 5. Calcium homeostasis and regulation by parathyroid hormone (PTH) and 
calcitonin 
 
C-cells can be stimulated to release calcitonin by gastrin and pentagastrin 
(Escalada et al., 1993). Both basal calcitonin and pentagastrin-stimulated 
calcitonin can be used as an investigative tool for patients with suspected 
MTC or C Cell hyperplasia (CCH: C-cells can undergo hyperplasia (increased 
cell number), a recognised premalignant change) as a guide to further 
investigation or treatment in the form total thyroidectomy (Milone et al., 2010). 
It can be of particular use in patients with a positive family history of MTC in 
whom no germline RET abnormality has been detected (see Chapter 3) and 
was used within our index family as a guide to treatment decision making with 
respect to prophylactic thyroidectomy in the offspring of the proband 
(Herrmann et al., 2010). As test of CCH however, pentagastrin stimulation is 
not totally reliable and indeed proved a poor marker of histopathological 
outcome in our index family (see Chapter 3). The presence of CCH in 
pentagastrin positive patients with benign thyroid (nodular and thyrotoxic) 
disease is reported as high as 50% (Scheuba et al., 2000). In addition, 
antibodies to calcitonin can be used to highlight C cells on histological slides, 
and it is worth noting that both C-cells and CCH are more common in men 
than women (Bléchet et al., 2007).  
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1.1.4 The embryology of the thyroid gland is important when 
considering the functions and dysfunction of cells of which it 
constitutes 
Medullary thyroid cancer (MTC) is a tumour derived from neural crest para-
follicular C-cells which have a distinct embryological and developmental origin 
to follicular cells and are dispersed throughout the thyroid gland (Kloos et al., 
2009). Thyroid tissue, consisting of thyrocytes surrounding follicles of colloid, 
develops in the foramen caecum of the tongue base and descends through 
the anterior neck during embryogenesis to lie in the lower neck (Sadler, 
2010). The tract through which the gland descends (thyroglossal duct) can fail 
to close resulting in a thyroglossal duct cyst or a thyroid tissue remnant within 
the duct (McCoul and de Vries, 2009), with such remnants are more prone to 
malignant change. In addition there may be failed migration of the gland along 
the duct with the entire thyroid gland can be found from anywhere between 
the tongue base and the neck (Organ and Organ, 2000).  
 
By contrast, the embryological origin of C cells is the neural crest, 
pleuropotent cells that originate from the dorsal and later aspects of the neural 
tube (Sadler, 2010). They possess the potential to both migrate and 
differentiate into a wide range of tissue types with myriad function. In the head 
and neck region, they migrate into the branchial arches where they form 
branchial arch structures such as the bones and cartilage of the facial 
skeleton, mandible and middle ear (Fagman and Nilsson, 2010). Lower in the 
neck, and in particular in the fourth branchial arch, neural crest cells migrate 
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with the ultimobranchial body, the final embryological inclusion of the ventral 
fourth arch (Kameda et al., 2013). The ultimobranchial body containing the 
neural crest inclusions then merges with the descending thyroid gland and the 
C cells are dispersed with it (Adams and Bronner-Fraser, 2009). 
Ultimobranchial dispersions can be seen quite clearly in the 
immunohistochemical studies (Chapter 7). The ultimobranchial body also 
forms the thymic structures which migrate into the upper mediastinum 
(Fagman and Nilsson, 2010). The differing embryological origin of C cells and 
primary thyrocytes has implications when studying models of cellular 
dysfunction. In particular, and as discussed later in this report, this has 
implications for in vitro analysis. Although distinct in their embryology and 
physiology, the shared microenvironment of the thyrocyte and C cell are a 
further important consideration when examining tumour predisposition, cancer 
development and spread.  
 
Elsewhere in the body, neural crest derived tissue forms a wide variety of 
functional tissues and structures. These include the peripheral nervous 
system, melanocytes within skin and elements of the autonomic nervous 
system (Adams and Bronner-Fraser, 2009). With regard to MTC, there are 
important associations including de-differentiation into neuroendocrine tissues 
such as Chief cells of the adrenal medulla from which pheochromocytoma 
arises and neuroendocrine elements in the gastrointestinal tract. 
Abnormalities of these tissues are features of multiple endocrine neoplasia 
(MEN2) and further discussed in section 1.3 (Raue and Frank-Raue, 2010).      
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1.2 Thyroid cancer  	
1.2.1 Thyroid cancer is the most common endocrine malignancy, with 
increasing incidence 
Thyroid cancer is the most common malignancy of endocrine tissue, and can 
be classified into four main morphological types, papillary, follicular, medullary 
and anaplastic (undifferentiated) thyroid cancer (Cooper et al., 2009). 
Lymphoma can also arise primarily within the thyroid gland and the thyroid 
gland can be the site of secondary metastasis but neither of these two clinical 
entities will be considered further here. Papillary and follicular thyroid cancer, 
also known as well differentiated thyroid cancer, arise from follicular cells 
within the thyroid gland and, as previously discussed, function around 
follicular subunits to organify iodine and produce and secrete T3 and T4. The 
unique properties of thyrocytes in relation to iodine uptake provide specific 
targets for treatment in the form of radioiodine (131I) which in part explains why 
the prognosis for these malignancies is much better than for MTC or 
anaplastic thyroid cancer (Tomoda et al., 2006).  
 
The incidence of well-differentiated thyroid cancer is increasing and in 
particular the incidence of early well differentiated papillary thyroid cancer 
(Cooper et al., 2009)(Figure 6). Indeed, papillary thyroid cancer now makes 
up the vast majority of malignancies identified in most large series with a shift 
in rates compared to other types of thyroid cancer (Enewold et al., 2014). 
Much of the reported increase can be attributed from a greater detection of 
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early disease, much of which may be indolent in nature (Malandrino et al., 
2013). A rising incidence in the diagnosis of thyroid cancer through more 
rigorous investigation of nodular diagnosis however is not leading to an 
increase in thyroid cancer mortality. Unlike PTC, MTC does not have an 
indolent form and no greater incidence of MTC has been reported.  
 
Figure 6. Incidence of and mortality from thyroid cancer in the US, 1975-2009 and 
advent of new technologies. (Brito, Morris and Montori, 2013).  
MTC accounts for approximately 5% of thyroid cancers in the UK and US 
(Kloos et al., 2009). In 2008, examination of national data on all types of 
thyroid cancer revealed 2154 new diagnoses with a incidence in the UK of 
around 4.8 per 100,000 in women and 1.9 per 100,000 in men (CRUK, 2013). 
Although the incidence is increasing, this is, for the majority, made of an 
increase in the diagnosis of papillary thyroid cancer.  
 
The ability to identify cancer at an earlier stage clearly has implications for 
patients with MTC and prognosis is linked to stage at presentation (Modigliani 
et al., 1998). Interestingly, at UHB, we have not seen locally the international 
increase in disease detection of early disease that has been reported (Smith 
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et al., 2014)(Brito, Morris and Montori, 2013). As discussed, the outcome in 
patients with MTC is linked to stage of disease at presentation. The fact that 
an increase in early disease identification is not seen locally seenhas 
significant implications for patients with MTC as outcomes based on current 
trends and available treatments is unlikely to improve detection and therefore 
survival. There is however, no evidence internationally that MTC is being 
diagnosed at an earlier stage.    
 
This increased detection of thyroid cancer comes both through a greater 
awareness of nodular thyroid disease and an increase in the use of imaging 
modalities such as ultrasound scanning and cross sectional imaging in the 
form of CT and MRI scanning (Brito, Morris and Montori, 2013). In spite of an 
increasing incidence, the mortality rate from well-differentiated thyroid cancer 
has remained stable, adding weight to the theory of early detection of indolent 
disease (lead time bias). National data from the cancer registry on the 
incidence and disease specific mortality in thyroid cancer highlights these 
trends (Cancer Research UK, 2013). Whether ultimately we are witnessing a 
lag in the mortality data and mortality will increase in line with incidence has 
yet to be seen. In contrast to well-differentiated thyroid cancer the incidence 
and rate of MTC has remained stable. This may reflect differences between 
these two types of thyroid cancer in that although micro-carcinomas occur in 
both, medullary micro carcinomas are progressive rather than indolent in 
nature.  
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1.2.2 Like other forms of thyroid cancer MTC most commonly presents 
with a neck mass in a clinically euthyroid patient 
Where MTC presents primarily without a known familial predisposition 
(sporadic disease), its presentation is often indistinguishable from other forms 
of well-differentiated thyroid cancer. Most commonly, MTC presents with a 
neck mass, either within the thyroid gland or as locoregional neck nodal 
metastasis commonly in level six or in the lateral neck (Kloos et al., 2009). 
Presentation with locally invasive or distant disease occurs but is less 
common. Where MTC presents as part of a multiple endocrine neoplasia 
syndrome however, systemic symptoms secondary to phaeochromocytoma 
including diarrhoea and flushing, with signs of hypertension may occur prior to 
thyroid specific changes.  
 
1.2.3 Investigation of MTC  
As with other forms of suspected thyroid cancer, fine needle aspiration 
cytology (FNAC) in conjunction with a specialist performed ultrasound scan of 
the thyroid and neck are the mandatory initial assessment criteria (Perros, 
Boelaert, Colley, Evans, Rhodri M. Evans, et al., 2014). Most thyroid nodules 
that are investigated in clinical practice will be benign and as the incidence of 
MTC in a routinely investigated nodule is so low (0.83%), routine screening of 
all nodules with calcitonin estimation is unwarranted (Daniels, 2011). Where 
FNAC and USS characteristics are suspicious of MTC however, calcitonin 
estimation can be a useful adjunct to diagnostic work-up and is advocated in 
treatment planning by the American Thyroid Association (ATA) (Kloos et al., 
2009). In many cases, where disease is limited to the thyroid gland, FNA and 
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USS will be insufficient to reach diagnosis of MTC and diagnostic thyroid 
lobectomy will be indicated (Perros, Boelaert, Colley, Evans, Rhodri M Evans, 
et al., 2014a). Where a diagnosis of MTC has been established prior to 
surgery, complete staging of both primary nodal and metastatic disease 
should be completed and will likely involve cross-sectional imaging of the 
neck, chest and liver to screen for secondary deposits as well as imaging of 
the adrenals to screen for phaeochromocytoma which may indicate a 
diagnosis MEN 2 and require treatment prior to the thyroid (Perros, Boelaert, 
Colley, Evans, Rhodri M Evans, et al., 2014c). Once a diagnosis of MTC has 
been established, conformation of RET (RE-arranged during Transfection) 
mutational status with genetic counselling and cascade testing as appropriate 
will be carried out and is a major tool for the identification of preclinical 
disease (Romei et al., 2011). Current recommendations for the RET mutation 
analysis include direct sequencing of germline DNA derived from leukocytes 
taken from peripheral blood with screening of exons in which RET mutations 
most commonly occur (exons 10, 11 and 13-16) (Eng, 1999). The exact exons 
tested and the algorithm for testing differs between laboratories.   
1.3 MTC and multiple endocrine neoplasia type 2 (MEN 2) 
MTC either occurs in isolation (sporadic MTC), in a familial form (FMTC) or in 
conjunction with other tumours of neuroendocrine origin (neural crest 
derived), multiple endocrine neoplasia (MEN) type 2A or MEN 2B (Kloos et 
al., 2009). MTC was first described as a malignant tumour with amyloid in 
1906 but not histologically characterised until 1959 (HAZARD, HAWK and 
CRILE, 1959).  Familial disease accounts for around 25% of cases of MTC 
with sporadic MTC accounting for the majority (75-80%). Since the advent of 
	 	 	
	 	 	 	 21	
diagnostic RET testing, identification of extrathyroid manifestations to 
distinguish FMTC from MEN 2A has become less important and the two 
entities are considered part of a spectrum of the same disease (Eng et al., 
1996). Where extra thyroidal features are present, there is a variable 
presentation with phaeochromocytoma (approximately 50%) and primary 
hyperparathyroidism (30%) (Iihara et al., 1997). In MEN 2B there are 
additional clinical factors relating to abnormalities of neural crest derived 
tissue including Marfanoid facial features (high arched palate, mucosal 
abnormalities), amyloidosis and multiple cutaneous and gastrointestinal 
neuromas (Mulligan et al., 1993), (Donis-Keller et al., 1993), (Eng et al., 
1995). MEN2 is caused by missense mutations of the RET  proto oncogene 
with direct correlation between mutation and disease phenotype (Zbuk and 
Eng, 2007), (Eng et al., 1996). RET mutation-mapping forms the basis of 
clinical testing in MTC and MEN and forms the basis for cascade testing and 
clinical planning. In familial disease, RET mutations are causative in 85% of 
FMTC, 95% of MEN 2A and 98% of cases of MEN2B.  
 
The study of these familial forms of cancer not only informs management of 
the patients and their families but it also provides important clues to the 
pathogenesis of the more common sporadic forms of the tumour. Thus, 
somatic mutation of RET has been detected in up to 60% of sporadic MTC 
(Eng and Mulligan, 1997). In addition, approximately 10% of patients with 
apparently sporadic MTC have a germline RET mutation and diagnostic 
testing, with subsequent cascade testing where appropriate, should be offered 
to all such patients (Eng et al., 1995) (Wohllk et al., 1996), (Schuffenecker et 
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al., 1997). This may reflect incomplete penetrance for MTC associated with a 
germline RET mutation although the de novo RET mutation rate has been 
estimated to be as high as 10% (Schuffenecker et al., 1997). 
 
 
1.4 The molecular basis of MTC  	
1.4.1 The RET proto-oncogene  
RET was identified in studies of NIH 3T3 cells transfected with lymphoma 
DNA as a novel rearranged protein; the coding region of which has retained 
the nomenclature (Takahashi, Ritz and Cooper, 1985). The RET gene 
encodes a receptor tyrosine kinase and, upon ligand activation by glial cell 
derived neurotrophic factor (GDNF) or one of its superfamily (GDNF family 
ligands (GLFs)), leads to RET receptor dimerization and activation (Jing et al., 
1996). The RET gene is located on chromosome 10q11.2 and consists of 21 
coding exons which, when transcribed, combine to encode a protein with 
three distinct domains (Takahashi and Cooper, 1987). The extra cellular 
binding domain contains 4 cadherin-like repeats in addition to a cysteine rich 
domain that is highly conserved across a range of species and in which many 
of the pathological mutations leading to MEN2 and FMTC occur (Figure 8 
page 26) (Ponder, 1999). In addition, the RET tyrosine kinase has a 
hydrophobic, transmembrane domain as well as a cytoplasmic portion 
(Iwamoto et al., 1993). As a tyrosine kinase, RET is part of the superfamily of 
cell membrane bound growth factors that act as growth hormones and, when 
activated, lead to down-stream transcription and ultimately to cellular 
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differentiation and proliferation. As with other tyrosine kinases, the RET 
tyrosine kinase plays a key role in oncogenesis and plays a role in multiple 
cancers including thyroid, breast and lung (Gschwind, Fischer and Ullrich, 
2004) (Mulligan, 2014).   
 
Activation of RET with phosphorylation of the tyrosine residue tyr1062 causes 
downstream binding of SHC (Src homology 2 domain containing) producing a 
cascade of transcriptional activation which subsequently leads to cellular 
proliferation (Figure 7) (Zbuk and Eng, 2007). Mutations of the extracellular 
cysteine rich domain account for the majority of MEN 2A with C634W 
accounting for 85% alone (Zbuk and Eng, 2007), (Ponder, 1999). Cysteine 
codon mutations produce a RET receptor that is unable to form a disulphide 
bond with its intracellular binding partner (GFL-GFRα) and instead binds to 
another mutated receptor mimicking ligand binding with consequent up 
regulation. The missense mutation M918T (exon 16) gives rise to the majority 
of MEN2B with a mutation on the intracellular phosphorylation site and SHC 
binding domain. M918T is thought to increase RET-ATP binding affinity 
making RET more active (Wagner et al., 2012). It is rare to have a situation 
where familial cancer predisposition is caused by an activating mutation, 
where mutations of tumour suppressor genes are more commonly described 
(Chau and Wang, 2003) .   
 
1.4.2 RET mutations in MTC  
Activating missense mutations affect RET functioning in differing ways. The 
clinical presentation of the disease is phenotypically closely linked to the 
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position and effect of the point mutations in RET and as such RET 
phenotypes can be defined in broad terms at a molecular level (Zbuk and 
Eng, 2007). In FMTC, MTC arises in isolation and the majority of cases have 
a RET mutation (85%)(Eng et al., 1996). Where sporadic MTC arises with 
other neural crest tissue tumours the clinical syndrome is defined as multiple 
endocrine neoplasia (MEN) type 2A (pheochromocytoma and parathyroid 
hyperplasia) or 2B (pheochromocytoma, parathyroid hyperplasia and GI and 
cutaneous neurogangliomas) and almost always arise from a gain of function 
of the RET tyrosine kinase.(Donis-Keller et al., 1993), (Mulligan et al., 1993), 
(Eng et al., 1995). More than 98% of MEN2B has an identifiable RET mutation 
(Eng et al., 1996). Loss of function mutations of the RET tyrosine kinase 
predisposes to Hirsprung’s disease (abnormal development of intestinal 
neuronal ganglions) (Zbuk and Eng, 2007). 
 
With the routine availability of diagnostic RET testing it has become apparent 
that there are families and individuals with a suggestion of a genetic 
predisposition to the development of MTC or CCH, for example with a young 
age at onset or a positive family history, in whom no RET mutation can be 
detected. Although possible explanations may include the presence of a RET 
mutation which has eluded detection or a sporadic occurrence of disease, it is 
likely that there are genes other than RET, predisposing to MTC/CCH which 
remain to be detected. The BTA has specifically recommended investigation 
of familial non-RET families in order to identify novel predisposing genes 
(Perros, 2007).  
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Figure 7. Activation mechanisms of the RET tyrosine kinase protein. Adapted from 
Mulligan (Mulligan, 2014). 
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Figure 8. The RET (Re arranged during Transfection) proto-oncogene pathway and its 
downstream transcriptional activity (Zbuk and Eng, 2007).  
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Figure 9. RET downstream stimulatory activation leading to cellular proliferation and 
angiogenesis via ERK, JKN, mTOR and VEGF pathways (adapted from (Mulligan, 
2014)).  
 
In MEN2, MTC presents either in isolation or with other tumous of neural crest 
origin, most commonly phaeochromocytoma. Additional neural crest tumours 
are rare in sporadic (non-familial, RET negative) disease (Eng and Mulligan, 
1997)(Ponder, 1999). MEN2 is regarded as a paragon of phenomics, where 
specific point mutations in the RET gene give differing clinical presentations of 
the disease and there is close genotype phenotype correlation (Zbuk and 
Eng, 2007). It appears for example that mutations affecting the intracellular 
domain (most commonly M918T) of the transcribed transmembrane tyrosine 
kinase, lead to more severe forms of the disease, typically MEN2B, with 
ERK	
CREB	
SOS	
RAS	
RET	SHC	
GRB1/2	 GRB2	
JNK	
JUN	
Proliferation	
AKT	
mTOR	HIFI1α	
Angiogenesis	 Proliferation	
VEGF	 P7056K	
	 	 	
	 	 	 	 28	
younger age at disease onset and more aggressive clinical course. In 
contrast, activating missense mutations leading to RET tyrosine kinase 
structural anomalies in the extracellular domain (most commonly p. C643W) 
lead to milder forms of the disease, with the distance from the membrane 
being the most important factor in disease severity (Zbuk and Eng, 2007). 
Mutations at maximum distance from the cellular membrane typically cause 
FMTC that tends to present later and has rare association with other neural 
crest tumours. This may have important implications within the context of this 
study with regard to the likely genotype aberrations leading to the identified 
phenotype within our index family.   
 
1.5 The treatment of MTC 
1.5.1 Non-surgical treatment of MTC  
MTC is a surgical disease, with complete resection representing the only 
chance of permanent cure (Kloos et al., 2009). Surgery is also indicated for 
the prophylactic management of RET mutation positive familial disease and 
for local control of symptomatic but incurable local disease. As C cells do not 
possess the ability to uptake iodine, radioiodine therapy is not effective and 
goes some way to explaining the disparity between survival outcomes in MTC 
versus well differentiated thyroid cancer (Perros, Boelaert, Colley, Evans, 
Rhodri M Evans, et al., 2014c). In addition, MTC is relatively refractory to 
external beam radiation and its use in primary treatment and treatment of 
recurrent disease is controversial (Schwartz et al., 2008) (Brierley et al., 
1996). Standard chemotherapeutic agents are not recommended in MTC due 
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to lack of tumour response (Kloos et al., 2009). Small molecule inhibitors of 
tyrosine kinase receptors such as Vandetanib have shown some promise in 
inducing tumour remission in more recent trials. However, none have been 
shown so far to improve life expectancy (Wells et al., 2012). This highlights 
the need for better understanding of the genetic events leading to MTC as a 
better understanding of the downstream effector pathways is likely to reveal 
further molecular targets. As a surgical disease with limited adjuvant 
treatment options, survival and prognosis are very much linked to the stage of 
disease at presentation. As such, survival in stage one disease at 10 years is 
as high as 100%. MTC often presents late, however, with 50% of patients at 
stage III or stage IV at diagnosis with five-year survival in advanced (stage IV) 
disease is only 21% (Roman, Lin and Sosa, 2006).  
 
1.5.2 Who should manage patients with MTC?   
There is a move towards centralisation of cancer services in the UK and 
internationally and much debate regarding how best to manage patients with 
rare malignant diseases. MTC tends to be managed in the UK in tertiary 
centres, although significant numbers of patients are treated outwith of large 
centres. As regional genetics services generally coalesce in tertiary centres, 
there is certainly a logical argument based on geographical placement of 
services for this taking place. Recent debate on thyroid surgery has focused 
on the nature and training of surgeons undertaking thyroid surgery, of which 
the most important factor is the volume of surgery being undertaken by 
individuals and individual centres (Oltmann and Holt, 2014). It is clear that 
where high volumes of surgery are performed the outcomes are better and 
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there are consensus statements from national frameworks in support of this 
(BAETS national audit (Anon, n.d.)). Although initial surgery in MTC is often 
routine and performed without the knowledge of the diagnosis, subsequent 
surgery and further surgery for recurrent disease in the neck is challenging 
and should only be undertaken in large centres. I reviewed UK and US 
perspectives on these issues to provide an editorial with recommendation 
based on the on current evidence (Smith, Watkinson and Shaha, 2012). As 
the surgical treatment of MTC often involves dissection of the central and 
lateral nodal compartments of the neck as well as the surgical management of 
recurrent disease, regional concentration of cases to specific units is even 
more important for patients to receive optimal treatment.     
 
1.6 Cancer as a genetic disease 	
Mutations in genes that ultimately lead to alterations in the structure and 
therefore function of cell cycle regulator proteins are features of most cancers 
and vital for the confirmation of cellular reproductive function leading to clonal 
expansion of mutated cell lines. On a fundamental level, cancer is a disease 
of genes and gene regulation and most cancers are polygenetic (Vogelstein 
and Kinzler, 2004). Inherited mutations therefore only confer a propensity to 
develop cancer and many of the mutations in cell cycle regulatory pathways 
that eventually develop are somatically derived and may be secondary to 
environmental factors (Stratton, Campbell and Futreal, 2009). In an ideal 
state, tissues exist without growth or development, but in quiescence with loss 
and natural replacement of cells as required (Loeb and Harris, 2008). The 
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reality is somewhat different however, with constant changes in the genetic 
architecture often brought about through environment factors that cause direct 
DNA damage such as free radicals, ionising radiation, carcinogens and 
viruses (Talbot and Crawford, 2004) Although DNA replication has a very high 
fidelity, errors develop, a process accelerated by exogenous mechanisms of 
DNA damage (Lengauer, Kinzler and Vogelstein, 1998). It is the combination 
of inherited phenotype and genomic instability that ultimately pushes the 
balance within tissue in favour of malignancy.  
 
Groups of proteins that, when abnormal, can predispose to cancer include 
growth hormones and their receptors, intracellular transducers and receptors, 
DNA repair and cell cycle control proteins and proteins that induce apoptosis 
(See Figure 10)(Lodish et al., 2000). Somatic mutations that may lead to 
cancer include single point mutations (substitutions, insertions and deletions), 
translocations, whole chromosomal amplifications and copy number increases 
and decreases (Stratton, Campbell and Futreal, 2009). As the methods 
employed in this project using whole exome sequencing (WES) in the 
identification of novel predisposition gene mutations will generate a 
significantquantity of non-relevant data, using ‘biologically relevant pathways’ 
as a method of data filtration is a well recognised tool and forms part of the 
rational for targeted focus on specific mutations.  
 
1.6.1 Oncogenes and proto-oncogenes  
Oncogenes are genes encoding for proteins that transform a cell or tissue in 
culture or in an animal to cancer. Few of these are derived from proto-
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oncogenes that are normally occurring genes encoding proteins involved in 
cell cycle regulation (Pillai, 1992). To transform a proto-oncogene into an 
oncogene producing an onco-protein usually involves a gain in function, as 
highlighted by the gain in function mutation of the RET gene via well 
described missense mutations of the tyrosine kinase domains. Gain of 
function mutations account for the majority (90%) of disease causing somatic 
mutations (Mulligan, 2014). Other gain of function mutations include those in 
proto-oncogenes such as RAS and BRAF, with p. V600E  BRAF mutations 
being the most commonly described activating mutation in human cancer 
(Vogelstein and Kinzler, 2004). Other than point mutations, translocations 
such as RET/PTC rearrangements where a regulatory gene is inappropriately 
brought under the promoter region of another gene, and gene amplifications 
where there is localised over amplification of regional DNA sequence, may 
lead to inappropriate downstream gene amplification. Although in the example 
of point mutations, an oncoprotein is produced that has as a potential 
differential function to the original protein, in the examples of reduplication and 
translocation, abnormal amounts of a morphologically normal protein are 
produced (Lodish et al., 2000). This is an important consideration within the 
context of this study owing to the pathway up-regulation hypothesis proposed 
in Chapter 5.   
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Figure 10. Schematic representation of proteins and pathways in which mutations and 
functional changes can lead to cancer predisposition (Lodish et al., 2000).  
 
In well-differentiated thyroid cancer, RET/PTC rearrangements provide 
evidence of up-regulation of constitutionally normal RET tyrosine kinase can 
cause cancer. Common abnormalities in well differentiated thyroid cancer 
include point mutations in the BRAF and RAS pathways and also the 
RET/PTC and PAX8/PPARG rearrangements with point mutation BRAF 
V600E being the most common (Leeman-Neill et al., 2013). There are a 
number of RET/PTC rearrangements than effectively bring RET under the 
promoter region of other genes. RET/PTC rearrangements are more common 
in patients with thyroid cancer previously exposed to radioiodine where high 
levels of 131I, concentrated by the follicular cells have DNA damage induced 
by direct gamma radiation (Leeman-Neill et al., 2013). In these circumstances 
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RET is constitutively normal but direct over expression leads to activity similar 
to that of an oncoprotein. 
 
1.6.2 Tumour suppressor genes 
The protein products of tumour suppressor genes are cell cycle inhibitors that 
provide a balance between cellular proliferation and cell death by direct 
inhibition of the cell cycle with promotion of apoptosis (Chau and Wang, 
2003). Furthermore, tumour suppressors play a role in DNA repair and as 
inhibitors of cellular migration (Friend et al., 1986). Although tumour 
suppressor genes undergo a range of mutations typical of all genes, 
mutations that lead to loss of function of a tumour suppressor are classically 
described as recessive in nature and usually caused by point mutations or 
small insertions or deletions. The identification of the recessive nature of 
tumour suppressor gene inheritance lead to development of the two-hit 
hypothesis initially proposed by Knudson in 1976, and still widely employed in 
tumour suppressor gene research (Knudson et al., 1976). In his studies of 
patients with retinoblastoma (RB), Knudson recognised that a predisposition 
to the disease could skip generations within families, with others arising 
sporadically, without a family history (Knudson, 2002). Time to development in 
tumours occurring in patients with a family history was much sooner than 
those without and the rate of bilateral disease much higher in hereditary 
disease. Assuming that both RB1 genes needed to contain an error to lead to 
disease, by mathematically modelling rates of disease between two groups it 
could be predicted that time to disease development in those with a single 
gene defect (needing a single mutation in the unaffected allele) to be 
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significantly different to those without a gene defect requiring mutations of 
both alleles (two-hits) to develop disease. 
 
More recently some modifications to this hypothesis have been described 
which move away from the classic two point mutational theories. 
Haploinsufficiency; where a mutation of a single allele leads to an 
incompletely functional gene, which may rather than being absolute, be a 
product of the tissue in which the gene product is expressed or changes in the 
microenvironment (Payne and Kemp, 2005). As the rate of spontaneous 
mutation is so low, evolutionary theories of cancer development suggest the 
rates of cancer seen far outstrip that that would be expected by the two hit 
hypothesis alone. This adds weight to the theory that haploinsufficiency may 
confer a selective advantage within tissues, the so called ‘mutator’ phenotype 
(Loeb, 1991). Further, mutations in tumour suppressors can confer a gain of 
function or provide a dominant negative effect.  
1.6.3 Mutations that lead to cancer: Natural selection in cancer tissues 
Neoplasm evolution by mutation of normal cells within tissues gaining a 
selective advantage has been proposed as the model of cancer development 
since the mid 1970s (Nowell, 1976). Cancer is a disease of genes, where 
gene mutation provides opportunity for cellular progression, clonal expansion, 
evolution and competition with cells in surrounding tissues (Greaves and 
Maley, 2012). Macroscopically, cancers contain multiple cell populations with 
differing mutation profiles leading to a heterogeneous mix within a tumour one 
often finds in pathological specimens (Cairns, 1975). One major limitation of 
histopathological examination is that specific cell properties cannot be 
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predicted by cell appearance and the cell characteristics are driven by 
mutation profile rather than outward appearance. Neoplasic heterogeneity is 
driven by somatic mutations that give individual cells specific properties and 
form complex mosaics competing for resources (Merlo et al., 2006). In this 
way, on a microscopic scale, tumour evolution mirrors the evolutionary 
pathways and pressures experienced by other species (Merlo et al., 2006).  
 
Tumour cells are more genetically unstable than normal tissues and more 
likely to develop further mutations (Merlo et al., 2006). Thus, within tissues, a 
single initial mutation may predispose cells to development of further 
mutations and as such set up a somatic evolutionary pathway (Gerlinger et 
al., 2012). This initial mutation may be tissue specific as a mutation in a gene 
may give selective advantage in one microenvironment but not in another 
(Gerlinger et al., 2012). Once mutated, populations of cells within malignant 
tissue may live and develop symbiotic relations with cells with differing 
characteristics, for example, cells have the ability to invade blood vessels, 
evade the immune system whilst others have the ability to migrate through 
blood and lymphatics. Significant intra-tumoural evolution has been 
demonstrated with further unique characteristics found in metastases and 
distant disease although solitary mutations are usually found within all 
samples (Merlo et al., 2006)(Gerlinger et al., 2012). Specific properties of a 
tumour, whether is indolent or aggressive, whether it is locally invasive or 
metastasises may be due to individual or dominant properties of the cell mix 
within a tumour. The differing cell types found in tumours may also to a 
greater or lesser extent, be competing for the resources supplied to the 
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surrounding microenvironment as well as those of normal tissue. The interplay 
between these factors and the host environment is likely to provide an 
explanation for the specific clinical presentations seen and in part explain why 
tumours of the same histological type behave in different ways.  
 
It is clear that in heterogeneous tumours such as MTC, the cells within the 
tumour carry different characteristics to those of the original progenitor 
mutations that gave cells within a tissue a selective advantage. The most 
commonly found somatic mutation is of the RET gene, and it is likely that 
forms the driving mutation for most cases of MTC. Both C-cells and thyrocytes 
share a microenvironment within the thyroid and RET mutations are common 
to MTC and PTC through the RET/PTC rearrangement. This provides 
evidence that upregulation of the RET pathway is important in the 
microenvironment of both C cells and thyrocytes.   
 
1.7 Hypothesis and Aims  
 
MTC is a rare but aggressive disease where surgery offers the only chance of 
cure (Kloos et al., 2009). Surgery is only curative in early stage disease. The 
majority of patients with MTC present late, where the chance of long term 
cure is significantly lower. In familial disease, identification of disease causing 
mutations of the RET proto-oncogene allow prophylactic surgery to be offered 
to at risk individuals, and offers good rates of disease control (Kloos et al., 
2009)(Eng et al., 1998). In families without RET mutations, and in the more 
common sporadic disease, no such tests exist. A better understanding of the 
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molecular genetic events in MTC is needed such that further genetic tests, 
biomarkers and targets for novel therapies can be developed. In depth 
analysis of rare cancer phenotypes have demonstrated high likelihood of 
identifying such events and the study of such phenotypes informs the 
management of more common, sporadic disease. The aim of this project is to 
identify and understand these events.   
 
Aims  
1. To assess familial non-RET MTC using next generation sequencing to 
identify potential disease predisposition loci. 
2. To assess the presence of identified abnormalities in a wider cohort of 
sporadic disease 
3. To assess the functional effects of identified abnormalities    
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Chapter 2.  
 
Materials and Methods  
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2.1 Project design and recruitment  
2.1.1 Ethical approval 
Ethical approval for the project was sought and granted from the National 
Research Ethics Service and University of Birmingham: 
 
Awarding body Reference 
National Research Ethics Service (NRES 
REC)  
CA/5175 
University of Birmingham (UoB) Ethics  ERN_11-0775 
 
2.3.2 Recruitment through local physicians and surgeons and access to 
local databases  
Recruitment for the project commenced in August 2010. The University 
Hospital Birmingham NHS Trust (UHB) is a tertiary referral centre for both 
Head and Neck and Thyroid cancer. Birmingham Women’s Hospital (BWH) 
houses the regional genetics referral service and as such handles local, 
regional and in the case of some diseases, national referrals. To gain the 
maximum coverage for patient recruitment, a search strategy from both 
centres was employed. Initially, using the thyroid cancer database, a 
prospective database of all thyroid operations and malignancies maintained 
by the Head and Neck Department at UHB over the last 18 years, hospital 
records of all patients treated at UHB with a diagnosis of MTC were analysed. 
The database allows comprehensive analysis of details on all patients 
surgically treated at the UHB, as well as a portal of access for pathological 
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records, and clinical and follow up data. In addition to this, the clinical genetics 
files (CGU files) for patients referred for clinical testing with suspected or 
proven MTC either as an index case or as an individual with a positive or 
suspected family history were analysed. The current BTA guidelines 
recommend all patients with a diagnosis of MTC be referred for genetic 
testing and counselling and as such there was overlap between the two 
databases in terms of patients (Perros, 2007). There were, however, also 
differences with some patients receiving primary treatment outside of UHB 
prior to being referred for genetic counselling and testing. In addition, there 
was a cohort who had not undergone surgical treatment at UHB but were 
under the care of the genetics department at BWH. 
   
Familial cases and those with young onset sporadic disease are most likely to 
harbour identifiable genetic alteration and as such were targeted first for 
recruitment (Table 1). Recruitment consists in order of preference:  
 
 
 
 
 
 
 
 
Table 1. Recruitment strategy in order of preference  	
Familial non-RET MTC 
Young onset sporadic non RET MTC (Under 40 at diagnosis) 
Other sporadic non-RET MTC 
RET positive sporadic MTC 
RET positive Familial MTC (MEN2A/2B) 
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2.3.3 Recruitment through research meetings 
Several meetings were targeted as likely to have significant numbers of 
clinicians with a special interest in MTC. Focus was placed on surgical 
meetings, as surgeons are most often the primary treating clinician, as well as 
the person most likely to follow the patient long term. The project was 
advertised as a poster presentation at the British Association of Thyroid and 
Endocrine Surgeons (BAETS) in Birmingham in October 2010 where flyers 
and business cards were also handed to delegates (Appendix 1). Further 
advertisement was performed at the BAETS meeting in Poitiers, France in Oct 
2011 and in Cardiff, Wales in Oct 2012. Preliminary data from this project was 
presented orally at the BAETs in Rome 2013 (receiving the British Journal of 
Surgery (BJS) prize for best oral presentation) and several families were 
recruited as a direct result (see appendix 2). In addition, flyers and 
advertisement was performed at the BTA in Newcastle in 2011 and through 
the BTA newsletter. Furthermore, the preliminary data and research 
methodology has been presented orally both at the European Society of 
Endocrine Surgeons (ESES) in Cardiff in May 2014 and at the American Head 
and Neck Society (AHNS) in New York in July 2014.  
 
2.3.4 Recruitment through direct physician contact 
Through these meetings, collaborative links for recruitment were established 
with Great Ormond Street through Tom Kurzawinski, Consultant Endocrine 
and Paediatric Surgeon, the Freeman Hospital in Newcastle through 
Professor Tom Leonard, Consultant Endocrine Surgeon and the Glasgow 
General through Louise Clarke, Consultant ENT surgeon. In addition we have 
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established clinical collaborative contacts with Patrick Morrison in Northern 
Ireland and David Scott-Coombes, Consultant Endocrine Surgeon in Cardiff.   
 
2.3.5 Recruitment through charitable organisations  
Further advertisement was done via the internet through contacts at the 
AMEND charitable trust, the British Thyroid Foundation (BTF) and the 
Butterfly Cancer Trust who all posted information regarding project 
recruitment on their websites. In addition, the AMEND charitable trust, through 
contacts with their patient groups, hold a registry of patients with disorders of 
the neuroendocrine system. The BTA advertised the project through their 
newsletter Collaboration with their chief executive Jo Grey allowed 
communication through their organisation   
 
 
Figure 11. Online advertisement of the project via collaboration with AMEND (2011 
newsletter), and the British Thyroid Foundation website (newsletter 2011).  
(http://www.btf-thyroid.org/index.php/resources/news-archive/medullary-thyroid-cancer-study 
http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CC8QFjAA&url=http%3A%2F%2Fwww.amend.org.uk%2Fresources%2Fnew
sletters%2Fdoc_download%2F95-q4-2011-
newsletter.html&ei=IlruUdLzDMWa1AWa7ICYDg&usg=AFQjCNGKzcWHbyddGOgfK_kb4IVKLe6xcQ&sig2=OgnyKItmTa7Q0Oh4YoRuDQ&bvm=bv.49478
099,d.d2k 
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2.3.6 Recruitment through contact with other research groups 
In addition to recruiting patients directly to the study, an attempt was made to 
access archived tissue through collaboration with other groups identified 
through research networks. Literature searches were performed to identify 
groups with recent publications consisting of cohort of patients with MTC in 
whom genetic and or functional research had been performed. The principal 
investigators of eight groups worldwide were contacted to request 
collaborative links and gain access to fresh and archived tissue. Through 
establishing links with Professor Stan Sidhu’s group in Sydney and Professor 
Robledo’s group in Madrid we were able to gain access to multiple samples of 
DNA extracted from peripheral blood (lymphocytes), fresh tissue and FFPE 
embedded tissue. This has included samples from both familial CCH/MTC 
and sporadic disease. This enabled us to expand the scope of the search for 
somatic mutations in MTC far beyond what would have been possible using 
local or even national recruitment and tissue examination.  
 
2.3.7 Research protocols 
Where appropriate patients were identified, they were contacted using 
standard introduction letters and invitations amalgamated together in a study 
pack. Consent for those patients interested in being in the study was obtained 
by EW (principal investigator) and a file created as part of the National 
Institute of Health Research (NIHR) held by Professor E Maher (ERM). 
Recruitment involved informed consent to participate, permission to access 
medical records for full details on disease presentation and management. 
Tissue blocks were requested from which to extract paraffin embedded, 
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formalin fixed DNA and a blood sample was obtained so that leucocyte, 
germline DNA can be extracted. Recruitment is on-going. 
 
 
Figure 12. Protocol for enrolment of patients identified through UHB/BWH databases 
 
Patient	identidied	through	UHB	or	BWH	databases	
Patient	written	to	directly	to	request	involvement		
Does	not	wish	to	be	involved/patient	does	not	respond		
Excluded	
Patient	wishes	to	be	involved	
Project	discussed	with	patient	consented	over	the	telephone	
Does	not	wish	to	be	involved/unable	to	contact	patient 		
Excluded	
Patient	not	appropriate	for	study	
Excluded	
Wishes	to	be	involved	and	appropriate	
Information	pack	and	written	consent	obtained	
Germline	DNA	extracted	from	peripheral	blood	as	per	protocol	1 		
Access	to	medical	records	and	tumour	blocks	
DNA	extraced	from	tumour	and	normal	FFPE	embedded	tissue	as	per	protocol	2	
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 Figure 13. Protocol for enrolment of referred patients from other physicians  
Physician	expresses	willingness	to	be	involved	in	study	
Written	referal	of	specidic	patient	or	family	after	refering	physician	discussion	with	patient	
Project	discussed	with	patient	consented	over	the	telephone	
Does	not	wish	to	be	involved/unable	to	contact	patient 		
Excluded	
Patient	not	appropriate	for	study	
Excluded	
Wishes	to	be	involved	
Information	pack	and	written	consent	obtained	
Germline	DNA	extracted	from	peripheral	blood	as	per	protocol	1 		 Treating	hospital	contacted	for	access	to	medical	records	and	tumour	blocks	
DNA	extraced	from	tumour	and	normal	FFPE	embedded	tissue	as	per	protocol	2	
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Figure 14. Protocol for contact and access to tissue and DNA held by collaborating 
groups 
 
Potential	collaborating	PI	identidied		
acess	to	archived	tissue	suitable	for	analysis	assessed	
PI	wishes	to	collaborate	
Patient	not	appropriate	for	study/consent	to	be	included	cannot	be	veridied	
Excluded	
Consent	to	be	included	appropriate	
DNA	extracted	at	source	from	blood/fresh	tissue/FFPE	
Clinical	information	obtained		
DNA	logged	and	stored	for	analysis		
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Figure 15. Protocol for recruiting patients contacted through patient lead research 
databases 	  
Patient	wishes	to	be	involved	in	project	and	contacts	us	directly	
Patient	written	to	directly	to	request	involvement		
Does	not	wish	to	be	involved/patient	does	not	respond		
Excluded	
Patient	wishes	to	be	involved	
Project	discussed	with	patient	consented	over	the	telephone	
Does	not	wish	to	be	involved/unable	to	contact	patient 		
Excluded	
Patient	not	appropriate	for	study	
Excluded	
Wishes	to	be	involved	and	appropriate	
Information	pack	and	written	consent	obtained	
Germline	DNA	extracted	from	peripheral	blood	as	per	protocol	1 		
Access	to	medical	records	and	tumour	blocks	
DNA	extraced	from	tumour	and	normal	FFPE	embedded	tissue	as	per	protocol	2	
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2.2 Sequencing  	
All reagents were obtained from Sigma-Aldrich unless otherwise stated 
(Poole, UK) 
 
2.2.1 Primer design and Polymerase Chain Reaction (PCR)  
Primer pairs were designed using the online software, Primer 3: (WWW 
primer tool; University of Massachusetts Medical School, USA). University of 
California, Santa Cruz (UCSC, USA) databases were used to identify 
consensus sequences against which to design primers (Anon, n.d., p. 3). 
Primers were designed to bind to regions approximately 30-50 base pairs (bp) 
in the up or down stream pathways of the forward and reverse strand of each 
exon to minimise reading artefact around the exonic region.  
 
Initial PCR was performed using Faststart Taq DNA polymerase chemistry as 
per manufacturer’s instructions (Roche, Indianapolis, USA). Reagents were 
kept on ice and thawed prior to use and gently mixed by pipetting prior to 
PCR. Experiments were carried out using thin walled 96 well plates suitable 
for use within a thermal cycler (Tetrad 2, BIORAD, Gene Amp PCR system 
9700). PCR conditions are shown in Table 2. Thermal cycling properties are 
shown in Table 3. Amplicons were run out on an agarose gel to verify PCR 
success and measure amplicon size prior to sequencing.  
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PCR Reaction components  1 X volume (µl) 
10 X PCR buffer (20mM MgCl2) 2.5 
5x GC rich solution  2.5 
2mM dNTP mix (1 to 1 ratio) 2.5 
Primers (forward and reverse) 1.0 
Taq Polymerase (Roche) 0.2 
400ng template genomic DNA 
(leukocyte derived) 
2.0 (after dilution if needed) 
dH2O Made up to 25 
Total 25 
Table 2. Taq polymerase PCR conditions  
 
Step Temperature Duration (Min)  Cycles 
1. Hot Start 95 ̊C 5 - 
2. Denaturing 95 ̊C 30-45s  
3. Annealing 58 ̊C 30-45s  
4. Extension 72 ̊C Dependent on length of PCR 
product (Approx. 1kb/min) 
 
Cycle to step 2.   
25 times 
   
5.Final Extension  72 ̊C 10  
Table 3. Thermal cycling properties (BIORAD Tetrad 2) 
 
2.2.2 Agarose gels (PCR product estimation prior to DNA sequencing) 
A 1.5% agarose gel (1.5g agarose) was made by mixing 1X TBE (Tris-borate-
EDTA) made up to 200ml. The mixture was heated to boiling and swirled to 
mix the powder until completely dissolved. Once cooled, ethidium bromide 
was added to a final concentrate of 0.5 µg/ml. The gel was poured into a gel 
casting tray with the appropriate number of combs to run each reaction in a 
separate lane with a DNA quantification ladder in each comb. The gel was 
allowed to set completely at room temperature (RT) (approximately 20min). 
The combs were removed rubber ends if the casting tray were removed and 
the gel and tray place in an electrophoresis chamber containing enough 
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1XTBE to cover the gel and the wells. 5 µl of PCR complete DNA was loaded 
into each well with an equal v/v of loading dye (6X loading dye; New England 
Biolabs, Ipswich, USA). DNA quantification ladder was loaded to enable PCR 
band size recognition and the electrophoresis chamber run initially at 120mV 
increasing after 5 min to 180mv for a further 15min or until the gel and ladder 
had migrated sufficiently to allow quantification (1kb DNA ladder, New 
England Biolabs, Ipswich, USA).    
 
2.2.3 Exosap reaction  
The exosap reaction is a clean-up step required in sequencing to ensure 
clarity of the sequence and minimise signal noise created by unwanted 
products of the PCR reaction including unused primers and nucleotide 
triphosphates (dNTPs) that may affect sequencing.  
 
Exosap Reagent  Volume (µl) 
Fast AP (alkaline phosphatase) 1u/µl 1 
10X FastAP buffer 1 
Exonuclease I 20u/µl 0.25 
PCR product 5 
H2O 2.75 
Table 4. Exosap PCR clean-up conditions 
 
The reaction components were mixed well then incubated at 37 ̊C for 30 min 
in a thermal cycler before deactivating the enzymatic component by 
increasing the temperature to 85 ̊C for 20 minutes.  
 
200-500ng of purified PCR product was used in cycle sequencing reaction 
which involves the amplification of one strand of the PCR product using a 
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single primer. Dye terminator chemistry kits were used as per manufacturer’s 
instructions (Big Dye Terminator cycle sequencing kit v3.1: Life technologies , 
Paisley, UK) 
 
Reaction components  1 X volume (µl) 
5 x sequencing buffer for  2.0 
Big Dye Terminator v3.1 0.75 
Primer (forward or reverse) 1 (3.2pMol) 
Purified DNA product  200-500ng 
dH2O  up to 10 µl 
Table 5. Sequencing PCR conditions using Big Dye terminator chemistry (Life 
Technologies). 
 
 
Temperature (̊C)  
 
Duration  
1. Denaturation  95   25s 
2. Annealing  60 25s 
3. Extension 50 3min 
4. Cycle to step 1 X 28   
5. End   
Table 6. Thermal cycling conditions for sequencing PCR 
 
2.2.4 DNA precipitation 
3.5 µl of precipitation buffer  (0.5M EDTA equal v/v with sodium acetate 
(NaAc)) was added directly to the 96 well plate post sequencing PCR product 
volume of with 100 µl of 100% ethanol. A pellet was formed by centrifugation 
in a 96 well plate centrifuge at 4000rpm for 13minutes at 4 ̊C. The plate lid 
was removed and the plate centrifuged at 400rpm for 1 minute on dry 
absorbent towels without dislodging the pellet. Salt washes of the pelleted 
DNA were then performed using 70% ethanol at a volume of 200 µl, mixing 
thoroughly before centrifugation at 4000 rpm for 10min at 4 ̊C. Again, after 
each spin, the 96 well plate was inverted and then spun upside down at 
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400rpm on absorbent towels. Two washes were performed for each sample. 
Plates were then allowed to air dry at room temperature for 30min prior to the 
addition of 10 µl of formamide (Hi Di formamide, Life Technologies, Paisley, 
UK). The plate was then denatured on the thermal cycler at 95 ̊C for 5 min. 
Samples were incubated on ice until placing on the capillary sequencer.  
 
 Model Company 
Sequencer 3730 DNA analyzer Applied Biosystems 
Thermo 
cyclers 
Tetrad2 peltier thermal cycler 
GeneAmp PCR system 9700 
BIORAD 
Applied Biosystems 
Table 7. Technical data on PCR and sequencing machines 
 
2.3 Checking mutations 
Once the capillary sequencing technique had been completed, the 
chromatograms were checked prior uploading onto sequence comparator 
programs (4Peaks online sequence analysis tool: nucleobytes.com). A visual 
check was made at this stage to assess the interpretability with special 
reference to significant dye blobs, unclean sequence and abnormally small of 
large traces. Where the sequence race could not clearly be defined, the 
experimental technique was reviewed and repeated. Sequencing was 
performed in both 5’ and 3’ directions to act as an internal control. Where one 
or other sequence trace was clean enough to be appropriately checked 
against the reference sequence that was deemed sufficient assuming the 
entire length of the exon could be interpreted. Where a potential mutation had 
been identified, verification was sought at the corresponding position on the 
reverse strand. If a potential mutation was identified but could not be 
confirmed, the experiment was completed until a clean trace was produced. 
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Each case was deemed complete when all exonic regions had been assessed 
clearly and without cause for the possibility of a mutation.  
 
Once confirmed on both strands, the position of the mutation was recorded 
and interrogated in dbSNP (National Centre for Biotechnology Information, 
USA) and Ensembl (Sanger Institute, Cambridge, UK) databases. Catalogue 
of Somatic Mutations in Cancer (COSMIC, Sanger Institute, Cambridge, UK) 
databases were also interrogated for mutations identified in DNA extracted 
from tumours. Where mutations were found to be known single nucleotide 
polymorphisms (SNPs), the positional numbers were recorded along with the 
expected frequencies.  
 
Where confirmed mutations were found not to have been previously 
documented in the searched reference databases, the mutation was 
examined in further detail, by modelling the potential amino acid (AA) change 
that would likely come from the mutation and using online tools (PolyPhen 2, 
Harvard, USA) and SIFT (J Craig Venter Insitute, USA) to model the potential 
damaging effect of the mutation. The modelling programmes use certain 
parameters to predict protein shape changes based on the availability of 
known data on mapped mutations as well as understanding of the 
hydrophobic and hydrophilic properties of the wild type and mutated amino 
acid sequences.  	  
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2.5 Whole exome sequencing (WES) 
 
2.5.1 Patient selection  
All exome sequencing was performed at Kings College London as part of a 
bespoke sequencing service and with support from Michael Simpson. DNA 
was extracted by the genetics laboratory at Birmingham Women’s Hospital 
(BWH) from peripherally derived blood leukocytes from selected patients with 
our initial CCH/MTC pedigree family (germline DNA). A DNA shotgun library 
was created by DNA fragmentation and stabilisation using a standard protocol 
for exome sequence library generation as per manufacturer’s instructions 
(Agilent; Santa Clara, USA). Exomes were captured using the Agilent 50Mb 
capture microarray. Sequencing was performed using the Illumina HiSeq 
2000 platform with percentage exome capture reads to >20x depth base 
calling threshold (Illumina; San Diego, CA, USA). Results were expressed as 
a mean base depth read as well as the proportion of the exome that was 
captured above threshold.  
 
2.5.2 Data filtering strategies: bioinformatics approaches  
Multiple strategies are employed in WES data analysis to filter the 20,000+ 
expected mutations from each sample (Ng et al., 2010). The key to successful 
filtering strategies is the application of a logical, scientifically bio-clinical sound 
principle based on what is known already or can be inferred about the 
disease. The strengths and weaknesses of these approaches are considered 
in greater detail in the Chapter 5 discussion. Figures in Chapter 5 show 
	 	 	
	 	 	 	 56	
iterative search strategies based on a no[1]-novo and non-de-novo paradigm. 
In addition to these search methodologies, by identifying a family with rare 
phenotype/genotype relationship we are by default adopting a rare phenotype 
approach. Once candidate mutations had been identified, each was checked 
in turn with variant servers to identify previously described interactions and 
ensure novelty. Searches were performed to ascertain any known biological 
interactions that may be plausible with regard to MTC development. 
Furthermore, evolutionary preservation was recorded and mutations were 
ranked for direct comparison using the grading system shown in Table 8.  
Characteristic Star rating  
Evolutionary preservation * 
Cancer related pathway  * 
MTC related pathway  * 
Mutation likely to cause significant alteration to protein 
structure 
* 
Known oncogene/tumour suppressor gene * 
Table 8. Scoring system for direct comparison of chosen mutations  
 
2.6 Cloning and sub-cloning  
 
Plasmid constructs containing CMV promoter regions for the transient 
transfection into cell lines are an established method of in vitro hypothesis 
testing. Each construct has a tagged region for identification following 
transfection. For each chosen construct the following open reading frames 
were incorporated to allow comparison of WT ERα and WT ERβa/WT ERβb 
ER beta isoform effects to be measured against cells transfected with vector 
only controls. Once wild type constructs had been created and verified by 
Sanger sequencing, mutations were induced in the two ER beta isoforms 
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using specifically designed primers and site directed mutagenesis to mimic 
directly the mutations in ERβ c. 948delT and ERβ p. V128L identified from the 
cohort of patients with MTC. All constructs including those undergoing 
mutagenesis were sequence verified by capillary sequencing prior to use in 
cell models as previously described.  
 
Two specific backbones were chosen (Figure 18: Origene, Rockville, Ma, 
USA). Initially, pCMV6-Entry vectors were used but were problematic in 
experiments using the c. 948delT mutation due to suspected premature stop 
codon and the inability to therefore detect C terminal Myc tagged product.   
Wild type ERβ plasmids were created using the following protocol.   
 
Figure 16. pCMV6 vector maps N and C terminal tagging  
 
2.6.1 Open reading frame generation by cDNA amplification  
cDNA libraries were created using reverse transcription chemistry kit (Life 
Technologies, Paisley, UK) from pre-held RNA libraries as per manufactures 
instructions. Multiple RNA libraries were searched to find a line in which ESR1 
and 2 were expressed with the best being chosen for amplification. Exonic 
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primers were designed to amplify the appropriate section of RNA and to check 
the final sequence and ensure pre-existing ESR mutations were not present 
or induced the amplification process. 
Reverse transcription 1  
Ramdon primers  0.5ul 
RNA 1ul 
dNTPs 1ul 
dH2O 10ul 
Total volume 13ul 
Table 9. Reverse transcription 1 
The mixture was denatured at 65°C for 5 minutes before incubating on ice for 
>1min, before adding reagents listed in RT2.  
Reverse transcription 2  
X5 Stranded buffer 4ul 
0.1M DTT 1ul 
Superscript III 1ul 
Table 10. Reverse transcription 2.  
The reagents were mixed by pipetting  
Reverse transcription 
cycling parameters  
 
Incubate 25°C 5min 
Incubate 50°C 30-60min 
Incubate 70°C 15min 
Incubate 12°C Forever 
Table 11. Reverse transcription cycling parameters.  
 
2.6.2 Digestion reaction  
Plasmids and open reading frame were digested using complementary 
restriction enzymes (New England Biosciences, MA, USA) to match ESR1 
and ESR2 gene created complementary products for ligation to ultimately 
allow ORFs to be incorporated into the plasmid. Initial digestion of both 
pcDNA and CMV Flag plasmids were as follows.   
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Digestion reaction 2 ORF for 
pCMV6-Entry 
 
Hind III 2ul 
BamH1 2ul 
Buffer E 4ul 
DNA 30ul 
dH2) 2ul 
Total 40ul 
Table 12. Digestion reaction 1 
Digestion reaction 4 ORF for 
pCMV6-Entry 
 
Hind III 2ul 
BamH1 2ul 
Buffer E 4ul 
CMV flag 1ul 
dH20 4ul 
Total 10ul 
Table 13. Digestion reaction 2 
 
Restriction enzymes, reagents and DNA were incubated at 37°C for 4 hours. 
Products were separated and as such purified from unwanted DNA and 
reagents by gel electrophoresis and checked for correct product size against 
1kb DNA ladder (Generuler, Thermoscientific, Paisley, UK).  
 
2.6.3 Gel purification and extraction  
Products were run out on 2% agarose gel blocks created as previously 
described using a 30ul well with equal volumes of product and DNA loading 
buffer. Gel electrophoresis was carried out at initially at 100mv for 10min 
before increasing to 180mV for enough time to adequately separate the 
ladder and allow an estimate of mass quantification against the 1kb DNA 
ladder. Once separated, the gel block was transferred to a dark room and 
visualised under a UV light to identify the appropriate DNA band to be 
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extracted. Bands were cut using a scalpel as close to the band as possible to 
reduce the likelihood of unwanted DNA capture and quantity of gel product to 
be removed by the extraction.  
 
Gel extraction was performed using a gel extraction kit following the 
manufacturers protocol (Qiagen; Hilden, Germany). In brief, following band 
excision the fragment was weighed and added to a microcentrifuge tube with 
6 volumes of supplied buffer (QG) prior to incubation at 50°C for 10min or 
until the fragment had completely dissolved. The mixture was vortexed 
periodically during incubation to ensure adequate mixing. The colour of the 
mixture was checked prior to proceeding. As the QG buffer contains indicator 
yellow at pH 7.5, orange mixture after dissolution was mixed with 10ul 3M 
sodium acetate pH 5.0 until the mixture resembled the colour of the initial 
buffer. Isopropanol was then added to the mixture to an equal v/w ratio of the 
initial gel block: 1ul per mg. The mixture was then placed in a micro-centrifuge 
into the manufacturer-supplied, DNA binding tube and spun at high speed 
(>10, 000 rpm) the flow-through was discarded and the step repeated as 
necessary until all of the dissolved mixture had passed though the membrane. 
Additional wash steps were then applied to the DNA binding column to 
remove traces of agarose and salts that may impair further reactions, each 
time spinning at high speed. Finally, the DNA was eluted in to a clean micro-
centrifuge tube using 30ul of 10mM TRIS-CL, pH 8.5 placed directly on the 
membrane for 1 min prior to high speed centrifugation for an additional 
minute. DNA concentrations of the eluted product were measured using the 
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Nanodrop® ND-1000 spectrophotometer on DNA settings (Thermo Scientific, 
Willmington, DE, USA).  
 
2.6.4 Ligation reaction  
Purified plasmids and open reading frames (ORF) were ligated under the 
following conditions. Ligation conditions were calculated (quantity of ORF in 
ng was calculated for a 1:1 ORF to plasmid ratio) using the following equation.   
 
 
Insert length (base pairs) x Vector mass (ng)  = Insert mass 
(ng) 1:1 ratio 
             Vector Length (base pairs) 
 
Although it is generally recommended that an ORF to plasmid ratio of 3:1 is 
optimal for ligation, conditions were optimised by running multiple experiments 
and controls with varying ratios of ORF to plasmid. Each combination of ORF 
to vector was run in the ratios 1:1, 1:2, 1:3 and 1:6.    
 
Ligation reaction  
T4 ligase 1ul 
Buffer 1ul 
dH2O Up to 10ul 
DNA insert Variable depending on ratio 
DNA vector Variable depending on ratio 
Table 14. ligation reaction  	
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2.6.5 Bacterial transformation  
Silver competent cells were used to transform ligated ORF containing 
plasmids for maxi preparation under the following conditions. 10ul of ligated 
product was mixed with 100ul of DH5α (silver competent e coli cells thawed 
for -80 on ice for 20min: Life Technologies, Paisley, UK). Plasmids and 
bacteria were gently mixed by swirling and incubated on ice for 30min. A heat 
shock was performed to encourage bacterial uptake of plasmid using a heat 
block set at 42°C for 45 sec. The mixture was then incubated on ice for 2 min 
prior to adding 500ul of prewarmed super-optomised[2] media (SOC, Sigma 
Aldrich: St Louis, USA) 20g/l Tryptone, 5g/l yeast extract, 4.8g/l MgSO4, 
3.603g/l dextrose, 0.5g/l NaCl, 0.186g/lKCl) for transformation and incubating 
at 37°C for 60-90min. The mixture was pelleted by gentle centrifugation at 
1000rpm for 1min. The supernatant was removed and the pellet re-suspended 
in 150ul of SOC media prior to plating and spreading on pre-prepared, 
prewarmed Luria Bertani (LB) agar (Sigma Aldrich: St Louis, USA) plated with 
Ampicillin at a ratio of 1:1000. Plates were incubated overnight at 37°C. 
 
After overnight incubation, colonies were picked using a sterile pipette tip and 
placed in 2mls LB broth with ampicillin 1:1000 and incubated overnight in a 
rotatory incubator at 220rpm at 37°C to create a starter culture.  
 
Following overnight incubation, 1.5ml of starter culture was harvested for mini 
prep and sequencing to verify the ORF, promoter region and ensure no 
inadvertent mutations had been induced. Once confirmed the cultures 
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containing the correct sequence ORF and promoter regions were selected for 
maxi prep and purification. 		
2.7 Site directed mutagenesis  
 
Once wild type plasmid backbones had been established and checked by 
capillary sequencing, site directed mutagenesis was performed using a 
standard kit (Agilent II XL SDM, Santa Clara, USA) to induce the mutations c. 
948delT and p. V128L. The kit uses a process of PCR amplification with 
primers specifically designed to induce to desired mutation. Following plasmid 
dsDNA denaturing, mutagenic primers are annealed to the template backbone 
and extended using DNA polymerase. Dpn I endonuclease is then used to 
digest parental template DNA by digesting methylated and hemi-methylated 
DNA thus selecting for non-mutated DNA.   
 
Specific primers were designed using the following protocol as recommended 
by the manufacturer for SDM primer design. The primer designing software, 
Primer X, web-based package was used to create a primer pair with 10-15 
bases of normal sequence either side of the mutation (deletion or single base 
change)(Primer X; bioinformatics.org). Primers were designed to anneal to 
either strand of the ORF with its plasmid backbone such that the mutations 
were in the same position. Recommendations for primer design include 
primers of 15-25bp length to minimise the risk of secondary structure creation 
and melting temperature of >78°C. Primers designed on Primer X were 
checked against the following equations for single base deletion and base 
	 	 	
	 	 	 	 64	
substitution respectively where the value N is the length of the primer in base 
pairs as previously described. Further, primers with 10-15 bp either side of the 
mutation and >40%GC content ending in multiple C or G bases are favoured. 
Primers were purified prior to use using polyacrylamide electrophoresis 
(PAGE) to increase annealing efficiency.  
 
Tm = 81.5 + 0.41(%GC) – (675/N) 
Tm = 81.5 + 0.41(%GC) – (675/N) - %mismatch  
 
A control reaction was set up as per the manufacturers instruction using the 
supplied control plasmid and predesigned primers. The control allows an 
assessment of the success of cycling and digestion stages of the experiment 
colony assessment and picking.  
 
Site directed mutagenesis reaction  
10 X reaction buffer  5ul 
dsDNA template 15-45ng (1-3ul) 
Forward primer 125ng 
QuikSolution 3ul 
Reverse primer 125ng 
dNTP mix 1ul 
dH2O Up to 25ul 
Table 15. Site directed mutagenesis  
 
1ul (2.5U/ul) of Pfu Ultra HF DNA polymerase was then added  
 
In the control sample, the control plasmid primers were substituted and 
cycling parameters adjusted to plasmid specific length to enable adequate 
extension.   
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SDM cycling parameters  Cycles  Time 
Incubate 95°C 1 1 min 
Incubate 95°C 1 50 sec 
Incubate 60°C 1 50 sec 
Incubate 68°C 1 1 min/kb plasmid length 
Incubate 68°C 1 7 min 
Incubate on ice for 2 minutes following thermal cycling  
Table 16. Site directed mutagenesis cycling parameters  
 
2.7.1 Amplification of selected plasmids to verify sequence and for use I 
in-vitro work (mini and maxi prep.)  
In order to determine which of the selected colonies contain the correct 
plasmid and insert and to ensure that additional mutations had not been 
introduced during the cloning process, DNA purification was performed from 
overnight colony cultures. Purified DNA was then sequenced using previously 
described methods. DNA purification was performed using a kit designed for 
use with a micro-centrifuge using the manufacturers protocol (Qiagen Spin 
Miniprep)(Anon, n.d.). In brief, starter cultures were created by picking a 
single colony from an antibiotic selective agar plate incubated for 18 hours as 
previously described. After overnight incubation, colonies were picked using a 
sterile pipette tip and placed in 2mls LB with ampicillin 1:1000 and incubated 
overnight in a rotatory incubator at 220rpm at 37°C to create a starter culture. 
Bacterial cells were harvested (from 1ml of starter culture) by centrifugation in 
a 1.5ml bench top microcentrifuge tube at 8000rpm for 3min. The remaining 
starter culture was catalogued and stored a 4°C until sequencing had been 
completed and to provide starter culture for maxi preparation if confirmed 
successful.  
 
	 	 	
	 	 	 	 66	
Pelleted bacterial cells were re-suspended in 250ul of re-suspension buffer 
(P1) including RNase and mixed to ensure no clumping of bacterial material. 
The bacterial cells were then lysed with an equal volume of lysis buffer 
(NaOH/SDS: buffer P2) to release cellular contents including chromosomal 
and plasmid DNA, RNA and cellular proteins all of which are denatured. 
Following neutralisation with 350ul of buffer N3, which contains high salt and 
enables plasmid DNA to renature whilst other cellular debris including 
chromosomal DNA to precipitate, the solution was placed in micro-centrifuge 
at high speed (13,000rpm) for 10min. The precipitated lysate material forms a 
white pellet with plasmid DNA remaining in suspension in the supernatant. 
The supernatants were then added to the silica containing spin tube and 
plasmid DNA adsorbed onto the membrane by centrifugation at high speed for 
1 min. A series of wash steps were then performed to remove nucleases and 
reduce the salt content prior to elution as per manufacturer’s instructions. 
Finally, the purified plasmid DNA was eluted into a clean micro-centrifuge 
tube using 50ul of 10mM Tris-Cl, pH8.5, & left standing for 1 min prior to 
centrifugation at high speed for 1 minute.  
 
2.7.2 Maxi preparation and sequencing  
Once the starter culture integrity had been confirmed by sequencing of 
plasmid[3] DNA purified using the mini prep technique outlined (Sigma Aldrich: 
St Louis, USA). Maxi preparation of plasmids works on a similar principle to 
mini preparation including, alkaline lysis, precipitation of non-plasmid lysate 
products and plasmid DNA binding by resins which can then be washed and 
desalted prior to elution. In brief, starter culture as previously described was 
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diluted to 1 in 500 in 100ml antibiotic selective LB media in a large conical 
flask Ampicillin 1 in 1000). The flask was incubated overnight at 37°C for 16 
hours, with vigorous shaking at 220 rpm. Cells were harvested from the media 
by centrifugation at 6000 x Gravity (G) for 15min at 4°C and decanting and 
discarding the supernatant. Cells were re-suspended in 10mls of the 
manufacturers buffer (P1) containing RNase in a 50ml flacon tube. Lysis of 
the bacterial cells to release the cellular contents was achieved by adding 
10ml of lysis buffer (P2) and gentle mixing to avoid inadvertent chromosomal 
DNA shearing that could contaminate the purified plasmid. Precipitation of 
chromosomal DNA, RNA and cellular proteins was achieved by gentle mixing 
of 10mls of chilled precipitation buffer after which a floating white material 
could be observed. The supernatant was separated from the precipitated 
product by centrifugation at 20,000 x g for 4°C.  
 
The plasmid binding resin column was prepared by applying 10mls of the 
equilibration buffer and flow to be driven by gravity. The supernatant was then 
added to the activated resin and allowed to flow through by gravity. Two salt 
removing wash steps were then applied to the bound plasmid DNA prior to 
elution in 15mls of manufacturer supplied elution buffer (buffer QF). The DNA 
was then further precipitated by adding 10.5mls of isopropanol prior to 
centrifugation at 15,000 x g at 4°C for 30min. The supernatant was removed 
and discarded prior to the pellet being washed in 5ml of 70% ethanol 
centrifuged for 10min at 15, 000 x g. after decanting and discarding the 
supernatant the DNA pellet was air dried for 10min and eluted in 10mM Tris-
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Cl, pH 8.5. Concentration was determined using spectrophotometry as 
previously described.   
 
2.8 Cell culture  	
MCF7 cells were kindly supplied by Professor CJ McCabe (School of Clinical 
and Experimental Medicine, UoB, UK). MCF7 cells maintained in RPMI 1640 
media (Sigma-Aldridge, Poole, UK) supplemented with 1% Pen/Strep 
(Penicillin/Streptomycin: Invitrogen, Paisley, UK), 1% L-Glutamine (Life 
Technologies, Grand Island, NY, USA) and 5% Fetal Bovine Serum (FBS) 
and passaged twice weekly. T47D were maintained in Delbecco’s modified 
Eagles Media (DMEM) supplemented with 10% sterile FBS 1% Pen/Strep and 
1% L-Glutamine. All transfection experiments were carried out between 
passage 20 and 40 after which cells were discarded. Cells were maintained 
as a monolayer in T75 flasks at 37 ̊C in an incubator with 5% CO2. On 
passage, the media was removed and cells washed with 5mls of sterile PBS. 
Cells were trypsinised with 1ml 0.25% trypsin and incubated for 5 minutes at 
37 ̊C prior to being loosened and re-suspended in media. Cell counts were 
performed using cell counting slides. Cells were seeded at a concentration of 
150,000 and 75,000 cells per well in 6 and 12 well plates respectively. 
Optimum seeding count varied between experiments although cells were only 
transfected on reaching 50-60% confluence under the following conditions. TT 
cells were maintained in Ham’s F12 media (Life Technologies, Grand Island, 
NY, USA) supplemented with 10% sterile FBS but were otherwise managed 
as pre MCF 7 cells.   
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Reagent/plasmid  
LT1 6ul 
Optimem 200 µl  
Plasmid 2 µg 
 
The transfection reagent LT1 (Mirus Bio, Madison, WI, USA) was allowed to 
reach room temperature for 20 minutes prior to use as per manufacturers 
guidelines (Anon, n.d.). Reagents were mixed gently in 1.5ml centrifugation 
tubes for 25 minutes in sterile conditions prior to transfection. Transfection 
reagent containing media was changed for fresh media 5 hours post 
transfection. To lyse and harvest, the media was removed and washed with 
sterile PBS. Cell lysis and protein harvest was performed using 150µl 
radioimmunoprecipitation assay (RIPA (150 mM NaCl, 1.0% IGEPAL® CA-
630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0)) buffer 
supplemented with a premixed cocktail of protease inhibitors to specifically 
inhibit serine, cysteine and aspartic proteases, and amidopeptidases (6%: 1.5 
mM Pepstatin A, 104 mM 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF) 
80 µM Aprotinin, 1.4 mM E-64, 2 mM Leupeptin, 4 mM Bestatin, in dimethyl 
sulfoxide (DMSO). 
 Cell plates were incubated at -20 ̊C for a minimum of 30min. Lysed cells and 
protein were harvested from the cell plate using a rubber policeman and the 
solution transferred to a clean micro-centrifuge tube prior to centrifugation at 
13,000 RCF at 4 ̊C for 10 minutes. The supernatant was decanted into a 
clean micro-centrifuge tube and the pellet consisting of cellular debris, 
discarded.  
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2.9 Western blotting  
2.9.1 Preparation of polyacrylamide gel for protein electrophoresis 
Corresponding glass slides and gel combs were selected to produce a 
polyacrylamide gel 2mm thick (SDS-PAGE). Western blotting apparatus 
(BioRad) were set with glass side holders up and tested for leaks by filling 
with water. 12% polyacrylamide gels were used in all experiments. The 
resolving gel was prepared using the recipe in table 1 with 
Tetramethylethylenediamine (TEMED) and APS (ammonium persulphate) 
which, together, catalyse the polymerisation of acrylamide. TEMED and APS 
are added just prior to pouring to allow sufficient time to pour all gels before 
the acrylamide polymers form and the gel sets. The quantities shown in table 
one were sufficient for two gels. Resolving gels were poured between glass 
slides to a point just below where the comb sits when fitted. Once poured, 
50% methanol was added to the top of the gel prior to setting to encourage an 
even spread of gel and remove any bubbles which may affect the direction in 
which the proteins migrate during electrophoresis. Resolving gels were left in 
the apparatus at room temperature for 30 min. Stacking gels were made using 
the recipe in table 18 and 19, again omitting the TEMED and 10% APS until 
the end to prevent premature setting of the gel. The methanol was removed 
from the top of the resolving gel and the stacking gel poured on top prior until 
the recess between the glass slide was full. The comb was then placed into 
the non-set stacking gel and any excess displaced gel removed. Again, the 
gel was left at room temperature for 30 min to fully set. Once set the combs 
were removed and the wells rinsed with 1 X running buffer and checked for 
integrity prior to protein loading. 
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Acrylamide resolving gel for western blotting (12% gel)  
dH2O 4.935ml 
1.5M Tris-HCl pH 8.8 3.75mls 
Acrylamide  6ml 
10% SDS 150ul 
TEMED 15ul 
10% APS 150ul 
Table 17. Western blotting 1 
Acrylamide stacking gel for western blotting (5% gel)  
dH2O 2.71ml 
0.8M Tris-HCl pH 6.8 1.25mls 
Acrylamide 833ul 
10% SDS 100ul 
TEMED 10ul 
10% APS 100ul 
Table 18. Western blotting 2 
 
2.9.2 Protein preparation and loading  
Protein concentration was estimated using the bicinchoninic acid (BCA) 
colcorimetric assay kit  (Pierce) where protein from each experiment is 
compared against a reference standard using a spectrophotometer or 
microplate reader (Victor 3 1420 Multi-label counter, Perkin Elmer). 
Coomassie Brilliant Blue G-250 dyes bind to protein in a stable manner 
altering the wavelength of light absorbance from red in acidic conditions (A 
max = 470 nm) to blue when protein bound A max = 595 nm) in which form it 
can be detected. In ideal systems, the reference standards are purified and 
calibrated versions of the protein of interest however in the absence of these, 
we used purified bovine serum albumin (BSA) as a surrogate standard 
against which to measure our extracted protein.  
 
Protein estimation was performed using duplicate wells of protein extracted 
from each experiment compared against 10 duplicate reference standards. 
The standards ranged from 0.0 to 5.0mg/ml of BSA and were arranged in a 96 
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well plate suitable for analysis in a micro plate reader (Wallec: 560 nM 
absorbance setting).  In each well, 80 ul of manufacturers solution (Buffers A 
and B in a ratio 50:1) was added followed by a further 4ul of either protein 
standard BSA or protein extracted from cell lysis. Once the protein had been 
added the plate was incubated at 37°C for 30 min prior to placing on the plate 
reader. By plotting the standards absorbance against concentration, a 
standard curve can be generated against which experiment protein 
concentrations measured. By plotting the absorbance of the sample protein, 
an estimate of protein concentration can be made. Using there[4] estimates of 
concentration allows an equal quantity of protein to be loaded in each well 
prior to electrophoresis such that ultimately, quantitative measures of relative 
protein expression can be made between differing experiment conditions. 
  
The set gels were transferred to electrophoresis chamber and the dam filled 
to the level specified by the number of gels with 1 X running buffer. 15-30 ug 
of protein was denatured by incubating with loading buffer (lamelli buffer: 
Biorad with DTT (50mg/ml) at 95°C for 5 min. Samples were then mixed with 
loading buffer and loaded into the appropriate wells in the polyacrylamide 
gels. A protein ladder was used to confirm presence or absence of proteins of 
the appropriate size (Precision Plus Protein Standards: Biorad). The 
apparatus was topped up with running buffer and the apparatus run at 70mV 
until the samples and ladder had progressed through the stacking gel. Once 
in the resolving gel the voltage was increased to 110mV-130mV and run until 
the loading dye reached the bottom of the gel. 
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2.9.3 Protein transfer onto nitrocellulose membrane 
Polyvinylidene difluoride (PVDF) membranes were cut to the appropriate size 
and activated with 100% methanol for 30s prior to use. Transfer cassettes 
were loaded with fibre pads, filter paper, polyacrylamide gel, PVDF 
membrane, filter paper and further fibre pads. All contents were thoroughly 
soaked in transfer buffer prior to use. The cassettes were closed and placed 
in the transfer apparatus. The apparatus was filled with transfer buffer and 
cooled by adding an ice block before running for one hour at 350mA. In this 
time protein from within the gel is able to pass down an electrochemical 
gradient and onto the PVDF membrane which avidly and non-specifically 
binds protein and will display on probing, proteins in the relative position as 
they were in the gel. Once transfer had completed, the membranes were 
blocked with TBS-T 5% non-fat milk (Marvel) for 2 hours. TBS-T was replaced 
with TBS-T 5% milk and primary antibody at a concentration specified in each 
experiment. Blocked membranes were incubated with primary antibody on a 
mobile agitator overnight at 4°C.  
 
After overnight incubation with the primary antibody (specific to the protein of 
interest), the membrane was washed with TBS-T for 15 min on a mobile 
agitator for 1 hour with four changes of TBS-T during that time. The 
membrane was then incubated at room temperature with secondary antibody 
(specific to the primary antibody and containing detectable horseradish 
peroxidase: HPA) in 5% milk TBS-T for 1 hour. Further washing for one hour 
was then performed, washing with TBS-T with changes every 10 minutes (six 
in total). 
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Running buffer   
dH2O 4.935ml 
1.5M Tris-HCl pH 8.8 3.75mls 
Acrylamide  6ml 
10% SDS 150ul 
TEMED 15ul 
10% APS 150ul 
 
Transfer buffer  
dH2O 4.935ml 
1.5M Tris-HCl pH 8.8 3.75mls 
Acrylamide  6ml 
10% SDS 150ul 
TEMED 15ul 
10% APS 150ul 
 
2.9.4 Developing nitrocellulose membranes following antibody 
incubation 
Membranes were developed using ECL plus (Pierce: Thermo Scientific) as 
per manufacturers recommendations (Anon, n.d.). In brief, membranes were 
face up on sheets of cling-film and patted dry with paper towels.  ECL 
reagents, which, when combined react with HRP to produce a 
chemiluminescence detectable on exposure to camera film, were premixed in 
a v/v ratio Buffer A: buffer B = 40:1. Approximately 500ul of the mixed ECL 
solution was applied to each membrane and gently spread with a pipette tip to 
ensure even spread and remove bubbles. The membranes were incubated at 
room temperature for 5 min after which excess developing solution was 
removed and the membrane secured and sealed in a clear plastic wrap. 
Membranes were developed in a dark room using Xray film (Kodak Biomax, 
Sigma Aldrich: St Louis, USA) and chemical developer. The length of 
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exposure between the membrane and the film was varied using a standard 
protocol tailored to the individual developing characteristics of each 
membrane.  
 
Once developing of the protein of interest was complete, the membranes 
were washed as previously described and then re-probed for Beta actin 
(primary antibody) and the appropriate HRP conjugated secondary antibody 
(see table). As Beta actin binding was so strong, re-probing membranes 
without first stripping and re blocking caused no problems with interpretation.   
Primary antibodies  Manufacturer Animal  
ERα  Abcam (ab37438) Rabbit  
ERβ Abcam (ab288) Rabbit 
MYC Cell signalling  (2272) Rabbit  
RET New England Biolabs 
(C31B4) 
Rabbit 
Table 19. Antibodies for western blotting  	
2.10 Immunofluorescence  
 
Cells were cultured and transfected under standard conditions as previously 
described. The media was removed and cells were washed with 1ml sterile 
PBS. Cells from 6 well plates were fixed in 800ul of fixing solution (see table 
21) and incubated at room temperature for 20min. 
Fixing solution for Immunofluorescence   
0.2M NaHPO4 corrected to pH 7.4 
(Corrected with 0.2M NaH2PO4) 
20ml 
2% PFA 0.8g 
2% Glucose 0.8g 
0.1%sodium azide 8mls 
dH2O 12mls 
Table 20.Fixing solution for immunofluorescence  
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Once fixed, cells were rinsed twice with sterile PBS. To make cells more 
permeable, 800ul methanol (100%) was added to each well and left to 
incubate at room temperature for 10min. Two further washes with sterile PBS 
were then performed prior to blocking with 800ul of 10% NCS (in PBS) for 30 
min. 80ul of primary antibody was prepared with 80ul 1% BSA (in PBS) for 
each coverslip. An aliquot of the solution was then added to parafilm and each 
coverslip lowered face down onto the antibody. Antibody treated coverslips 
were incubated at RT for 1 hour in the dark. Cover slips were returned to 6-
well plates and rinsed three times with sterile PBS.  
 
Secondary antibodies (1:1250) were prepared in 80ul aliquots of 1% BSA (in 
PBS) with 1% NCS (Alexa Fluor 488-conjugated goat anti-mouse IgG and 
Alexa Fluor 594-conjugated goat anti-rabbit IgG: Invitrogen). Hoescht stain 
was then added at 1:1000. 80ul aliquots of solution were added to parafilm 
and coverslips lowered onto the solution. Incubation for 1hr at RT in the dark 
was then performed. Coverslips were then returned to 6 well plates prior to 
washing with sterile PBS three times. Coverslips were blotted prior to 
mounting on slides using Dako Flourescent Mounting Medium and left to dry 
in the dark for 2hours at 4°C.     
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2.11 mRNA Expression  	
Cells were maintained and passaged as previously described. To measure 
mRNA expression real time chemistry was employed. RNA was extracted 
following 24-48 hour transient transfection using an RNA extraction kit 
(RNeasy: Qiagen, Hilden, Garmany). In brief, cells were cultured in 12 well 
plates to avoid having too much RNA for the extraction technique (<107 cells). 
Cells were lysed in situ using the using the manufacturers buffer (RLT) and 
ethanol in volumes approximated to the number of cells present in each well. 
 
To release the maximum quantity of RNA from cells and organelles, lysates 
were disrupted and by passing through a homogeniser in a microcentrifuge at 
high speed for 2 min (QIAshredder, Qiagen, Hilden, Germany).  Once 
homogenised, 1 volume of 70% ethanol was added and mixed by pipetting 
prior to transfer to a RNA purifying microcentrifuge column, centrifuging for 15 
sec at >8000 x G. The flow through was discarded and the silica-trapped RNA 
in the spin columns was washed as per protocol using the supplied buffers at 
the described spin speeds to initially ethanol purify and then ethanol remove 
from the sample. Once complete the RNA was eluted into a clean micro 
centrifuge tube in nuclease free water and stored at -80°C until required.   
 
RNA concentration from each experimental condition was measured using the 
Nanodrop ND-1000 spectrophotometer on RNA settings prior to reverse 
transcription. Sterile H20 was added to 0.5ug RNA to a total volume of 4.9ul. 
Samples were incubated at 70°C for 10 minutes prior to pulse spinning and 
incubation of ice. A mastermix for RT-PCR was prepared using manufacturers 
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supplied products and mixed gently by pipetting adding the RNasin and AMV 
last and keeping on ice throughout (Promega; Madison, WI USA).  
RT PCR master mix  
MgCl2 2ul 
10xRT buffer 1ul 
dNTPs 1ul 
Random Primers 0.5ul 
RNasin 0.25ul 
AMV 0.3125 
  
An aliquot of 5ul of master mix was added to each RNA sample and incubated 
at room temperature for 10min prior to placing on PCR block under the 
following conditions.  
RT PCR  
I hour  420C 
5 min 950C 
5 min 40C 
 
The samples were pulsed and spun again prior to adding 30ul of H20 to give a 
final concentration of cDNA approximately 12.5ug/ul. Samples were stored at 
-20°C prior to use. 25ng of cDNA was used in each real time assay (see 
Chapter 7).  
 
2.12 Immunohistochemistry 
 
Immunohistochemistry was carried out on our behalf by the pathology labs at 
UHB using an automated system as per manufacturer’s instructions (Leica 
Bondmaz Immunostainer; Protocol F). 10 micron slides of tumour and normal 
tissue were cut for immunostaining and also for FFPE DNA and RNA 
extraction. Antibodies for immunohistochemistry were optimised prior to using 
on study tissue using breast and uterine controls. Antibodies (Novocastra 
Lyophilized Mouse Monoclonal Antibodies) were purchased from Leica 
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Microsystems. Tumour and normal slides were identified by re-examination of 
the H and E stained slides from corresponding blocks. Samples were 
deparaffinised by DEWAX using manufacturers protocol prior to rehydration 
with PBS. Samples were then immersed in distilled water.  
 
In brief, the manufacturers protocol includes a 20 minute heat induced epitope 
retrieval stage, undertaken at 90oC with an EDTA based buffer (Ph 9). 
Peroxidase was then added and incubated for 10 minutes to remove 
endogenous peroxides that may induce false positives. Once completed the 
slides were washed again in PBS. 
 
A set volume of 150µl of primary antibody ERbeta was added as per 
manufacturer’s instructions with an optimised dilution ratio of 1:50 using 
manufacturer’s antibody diluent. The antibody was then incubated on the slide 
for 15 minutes prior to two washings with PBS. Each wash step was 
performed for 5 minutes. The slides were then incubated with a mouse 
secondary antibody conjugated with horseradish peroxidise for 10 minutes. 
Again, slides were washed twice with PBS for 5 minutes per wash.  
 
2.12.1 Chromogenic reaction  
Slides were incubated in DAB after which the slides were washed in distilled 
water and then counterstained with Hematoxylin for 5mins. Once 
counterstained the slides were dehydrated in 75%, 80%, 95% and then 100% 
ethanol. Slides were then cleaned in Xylene prior to a cover slip being applied 
using DPX. 
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Chapter 3.  
 
Project design recruitment and collaboration 	
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3.1 Introduction 	
Although specific data on the incidence of MTC is not freely available on any 
of the public access cancer registries, the estimated incidence of MTC is 
around 3-5 per million or approximately 120 new cases per year in the UK. In 
the US there have been significant inroads into improving the investigation 
and research opportunities for people with rare or orphan diseases, defined 
as diseases with incidences <1 in 200 000 population and as such not 
commercially viable for drug development (Brewer, 2009). Significant funds 
have been made available and in addition, collaborations aiming to bring 
together researchers and patients (Wellman-Labadie and Zhou, 2010).   
 
Rare diseases pose specific problems in terms of research, not least in 
attracting funding for research and development of new therapeutics. Indeed, 
government funding is often required in such areas due to a lack of 
commercial interest (Commissioner, n.d.). The involvement of governmental 
organisations and well as governmental policy has, led to significant 
improvements and opportunities for research in rare disease, especially in 
collaboration with patient advocacy groups (Groft and Rubinstein, 2013). In 
the study of rare diseases, including this study, recruitment and strategies of 
data collection and capture are of vital importance if clinical data are to reach 
an appropriate numerical level to allow intra-cohort analysis.  
 
In the study of rare disease a number of well described methods are available 
for maximising the impact of research projects both in terms of their overall 
ability to draw conclusions and in applicability of those conclusions to the 
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populations being studied (DeWard et al., 2014). Firstly, rare diseases often 
have specific medical and surgical needs, access to which is not available in 
every centre. Using MTC as an example, patients often present with complex 
surgical needs or need revision surgery for recurrent disease; evidence 
supports improved outcome in these patients if managed in larger centres 
with high throughput (Smith, Watkinson and Shaha, 2012). Furthermore, the 
complexity of MTC with regard to the genetics and contact tracing[5] again can 
usually only be supported in larger centres with access to regional genetics 
services (Groft, 2013). As such, many of these rare conditions coalesce 
naturally towards larger or tertiary centres and within those centres towards 
individual practitioners and small collaborating groups (Richard Gliklich and 
Leavy, 2011). The head and neck surgical department and clinical genetics 
department collaboration for MTC and skull base tumours in Birmingham are 
an example of this.  
 
By identifying individual clinicians with a special interest in the disease it is 
possible to capture a large number of patients who are often regular 
attendees to follow-up and review clinics in these centres. MTC by its nature 
requires long-term or even lifelong follow-up with calcitonin monitoring and in 
some cases, serial imaging to monitor treatment response and recurrent 
disease (Kloos et al., 2009). The added advantage of approaching clinicians 
in tertiary centres is that patients under long-term review by clinicians with a 
special interest in their disease often have good relationships with their 
practitioners and as such are well motivated to take part in research project 
that may directly or indirectly benefit them (DeWard et al., 2014). Secondly, 
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practitioners with special interest often maintain databases of patients treated 
by their department and as such may have further access to patients not 
routinely seen in clinics or whom their local departments follow routinely 
(Richard Gliklich and Leavy, 2011). Access to databases as a point of contact 
has the potential to allow large numbers of patients to be contacted at a single 
point in time rather than recruiting through direct contact in the clinical setting.  
 
As well as medical practitioners and patient databases held within hospital 
departments, patients with medical issues and in particular, rare diseases are 
increasing forming their own groups and linking with charitable organisations. 
Patient advocacy groups have helped shift the debate and focus 
governmental departments and researchers towards their needs (Dunkle, 
Pines and Saltonstall, 2010). Often these groups form research registers and 
put themselves forward to be involved and studies have reported success in 
recruitment by accessing patient lead databases (Richard Gliklich and Leavy, 
2011). As a self-selected highly motivated group they can be useful point of 
contact for recruitment as well as dissemination of information regarding 
research around their own communities. The facilitation of interest in these 
groups has been made easy with the advent and uptake of social media and 
indeed some studies have recruited using only these methods (Schumacher 
et al., 2014).  
 
Finally, collaborations with groups across the globe have become easier and 
many groups have stored samples collected from previous projects that are 
amenable for analysis in subsequent projects. Forming collaborative links at a 
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global level allows projects to gain numbers quickly as well as widening the 
potential applicability of the results (Gupta, Bayoumi and Faughnan, 2011). In 
genetic terms it may help strengthen mutation searches by looking at DNA 
obtained from more variable and distantly related populations. Furthermore, 
collaboration on single projects often opens avenues to investigate other 
disorders and establishes a foundation for ongoing communication.  
 
3.2 Project design 	
This project aims to use exome sequencing (WES) technology to identify 
novel disease predisposing genes within the context of MTC. Although our 
general hypothesis is that genes other than RET predispose to MTC, 
additional hypotheses regarding the nature of any discovered causative links 
will be subsequently generated by our exome sequencing data. To be able to 
test any generated hypothesis, or to add weight to a theory, we need to be 
able to draw on a cohort of individuals with both familial and sporadic disease 
as well as be able to examine germline as well as somatically derived DNA. 
Individuals who are most likely to have inherited a disease predisposing 
mutation are those with familial disease or sporadic cases where disease is 
diagnosed at a young age (<40 years old at diagnosis). The project design is 
to identify using WES in an index familial non-RET MTC to a panel of 
candidate germline mutations. Identified genes can then be interrogated in 
more detail in other families with non-RET MTC as well as individuals with 
sporadic disease. If other mutations are found within the same genes within 
these two comparator cohorts, this would provide sufficient evidence to take 
that mutation forwards for further interrogation in vitro. This method of 
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hypothesis generation has been shown to be successful in identifying novel 
candidate genes in a number of diseases including kidney cancer and 
phaeochromocytoma (Comino-Méndez et al., 2011).   
 
The first aim of the project therefore was to locate patients with familial non-
RET positive MTC and sporadic young onset disease. We know these are 
likely to be difficult to find and as >95% of families with MEN2 have a RET 
mutation and >85% of FMTC (a rarer clinical entity) also have disease 
predisposing RET mutations (Perros, Boelaert, Colley, Evans, Rhodri M 
Evans, et al., 2014c). In addition to this, our understanding of the role of 
disease predisposing mutations in cancer is best exemplified by breast cancer 
where the BRCA1/2 genes make up the majority of disease causing mutation 
in families with breast cancer predisposition and the remaining disease 
causing mutations consist of multiple mutations of different genes in relevant 
pathways, each making up just a small proportion of the heritable disease 
(Sapkota, 2014)(Lee and Ang, 2014). Clearly, when dealing with a disease 
such as MTC that is several orders of magnitude rarer than breast cancer, the 
likelihood of finding multiple families that can be recruited to the study and the 
chance that those families harbour the same genetic alteration based on the 
experience with breast cancer is significantly reduced. If however, the same 
mutation were found in unrelated families, within this context, it would serve 
as good evidence that that mutation were indeed disease predisposing and 
the same would be true of patients with young onset sporadic disease.  
 
 
3.3 Results  
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3.3.1 RET negative index familial disease  
This study was conceived and followed through by the identification of the 
following family with MTC, CCH pedigree (Figure 18). Disease in the family 
was identified incidentally when a neck mass was identified in the proband 
aged 33, who on attendance to the Accident and Emergency department 
following a road traffic accident. Investigation of the neck lump revealed a 
thyroid tumour which was later found to be medullary thyroid cancer on 
diagnostic lobectomy. The patient went on to have completion thyroidectomy, 
lateral and central compartment nodal clearance. RET testing (sequencing) 
performed at the time of exons 10, 11, 13-16 was found to be negative and as 
such disease was presumed to be sporadic. As the proband has a 
monozygotic twin, investigation was offered in the form of clinical testing, 
calcitonin and pentagastrin stimulation testing with no nodular thyroid disease 
and no overt nodal disease either clinically or on radiological parameters. The 
proband’s twin was found to have elevated baseline and stimulation calcitonin 
and was offered treatment or surveillance. He opted for surgery and was 
found to have C cell hyperplasia with no evidence of frank MTC or nodal 
metastasis.  
 
Based on the finding in the proband twins, cascade testing in the form of 
baseline calcitonin and pentagastrin stimulation was offered to all of the 
offspring of the twin on the basis of increased likelihood of an inherited 
predisposition to CCH/MTC rather than another environmental factor. 
Ultimately, based on clinical testing, elevated calcitonin at baseline or on 
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pentagastrin stimulation and parental preference, all of the five offspring of the 
twins had a prophylactic thyroidectomy before the age of ten.  
 
All histological slides were reviewed by me and a blinded, independent 
pathologist with a special interest in head and neck oncology (Rachel Brown, 
RB). Blocks were re-cut and re-stained where necessary. There was 
divergence from the initial classification in two of the proband’s off spring with 
one case of CCH identified in one prophylactic specimen previously classified 
normal and normal histology classified in a specimen previously defined as 
CCH. The explanation for this lies in the subjective nature of CCH 
confirmation as further discussed in Chapter 7. more important in this case 
was the nature of the initial histological examination that is, the ruling out of 
MTC rather than closer inspection and diagnosis of CCH. Finally, Calcitonin 
staining was not routinely used in the initial staining and assessment of these 
specimens, partly again as the premise of the examination was to rule out 
MTC rather than ruling in CCH, which clearly makes a significant difference in 
the identification of the disease. 
 
It should be noted also that on cascade testing the parents of the proband 
were also offered calcitonin and pentagastrin stimulation and the father had 
an equivocal stimulation test with mildly elevated calcitonin but normal 
imaging and chose not to pursue any further treatment.   
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 Figure	17.	The	index	family.	Proband presented age 22y with a medullary thyroid 
carcinoma. Following clinical work-up (abnormal calcitonin following pentagastrin (PG) 
stimulation (basal calcitonin 14.0, stimulated 105-Neil Gittoes QEH)). Initially the PG 
stimulation had been normal in 1992 and 1998), his monozygotic twin brother, underwent a 
total thyroidectomy age 33y with level 6 neck dissection and C Cell hyperplasia was noted on 
histological review. In view of the diagnoses in these two individuals, the 5 offspring were 
tested and opted to go on to have total thyroidectomy.  From left to right, Child 1 had total 
thyroidectomy in 2008 age 8y – CCH present. Child 2 had some abnormal PG stimulation 
results so total thyroidectomy in 2006 age 4y – CCH. Child 3 had total thyroidectomy in 2008 
age 4y – CCH. Child 4 had equivocal (slightly elevated basal, equivocal following PG 
stimulation) results in 2006 age 5y, so decision made to have total thyroidectomy in 2007 – 
No CCH/MTC. Child 5 Total thyroidectomy in 2010 age 6y – No CCH/MTC  
 
 
3.3.2 Recruitment strategy 
Based on the adopted strategy for recruitment of a comparator cohort, 
patients were recruited directly and other tissue samples accessed by direct 
collaboration. In terms of direct patient recruitment, 54 patients have been 
recruited to date with the majority (48%) coming through direct referral from 
physicians within the UK with local data base searches (28%) and patient 
advocate groups (24%) making up the remainder (Figure 19). 110 DNA 
samples were available in the wider cohort, the majority of which were 
acquired through collaboration with groups in Australia and Spain (42%). A 
significant proportion of tissue samples came through direct referral 
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mechanisms with direct UK clinical referral being the most frequent (28%) 
(Figure 20). The breakdown of these samples into germline DNA and DNA 
extracted from fresh or formalin fixed paraffin embedded tissue as well as the 
relative frequencies in each sub-group of familial and sporadic disease is 
shown in Figure 21. Two additional families with MTC/CCH pedigree were 
identified through collaborations with the Madrid group and included in this 
study (Figure 22). In addition, further families with MTC/CCH pedigrees have 
been identified though the advertisement and recruitment strategy, although 
they were identified too late in the process to have been included for further 
analysis here (Figure 23).     
 
 
Figure 18 and Figure 19. The relative frequencies of patients and DNA/tissue available 
from entry point into the study 
 
28%	
24%	
48%	
Recruitment	to	the	study		
n	=	47		Local	data	base	(BWH/UHB)	Patient	Lead	organisation		UK	clinician	referal		
42%	
16%	14%	
28%	
Access	to	DNA	for	molecular	
testing	
n	=	110		International	collaboration	with	other	interested	groups	Local	data	base	(BWH/UHB)	
Patient	Lead	organisation		
UK	clinician	referal		
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Figure 20. Flow diagram illustrating the number, type and origin of all DNA samples 
used within this study    
 
 
 
Figure 21. Two further RET negative families with MTC and CCH pedigree obtained 
from collaboration with Mercedes Robledo, Madrid.   
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Figure 22. Two further families recruited since the project started with MTC/CCH 
pedigree.  
 
3.4 Sporadic cohort characteristics 	
3.4.1 Age and sex characteristics  
In the recruited cohort, no significant differences were noted when comparing 
age and sex characteristics at presentation between patients with RET 
positive and RET negative disease with a median age of 52 and 60 for RET 
positive and RET negative disease respectively (Table 21). This comparison 
is made after excluding those individuals identified through family tracing. 
Peak age at disease onset was consistent with other series of sporadic MTC 
as was an equal male to female distribution and although there were more 
males than females in the RET negative group in the cohort, the differences 
were not significant and could be explained by relatively small sample size 
(Figure 25).    
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Figure 23. Age range for sporadic and index case RET positive and RET negative 
familial disease.  
 
Disease 
presentation 
Mean age 
(range) 
Median SD p = (paired 
T-Test) 
RET 
Positive  
43.7 (26-52) 52 12.0 - 
RET 
negative  
48.6 (31-72) 60 13.4 0.2 
 
Table 21. Age at presentation for germline RET positive and germline RET negative 
disease  
 
 
Figure 24. Sex distribution of sporadic RET negative and RET positive disease 
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Figure 25. Stage at presentation of sporadic MTC. Figure 26. Clinical presentation of 
disease.  
 
3.5 Presentation and survival  	
In terms of disease presentation in sporadic RET negative and RET positive 
disease presenting as an index case, the vast majority presented with loco-
regional disease (nodular thyroid disease or more commonly regional nodal 
metastasis). There were no differences in disease presentation between RET 
positive and RET negative disease (data not shown here). Although a 
relatively small number in this cohort were identified through asymptomatic 
screening of affected family members, this may reflect the recruitment 
strategy adopted during this study. Distant metastases were an unusual form 
of disease presentation although distant metastases in those presenting with 
loco-regional disease that developed following treatment and follow-up were 
more common.   
 
6%	
12%	
59%	
23%	
Stage	of	disease	at	presentation	
(AJCC,	2007)	
Stage	1	Stage	2	Stage	3	Stage	4	
32%	
52%	
4%	 12%	
MTC	disease	presentation		
Solitary	nodule/thyroid	mass		Local	nodal	disease		
Distant	metastasis	
Asymptomatic/familiy	history		
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Stage I and II disease was an unusual finding in this cohort. The vast majority 
(82%) of disease in our cohort presented with stage III or IV disease. Follow 
up with the cohort (time between disease presentation and the time of 
enrolment in the study) ranged from 2-15 year with a median follow-up period 
of 8 years (SEM 2.5). At the point of enrolment, 27% were alive with no 
documented evidence of biochemical or clinical disease. In a further 27% of 
patients who were alive following treatment, presence or absence of recurrent 
or residual disease could not be established from available clinical records. 
The majority of patients with known status (41%) within our cohort have 
documented evidence of residual or recurrent disease either on clinical or 
biochemical parameters (Figure 28).  
  
 
Figure 27. Disease status at follow up following primary treatment.   	  
27%	
41%	
27%	
5%	
Current	clinical	status		
Alive	Disease	Free		
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3.6 Discussion 
  
3.6.1 Recruitment  
In line with recommendations for studies of rare diseases, the recruitment 
strategy, advertising the project and collaborating has significantly increased 
the number of patients and samples we are able to draw on for the rest of the 
project (Groft, 2013). This gives us the potential to generate more data when 
interrogating genes and gain a truer idea of the frequency of any identified 
mutations. Clearly, at some point, a decision has to be made on a specific 
mutation or small group of mutations to take forwards for in vitro interrogation. 
Being able to draw on a wider cohort may make this significantly less difficult 
as the identification of the same mutation of additional novel mutations within 
the cohort adds weight to genotype/phenotype presumptions. The significance 
of any finding is related to the individual in which the mutation was identified 
and the type of mutation and its predicted effect.  
 
3.6.2 Strengths and weaknesses  
Although recruitment has been successful and indeed as this represents one 
of the largest cohorts of patients with MTC currently under investigation, what 
is somewhat unfortunate is the small numbers of patients in the categories in 
which we would most be most likely to find mutations, that is, familial disease 
and disease of young onset. The implication of limited datasets from which to 
draw direct comparison provides a degree of uncertainty regarding the genes 
taken forward for further interrogation. Ultimately it may have to be accepted 
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that this was likely to be a limitation of the study and could fundamentally 
undermine the ability to prove assertions or fully test hypotheses. However, by 
maintaining the promotional aspects of the study by collaboration and 
advertising and presenting preliminary findings, the hope is to build on the 
current cohort and ameliorate some of the disadvantages of limited cohort 
size. To this end data have been presented at multiple meetings within the UK 
and internationally to raise awareness, whilst continuing to collaborate with 
groups and clinicians to recruit patients. As the project moves forwards and 
we present and publish findings, the hope is to increase on the numbers 
presented here and ultimately provide a repository for the identification of 
multiple mutations important in the development of MTC.   
 
As with novel gene discoveries in more common forms of cancer such as 
breast, over and above the most prevalent mutations (e.g. BRCA1/2), the 
remaining burden of inherited disease is made up from numerous mutations in 
related but ultimately common pathways to those that account for the majority 
of the disease (Haanpää et al., 2013) (Lee and Ang, 2014). We may have to 
accept that as such a large burden of inherited disease in MTC is accounted 
for by RET mutations that all familial cases that do not have either an un-
described RET mutation, novel mutations may be so rare as to be family 
specific. With this in mind it seems unlikely that the same mutation would be 
found in multiple unrelated families based entirely in the scarcity of the 
phenotype. The recruitment of other families to this project however may be a 
starting point for further investigation in the form of whole exome or whole 
genome sequencing ultimately working toward a battery of novel mutations in 
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related pathways from differing families. What is clear is that investigation of 
rare phenotypes of more common diseases always has the potential to add to 
the knowledge and understanding of the molecular biology of cancer 
predisposition and as such has the potential to benefit everyone with that 
disease.    
 
3.6.3 Cohort characteristics  
There are important similarities and differences between our cohort and the 
wider population of patients with MTC that require further examination in order 
to validate subsequent results (Roman, Lin and Sosa, 2006). We observe no 
difference in sex distribution between our cohort of RET negative and RET 
positive patients. This has implication in gene mutation searching and 
assessment of the likelihood of mutations causing disease. It would for 
example be reasonable to assume that mutations on the X and Y 
chromosomes could be safely eliminated from further interrogation. Equal 
male and female distribution in cancer is seen across a range of malignancies 
in differing tissue types. Well-differentiated thyroid cancers however, are 
significantly more prevalent in women with a number of possible explanations 
for this, not least the exposure of female thyroid tissue to hormonal factors 
including oestrogen & the possible balance of oestrogen and androgen 
receptors (Perros, Boelaert, Colley, Evans, Rhodri M Evans, et al., 2014c) 
(Magri et al., 2014). As outlined in the general introduction, C Cells are both 
embryological and physiologically distinct from the surrounding thyroid tissue. 
They do however share a common microenvironment so to what extent these 
factors are important is not known.  
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The age range, and in particular the median and mean ages of our recruited 
patients is higher than in some other reported series (Roman, Lin and Sosa, 
2006). There are several explanations for this. Firstly, recruitment is a factor 
as our cohort has inherent bias with a proportion of self-referring patients 
rather than national data or data extracted directly from locally held databases 
(UK, 2013). The older group we have identified here may in some part be 
representative of older patients being more willing to take part in research. 
Furthermore, as our search strategy has focused on patients with sporadic 
disease, we have not got significant numbers of patients in younger age 
ranges, which are likely to skew the data from other large series in which 
there are significantly more of these individuals. Finally this may be slightly 
higher than observed in other large series of MTC although again could be 
partially explained by the recruitment strategy performed to assemble this 
cohort and the small number of patients identified through contact tracing[6] 
rather than through clinical signs or symptoms.  
    
3.6.4 Presentation and outcome 
our recruitment and cohort differences may go some way to explain the 
differences we see between the cohort presented here and elsewhere in the 
literature (Gimm and Dralle, 2001). We certainly have a higher than expected 
proportion of patients with advanced disease (stage 3 and 4) then presented 
elsewhere (Hundahl et al., 1998). This could be explained in part by some of 
the differences outlined within our own cohort in terms of an older group and 
in a group self-selected by willingness to be involved in the study. It is 
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possible that those with more advanced disease and, as such less likely to 
achieve biochemical and clinical cure, have a greater vested interest in being 
involved in research than those cured at initial surgery due to limited disease. 
Furthermore, and as previously stated, a bias in our group towards sporadic 
disease presenting as index cases rather than detection through screening 
may go some way to explaining this.  
 
Our data on outcome to date is skewed somewhat by missing data on the 
biochemical and clinical picture currently. The main factor here is that even 
with copies of clinical letters and follow-up information it is often not clearly 
stated what the current disease status is. This is an issue for any clinical 
project where the clinical data has to be collated in a retrospective manner 
and we accept that this weakens these results somewhat. an attempt will be 
made to complete this data in the future, but this is beyond the scope of this 
project. Although there are significant missing data we have no reason to 
assume that data not being available is for any other reason than a random 
event. As such, we believe that the overall data would not change 
significantly, that is to say, that a large proportion of patients with MTC 
following treatment will remain alive at follow-up but with evidence of either 
clinically residual disease or with biochemical but clinically unidentifiable 
residual disease. This is a common finding in the treatment and management 
of MTC and is a feature of a disease that presents at an advanced stage and 
has limited treatment options over and above local surgical tissue clearance.   
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3.6.5 Implications  
Overall, a significantly higher rate of advanced disease in MTC when 
compared to other forms of thyroid cancer is to some extent not surprising 
when comparing the differing grading systems of thyroid malignancy (Anon, 
n.d.). The change in the grading system between the two diseases highlights 
the importance of nodal metastasis in the likelihood of achieving cure. In well -
differentiated thyroid cancer, nodal status is of relative unimportance in 
treatment and although 50% have micro or macroscopic nodal metastases, 
the difference in overall outcome between those with and without disease is 
relatively small (Nixon et al., 2014). In part this is due to the effectiveness of 
ablative radioiodine treatment post-surgery, which effectively controls disease 
both in the thyroid bed and the nodal compartments (Nam-Goong et al., 
2004). In MTC however, evidence of disease spread to nodal groups 
significantly reduces the likelihood of achieving cure (Perros, Boelaert, Colley, 
Evans, Rhodri M Evans, et al., 2014c). As much of this disease is microscopic 
and not clinically apparent, achieving full clearance of affected tissue 
surgically, whilst attempting to be conservative is a great challenge (Roman, 
Lin and Sosa, 2006). The most likely chance of achieving this is at the first 
operation, and this can be compromised if the disease has not fully been 
diagnosed. As can be seen by our data presented here, many patients 
presenting with stage 3 and 4 disease undergo multiple procedures.    
 
  
	 	 	
	 	 	 	102	
Chapter 4.  
 
Clinical and experimental RET testing   
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4.1 Introduction  	
4.1.1 Establishing cases  
Following recruitment, it was required that both our index family and our wider 
cohort were genuinely RET negative and therefore suitable for inclusion. As 
previously discussed, clinical RET testing is offered to all patients with a 
diagnosis of MTC with familial testing and further cascade testing as 
appropriate (if a mutation is confirmed) (Perros, Boelaert, Colley, Evans, 
Rhodri M Evans, et al., 2014c). Clinical RET mutation testing at UHB 
laboratories currently consists of capillary sequencing (Sanger) of exons 10, 
11, 13-16 as it is within these coding regions that the majority (95%) of 
disease causing mutations will be present (Mulligan, 2014). The exons tested 
and the sequence of testing differs between labs (Romei et al., 2011). Our 
methodological approach is based on the assumption that alteration in gene 
expression and or gene mutations other than the RET are implicated in the 
pathogenesis of MTC. Ensuring RET negative familial and sporadic cases are 
genuinely RET negative is therefore of vital importance if that hypothesis is to 
be tested. In a similar study involving WES in a Chinese family, the WES 
result actually identified a novel RET mutation rather than a novel gene 
mutation (Qi et al., 2011).  
 
As 5% of RET mutations (disease causing or potentially disease causing) will 
be outside of the exonic regions screened by clinical testing, it is prudent to 
screen the remaining exons for mutations and to ensure genuine RET 
negative status. Although primarily capillary sequencing has been completed 
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here, in cases that later went on to have WES, a secondary check was 
available. Although not the only method available, capillary sequencing is 
considered to be the gold standard for mutational analysis (Margraf et al., 
2006), (Bugalho, Domingues and Sobrinho, 2002). Although as the reliability 
and speed of next generation sequencing improves, this may well take over 
as a diagnostic screen (Strom et al., 2014).  
 
Sequencing as described by Sanger, involves amplification of short segments 
of targeted DNA by thermal cycling and using the principles of polymerase 
chain reaction (PCR) amplification (Sanger, Nicklen and Coulson, 1977). 
Genomic or somatic DNA extracted from blood or tumour cells is purified prior 
to melting at a specific temperature which leads to the two strands separating 
(Shendure et al., 2004). Specific primers (oligonucleotides designed to bind to 
the ‘5 and 3’ end of the target sequence) can then anneal to the DNA and the 
sequence extended using a polymerase on the presence of an optimised mix 
of deoxynucleotides (dNTPs). Thermal cycling through phases of melting, 
anealling and extending, ultimately lead to exponential increases in the 
quantity of the amplicon (the small segment of DNA that is being amplified). 
The amplicon can then be purified, removing excess dNTPs and template 
DNA prior to use in the sequencing reaction. With regard to RET this 
practically involves primer pairs for each of the 20 exons, with multiple primers 
for amplicons larger than 400bp.  
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4.1.2 PCR amplification  	
 
 
 
Figure 28. 
Intronic primer design for PCR amplification of a single exonic region <400bp 	
	
Figure 29. DNA sequence recognition by using oligonucleotide primers with extension 
by DNA polymerase (Sanger, Nicklen and Coulson, 1977)  
 	  
5’	
3’	Intronic	region	
Intronic	region	Exonic	region	Forward	primer	
Reverse	primer	
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4.2 Methods  
4.2.1 Primer design 
Primers were designed as previously described.  
  
Oligonucleotide Sequence Redesign needed 
RET Exon 1 Forwards GCGCTTACCTCGCTTCAGT - 
RET Exon 1 Reverse ACAGAAAGGCGCTTCTGAAC - 
RET Exon 2 Forwards TTCTCACCATCCCTCACTCA TTTTTGTCCTTGAAGAAGCCTTA 
RET Exon 2 Reverse GTGTCAGCGGCTGTGATAAG - 
RET Exon 3 Forwards CCCCACAGACCTGACTTCTC - 
RET Exon 3 Reverse GAGCAAGACCAGCAGTAGCA - 
RET Exon 4 Forwards CAAACTGCAAACTCGTGCTC CAAACTGCAAACTCGTGCTC 
RET Exon 4 Reverse ACACTGGGTAGACCACAGCA GACCGAGAAACGAACTGTGG 
RET Exon 5 Forwards ACTGACCAACGCCCTCTG GGACGTGCAGCATTCTAAGG 
RET Exon 5 Reverse AAGAGCGAGCACCTCATTTC - 
RET Exon 6 Forwards AGAGCAGCTTGGTGGTCATT ACATGAGGAAGCAGCCAGAG 
RET Exon 6 Reverse CCCCAGACAGGCAATAGGTA GTCACCTGCCTCCCTGTG 
RET Exon 7 Forwards AGCTGCCTGGCTAAGGTGT TACCCTCAGGCCATTACAGG 
RET Exon 7 Reverse AGGCCCAGGCTCCAGAAG GCTTTTCTCAAAGGGCAGGA 
RET Exon 8 Forwards CCTGTGACCCTGCTTGTCT - 
RET Exon 8 Reverse AGACCTGGAGCAGGGAGAG - 
RET Exon 9 Forwards GATCTGCCTAGGAGGTGGTG GATCTGCCTAGGAGGTGGTG 
RET Exon 9 Reverse GTTCCCATGCCCTGATTAAA TCTCCTACCTGTTCCCATG 
RET Exon 12 Forwards CCCCTGTCATCCTCACACTT - 
RET Exon 12 Reverse GGCAGGTACCTTTCAGCATC - 
RET Exon 17 Forwards AGCCACTCACTGGTCCTTTC CTCTGTGAGGGCCAGGTG 
RET Exon 17 Reverse GGGAATGCACACAGATGTCC - 
RET Exon 18 Forwards GGCTGTCCTTCTGAGACCTG - 
RET Exon 18 Reverse CAAGCCACTTTCAGCTTGTG - 
RET Exon 19 Forwards CAAGCCACTTTCAGCTTGTG TAGTTGTGGCACATGGCTTG 
RET Exon 19 Reverse CAAGCCACTTTCAGCTTGTG GATAGTGCAAAGGGGACAGC 
RET Exon 20 Forwards TTGCCAAGGCCTTACTGTCT - 
RET Exon 20 Reverse TCTTCCCCTTGTGAGTCCAT GAAAGGGCCGGTAGACTTTC 
Table 22. Intronic RET oligonucleotides to capture sequences for exonic regions not 
covered in conventional clinical testing.  
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4.3 Results  
 
Germline DNA was initially available for 24 patients with sporadic MTC for 
sequencing analysis. All patients had had laboratory clinical testing of RET 
exons 10, 11, 13-16 with no RET mutation identified by Sanger sequencing. 
After manipulation of cycling parameters and primer pairs all remaining exons 
were sequenced and screened for mutations. Figure 32 shows representative 
samples from each exonic region. No novel mutations were found in these 
patients (0/24). Single nucleotide polymorphisms (SNPs) were found in exon 
5 and exon 7 with frequency within the sample of 17% (5/24) and 33% (8/24) 
for each SNP respectively. Mapping and characteristics of these 
polymorphisms can be seen in Figure 34.  
 
4.3.1 Sequencing was performed in all exons not tested routinely by the 
clinical laboratory  
Exon 1 Forward 
Exon 1 Reverse  
Exon 2 Forward 
Exon 2 Reverse  
Exon 3 Forwards 
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Exon 3 Reverse  
Exon 4 Forwards  
Exon 4 Reverse   
Exon 5 Forwards 
Exon 5 Reverse 
Exon 6 Forwards 
Exon 6 Reverse 
Exon 7 Forwards  
Exon 7 Reverse  
Exon 8 Forwards  
Exon 8 Reverse 
 Exon 9 forwards 
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Exon 9 reverse 
Exon 12 Forwards 
Exon 12 Reverse 
Exon 17 Forward 
Exon 17 Reverse 
Exon 18 Forward 
Exon 18 Reverse 
Exon 19 Reverse  
Exon 20 Forwards 
Exon 20 Reverse 
Figure 30. Representative sections of chromatograms for each exon not routinely 
tested clinically 
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4.3.2 Possible mutations were checked on the reverse strand before 
logging as SNPs or mutations.  
Where reverse strand verification was not obtained the experiment was 
repeated. Figure 32 shows a possible mutation in the forward trace with T to 
C heterozygous change. The reverse trace from the same patient’s DNA can 
be seen below which shown normal signal at that position.   
  
 
Figure 31. An apparent mutation on RET exon 20.  
 
4.3.3 Multiple SNPs were identified through screening of the untested 
exons 
The most commonly identified SNPs were in exon 5 and exon 7. On exon 5, 
reverse strand is not readable at this position of this SNP due to its proximity 
to the primer binding site, but as the SNP is well described, the experiment 
was not repeated. Figure 33 shows the mutation on the forward strand with 
two overlying peaks. The corresponding normal trace the peak size of the G 
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at the position of the mutation is halved compared to normal, again indicating 
this is a heterozygous mutation. Figure 34 shows the SNP on exon 7 found in 
8/24 patients with apparently sporadic disease.  
 
 
Exon 5 Forward strand  
 
Exon 5 Forward strand normal  
Figure 32. Patients within the sample cohort carry this G to A mutation in RET exon 5.  
 
Exon 7 Forwards  
 
Exon 7 Reverse 
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Exon 7 Normal forwards  
Figure 33. RET Exon 7. 8 patients from the cohort of 24 have this heterozygous G to A 
mutation in exon 7.   
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4.4 Discussion  	
4.4.1 Mutation of the RET gene outside of the exons tested clinically are 
rare in sporadic MTC  
An important first end point to this project is the verification of genuine RET 
negative status in our both our index family and in our initial cohort of patients 
with apparently sporadic disease. We found no novel, non-synonymous 
changes in the RET gene. Two common SNPs in the RET gene were the 
most common alteration identified, but neither differed significantly in 
frequency from other analyses SNP databases (Karolchik et al., 2008). This is 
in no way a surprising finding, although important to establish as a point of 
principle for further investigation. As reported, 95% of all RET mutations that 
are established as disease-causing occur in exons 10, 11, 13-16 (Ponder, 
1999). RET mutations outside of these exonic regions have been reported as 
disease causing in MEN 2a (exon 8) (Bethanis et al., 2007). Where functional 
work has not established the molecular basis of disease, however, there is 
some dispute as to the disease causing effects of some rare mutations of 
RET (Eng and Mulligan, 1997). Further work is required before some of the 
identified mutations are routinely screened for clinically (Figlioli et al., 2013).  
 
4.4.2 The index family are RET negative confirmed by Sanger 
sequencing and therefore suitable for interrogation using WES 
With next generation sequencing still in its infancy, Sanger sequencing is still 
considered the gold standard for mutation identification and confirmation 
(Bugalho, Domingues and Sobrinho, 2002). As seen elsewhere in the 
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literature, families with MTC/CCH pedigrees that are assumed to be RET 
negative have subsequently been shown to harbour novel mutations (Qi et al., 
2011). The results presented here confirm that this is not the case and as 
such the index family represents an ideal start point for identification of novel 
MTC predisposing mutations.   
 
4.4.3 Based on these data, further RET testing within our wider cohort 
has not been performed  
As the focus of the project has moved on toward the examination of WES 
results a decision was made to not further interrogate samples from patients 
subsequently recruited to the project following the results for this initial cohort 
of 24. The size of the RET gene makes the interrogation by Sanger 
sequencing both time consuming and expensive in terms of consumables and 
as the yield in terms of potential new mutations is likely to be small. It is 
possible that there are RET mutations in our wider sample that we will miss by 
taking this approach however, based on the data presented here, the 
numbers are likely to be low and as such not significantly bias our results. The 
major consequence of missing large numbers of mutations would be to dilute 
the true frequency of other identifiable candidate mutations. As ultimately, 
novel candidate are likely to occur with low frequency,this is a justifiable 
approach.       
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Chapter 5.  
 
Whole Exome sequencing and analysis 
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5.1 Introduction 	
5.1.1 Whole Genome and Whole Exome Sequencing (WES) 
WES is a form of ‘next generation’ sequencing whereby an attempt is made to 
capture all of the coding regions (exons) of the genome (Ng et al., 2009). The 
exome represents 1% of the genome but is thought to harbour more than 85% 
of disease causing mutations (Mamanova et al., 2010). In humans, this region 
represents over 20,000 consensus coding regions accounting for over 18,000 
genes (Kim D. Pruitt et al., 2009). Using a method of exome examination is 
therefore a pragmatic solution to disease causing mutational analysis 
(Robinson, Krawitz and Mundlos, 2011). With respect to this project, WES has 
the advantage of being able to accurately unpick genotype/phenotype 
relationships between highly penetrant genes (as expected in the index 
family), where multiple samples are available and where the likely causative 
mutations are exonic, non-synonymous, frameshift or canonical splice 
variations (Biesecker, Shianna and Mullikin, 2011a). This stands in contrast to 
whole genome sequencing (WGS) where interrogation of small numbers of 
individuals with low penetrance and complex disease genotype phenotype 
relationships.   
 
The key to WES success is ‘targeted capture’ of the exome and various 
commercial applications are available employing similar technology. The 
technologies are similar in that they essentially employ nucleic acid probes 
and primers designed to hybridise with fragmented genomic DNA (Summerer, 
2009). Differences between capture platforms do exist however, most notably 
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in the type an character of capture probes used and in solid and liquid phase 
capture techniques (Summerer, 2009). The differences in methodology give 
commercial platforms different characteristics and will inevitably create 
variation between sample, both in terms of the depth and extent of the 
proposed exome coverage.   
 
Exome ‘definition’ differs somewhat between databases and in some cases 
and there is a lack of clear consensus of what exactly constitutes the coding 
region of a gene. Although coding of the human genome is complete, 
evolution of information regarding start and stop codon position and splicing 
variants is ongoing and may lead to differences between datasets (Kim D 
Pruitt et al., 2009). Work by the consensus group bringing together data from 
commonly used data sets such as National Centre for Biotechnology (NCBI), 
the Ensembl Genome Browser and University of California Santa Cruz 
(UCSC), has provided a point at which agreement can be made on key 
genomic coding properties (Birney et al., 2004), (Karolchik et al., 2008). To 
some extent these current next generation platforms and the results 
generated from them will be dictated by the exome definition used, the 
database or consensus and as such the specific probes used and the 
subsequent sequence capture. Some of these issues will likely diminish with 
time as an increasing amount of next generation sequencing takes place 
more data covering non-consensus regions is analysed.  
 
WES technology has recently been used in the investigation of MEN 2A 
where novel germline RET mutations were discovered (Qi et al., 2011). 
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Exome sequencing has also been used to delineate mutation in other 
diseases including identifying candidate genes conferring genetic 
susceptibility to phaeochromocytoma (Comino-Méndez et al., 2011). As such 
it makes WES an appropriate strategy for genetic investigation of both uni- 
and multifactorial disease (Michael J Bamshad et al., 2011), (He et al., 2011). 
Although it is accepted that whole genome sequencing (WGS) will most likely 
replace WES, the costs are currently prohibitive for most research projects. 
Further considerations for employing WES over WGS are managing the 
quantity of bioinformatics data produced and the time in which modern 
sequence analysers can process the results (Michael J Bamshad et al., 
2011).    
  
As well a pragmatic approach based on the likelihood of mutation discovery, 
WES has a significant advantage in terms of both scale and cost with regard 
to traditional sequencing techniques with an estimate of a 10 fold cost 
reduction and significantly higher genome coverage. The current estimated 
costs for WGS and WES at the time of writing are 20k and £800 respectively. 
The advantage of WES over WGS is primarily based on cost but also on the 
current abilities to manage the quantity of data and the likely need for 
bioinformatics input and associated costs produced by WGS. Current 
estimates of cost for WGS is in the order of 20 times that of WES due to 
access to analysers but also in the time WGS takes on each machine and the 
implications for flow through when processing multiple samples (Biesecker, 
Shianna and Mullikin, 2011a).  
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Next generation sequencing has led to a significant change in the scope and 
scale of genomics with significant expansion expected in the area (Robinson, 
Krawitz and Mundlos, 2011). Increasing availability and decreasing costs, 
offers a genuine shift in research paradigm from hypothesis testing to 
hypothesis generating. rather than developing a hypothesis based on clinical 
or biological behaviour of a cancer and developing an interrogation strategy to 
detect potential imbalances in pathways that could lead to cancer 
predisposition, all pathways, known and unknown can be interrogated 
simultaneously. Clearly, the key advantage in this situation is to provide 
evidence or linkage within and between pathways not previously considered.   
 
Designing an effective strategy that is inclusive of the type of mutations that 
could be disease causing without inappropriately eliminating potentially 
interesting findings will always be a challenge when managing such large 
quantities of data. Figure 36 highlights some of the data filtration strategies 
that can be employed based on possible clinical sampling scenarios. In 
strategy 1, the assumption of novelty between generations is applied. In 
strategy 2, multiple, non-related individuals are sequenced and mutation data 
cross-referenced to search for similar mutations. In strategy 3, rare 
phenotypes of more common disease are used as target points for 
identification of genetic clustering. In strategy 4. assumptions based on the 
inheritance pattern of a disease, in this case, autosomal dominant 
allowrecessive mutations to be screened out (Michael J Bamshad et al., 2011) 
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Figure 34. Schematic representation of WES methodology from extracted genomic 
DNA (Michael J. Bamshad et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
1.	De-Novo	hypothesis	
2.	Multiple	unrelated	individual	analysis	
Phenotype	
3.	Rare	phenotype	focusing/mutation	clustering	
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Figure 35. Strategies for identification of a targeted list of mutations based on disease 
specific, inheritance and novelty assumptions. ((adapted from (Michael J Bamshad et 
al., 2011)) 
 
	  
4.	Multiple	affected	members	of	the	same	family.	In	this	situation	choosing	comparators	most	distantly	affected	is	likely	to	yield	the	best	results.		
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5.2 Materials and Methods  	
5.2.1 Patient selection for Whole exome sequencing (WES) 
WES was initially performed on two members of the index CCH/MTC positive 
family (S0288 and SO289). A further two samples added to the analysis to aid 
in bioinformatics approach (the parents of the proband: S0540 and S0541 
Figure 38). Sequencing and data filtration was performed as previously 
described.  
 
 
Figure 36. Exome sequencing election within the index family  
 	  
SO541	SO540	S0288	S0289	
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5.3 Results  	
5.3.1 Whole Exome Sequencing (WES) 
Exome sequencing was successfully completed in all four selected 
individuals. Table 23 shows the average base read depth as well as the 
proportion of the exome covered at greater than 20 x read depth.  
Sample Mean base coverage 
(X) 
% of exome covered >20X 
S0288 105.18 89.29 
S0289 62.23 82.46 
S0540 89.04 85.69 
S0541 70.87 83.89 
Table 23. Exome coverage based on capture techniques including average number of 
per base capture and percentage of bases captured >20X in each sample.   
 
5.3.2 Whole exome sequencing: selecting candidate genes  
Type and proportion of mutation for each dataset are shown in Table 24 and 
25. Search strategies using the described bioinformatics assumptions are 
shown in Figure 38 (de-novomutation assumption) and Figure 39(rejecting the 
de-novo assumption). In the de-novo approach, all four datasets were 
combined and 13 novel mutations were identified between the proband and 
offspring and the parents of the proband. All novel alterations were non-
synonymous. Four of the 13 novel mutations were predicted to be damaging 
on in-silico analysis (SIFT and Polyphen2). Table 26 shows the 13 novel 
mutations with further analysis of the 4 predicted damaging mutations shown 
in Table 27.   
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In the second search strategy, where the de-novo assumption was rejected 
(the parents of the proband were removed from the analysis), 382 novel 
mutations were identified. The initial focus was on those mutations most likely 
to alter protein structure. There were 36 identifiable frameshift and non-
frameshift insertions and deletions, 7 of which were common to both samples 
and 2 of which were novel frameshifts. There were 346 novel, non-
synonymous changes of which 28 were common to both datasets (Figure 39). 
No RET mutations were identified in any of the datasets.  
 
Exome 
Sequence  
Total number of 
mutations 
Novel 
Change  
Exonic 
Mutation 
Splicing 
mutation 
S0540 23 736 64 21 086 2650 
S0541 23 757 82 21 050 2707 
S0289 23 509 261 19 077 4432 
S0288 24 342 283 19 756 4586 
Total 95 344 - - - 
Table 24. Total number of mutation within each data set prior to data filtration 
strategies (It should be noted that the data sets S0540/SO541 were performed at a later 
date that SO288 and SO289 and as such novel changes highlighted from these data 
sets were not subsequently recorded as novel in preceding analysis explaining the 
disparity).  
	
Table 25. Frequency of mutation in each dataset 
Exome 
Sequence  
Synonymous Non-
synonymous 
Unknown In-frame 
insertions 
and 
deletion 
Frame 
shift 
insertions 
and 
deletions  
Stop 
loss/gain 
 
S0540 10 786 9686 33 286 201 46/83  
S0541 10 744 9671 - 307 196 26/87  
S0289 10 677 9658 - 240 196 38/74  
S0288 10 922 10 068 - 261 208 37/83  
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5.3.3 Data filtration strategies and candidate analysis  
Figure 37 Data filtration using the de-novo assumption. The de-novo approach shown 
here uses the assumption that the disease causing mutation is novel in the affected 
proband and twin and as such, exome data from the parents can be used to filter out 
non-relevant mutations. Total number of mutations screened is the combination of all 4 
datasets within the family.  The de-novo approach employed here identifies 13 novel 
mutations between generations all of which are non-synonymous in nature and of 
which 4 are predicted damaging by in-silico analysis. The 13 novel candidate de-novo 
mutations are further analysed in Tables 26 and 27.   	  
Predicted	damaging		
Not	identidied	in	varient	serves	(db	SNP)		
Mutation	type	
Abscent	in	parental	exome	(de-novo	mutation)	
Dominant	pattern	of	inheritance	
Amino	acid	changing	
Novel	Changes	All	generations	
Total	number	of	mutations		 Mutations	95	344	
Non-novel	94	653	 Novel		691	
Synonymous	193 		 Non-synomous/insertions	and	deletions		498	
Heterozygous	485	
De-novo	mutation	13	
Frameshifts	0	 Nonsynonomous	13	
Possiblility	8	
Predicted	damaging	4		
Homozygous	13	
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Gene 
name  
Chr  Mutation type Identifier (NM)  Variant 
server check 
Polyphen/ 
Sift  
Candi
date 
ZMYN
D8 chr20 
Non-
synonymous 
SNV NM_012408:exon19:c.C2975T:p.A992V 
Not in variant 
server ? 
* 
UPF06
39 chr14 
Non-
synonymous 
SNV 
UPF0639:NM_001161498:exon11:c.C109
6T:p.R366W, 
No SNP 
reported  
Probably 
damaging  
** 
RBM4
B chr11 
Non-
synonymous 
SNV 
RBM4B:NM_031492:exon2:c.A335G:p.D
112G, rs147572851  
- 
PKD1 chr16 
Non-
synonymous 
SNV 
PKD1:NM_000296:exon15:c.C6001T:p.R
2001W 
Not in variant 
server 
46exons: exon 
25 huge 
* 
NDUF
B1 chr14 
Non-
synonymous 
SNV 
NDUFB1:NM_004545:exon2:c.G257A:p.
R86Q rs145473110  
- 
MUC4 chr3 
Non-
synonymous 
SNV 
MUC4:NM_018406:exon2:c.C6077T:p.S2
026F 
Not in variant 
server 
 Probably 
damaging 
** 
MED2
9 chr19 
Non-
synonymous 
SNV 
MED29:NM_017592:exon1:c.G11A:p.S4
N, 
Not in variant 
server 
Probably 
benign 
- 
CYP2
F1 chr19 
Non-
synonymous 
SNV 
CYP2F1:NM_000774:exon6:c.T790C:p.F
264L, 
Not in variant 
server 
Probably 
benign 
- 
CRIPA
K chr4 
Non-
synonymous 
SNV 
CRIPAK:NM_175918:exon1:c.G749A:p.R
250H rs143316662 - 
- 
C11orf
59 chr11 
Non-
synonymous 
SNV 
C11orf59:NM_017907:exon2:c.G109A:p.
E37K rs144101476 - 
- 
BCL9 chr1 splicing . Not splicing    - 
ATP13
A3 chr3 
Non-
synonymous 
SNV 
ATP13A3:NM_024524:exon28:c.G3070A:
p.G1024S 
Not in variant 
server 
Probably 
benign 
- 
APPL
2 chr12 
Non-
synonymous 
SNV 
APPL2:NM_018171:exon8:c.C560T:p.A1
87V rs140436242 - 
- 
Table 26. Candidate genes mutational analysis using a de-novo assumption approach.  
	
Table 27. Biological evaluation of candidates identified using the de-novo approach   				
 
Gene  Biological 
preservation 
Known interactions  Candidate 
score  
ZMYND8 Yes  Gene encoding protein kinase C binding protein. Antigen identified in 
T cell lymphoma. No phenotypic changes in heterozygous mouse. 
Homozygous mice do no survive beyond weaning (Gardin and White, 
2011).  
** 
UPF0639 Yes Pleckstrin homology domain containing, family D. Phospholipid 
binding properties. (PLEKHD1).  
* 
PKD1 Yes Needed for regulation of renal tubular development and ciliated flow. 
Major gene implicated in the development of polycystic kidney 
disease (Kurbegovic and Trudel, 2013).  
* 
MUC4 Yes  Role in production of mucin for maintenance of epithelial surfaces. 
May play a role in tumour progression. MUC4-ERBB2-ERBB3-NRG1 
complex has been shown to down-regulation of CDKN1B, resulting in 
repression of apoptosis and stimulation of tumour growth. Implicated 
in multiple tumours including gioblastoma (Li et al., 2014) 
** 
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Figure 38. Data filtration strategy excluding the de-novo paradigm. In this approach the 
assumption is made that the disease causing mutation has not occurred as a novel 
change between generations. The data presented here represent the amalgamation of 
datasets in the proband’s twin and affected offspring (parental datasets excluded as a 
filter). Using this approach, 382 novel potential mutations were identified of which 35 
were common to both datasets. Alterations in biologically relevant pathways were 
analysed in further detail and shown in Table 28. Candidate mutations warranting 
further analysis based on candidate scoring are shown in Table 29.    	 	
Biologically	relevant		
Common	to	both	data	sets	
Likely	to	affect	Protein	stucture		
Previously	characterised	
Amino	acid	changing	
Pattern	of	inheritance	
Total	number	of	mutations	 	 		 	 		 	 Mutations	47	851 		
Homozygous	18	650	 Heterozygous	29	201	
Synonymous	13	292 		 Non-synomous/insertions	and	deletions		15	909 		
Novel	382	
Insertions	and	deletions		36	
In	frame	mutation	5	
Cancer	pathway	2	
Frame	Shift	2	
Cancer	pathway	1	
Non-synonymous		346	
Commonality	28	
Cancer	pathway	17	
Non-novel	15	527	
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 Table 28. Targeted candidate analysis of alterations identified using an approach that 
excludes the de-novo paradigm. This analysis includes 17 non-frameshift alterations 
(non-synonymous and splicing) and 2 in-frame alterations. Both frameshift alterations 
that were common to the datasets were included here for further analysis.   
Gene 
name  
Chr  Mutation type Identifier (NM)  Variant 
server 
check 
Polyphen/SI
FT 
Candida 
te 
BCL9 1 splicing - 
Not in 
variant 
server Not splicing 
- 
CARD11 7 Non-synonymous 
CARD11:NM_032415:exon21:c.T2780C:p.
L927P 
rs2019214
26   Yes 
- 
MED17 11 Non-synonymous 
MED17:NM_004268:exon6:c.G938A:p.R3
13Q 
COSM690
935 
variant 
server 
SIFT 
tolerated/ 
possibly 
damaging 
 
* 
NUP98 14 Non-synonymous 
NUP98:NM_139132:exon22:c.C2983T:p.R
995C 
Not in 
variant 
server 
Probably 
benign 
- 
RBL1 20 Non-synonymous 
RBL1:NM_002895:exon17:c.A2387G:p.Y7
96C 
rs1487146
35 Damaging 
- 
TTC23 15 Non-synonymous 
TTC23:NM_001040660:exon7:c.C715A:p.
Q239K, 
Not in 
variant 
server 
Probably 
benign 
- 
C8orf42  Non-synonymous 
C8orf42:NM_175075:exon3:c.C377A:p.T1
26N 
Not in 
variant 
server possible 
- 
FOLR3 11 Non-synonymous 
FOLR3:NM_000804:exon3:c.G314A:p.C1
05Y 
COSM690
805 Damaging 
* 
JMJD6 17 Non-synonymous JMJD6:NM_015167:exon1:c.G44C:p.S15T 
rs2019904
97 
Benign/delet
erious 
- 
EXD3 9 Non-synonymous 
EXD3:NM_017820:exon16:c.C1713A:p.A5
71A, 
 
rs3722930
78 - 
- 
FAM166B 9 Non-synonymous 
FAM166B:NM_001164310:exon5:c.G733
C:p.V245L, 
 
rs3713405
02 - 
- 
KLHDC4 16 Non-synonymous 
KLHDC4:NM_017566:exon6:c.A559G:p.R
187G,KLHDC4:NM_001184854:exon4:c.A
388G:p.R130G, 
 
Not in 
variant 
server Benign 
- 
LOC8169
1 16 Non-synonymous 
LOC81691:NM_001199053:exon3:c.G213
T:p.K71N,LOC81691:NM_001144924:exo
n3:c.G213T:p.K71N,LOC81691:NM_0309
41:exon3:c.G213T:p.K71N, 
Not in 
variant 
server Benign 
- 
MICALCL 11 Non-synonymous 
MICALCL:NM_032867:exon3:c.C994G:p.
Q332E, 
 
Not in 
variant 
server possible 
- 
NCKIPSD 3 Non-synonymous 
NCKIPSD:NM_184231:exon9:c.C1490G:p
.S497C,NCKIPSD:NM_016453:exon9:c.C
1511G:p.S504C, 
 
Not in 
variant 
server possible 
* 
PLEKHN
1 1 Non-frameshift 
PLEKHN1:NM_001160184:exon9:c.867_8
69del:p.289_290del,PLEKHN1:NM_03212
9:exon9:c.831_833del:p.277_278del, 
 - possible 
- 
TTC3 21 Non-synonymous 
TTC3:NM_003316:exon23:c.T2106A:p.D7
02E,TTC3:NM_001001894:exon23:c.T210
6A:p.D702E, 
 
Not in 
variant 
server possible 
* 
ZNF829 19 Non-synonymous 
ZNF829:NM_001037232:exon5:c.A294T:p
.R98S 
Not in 
variant 
server possible 
- 
ESR2 14 frameshift deletion 
ESR2:NM_001437:exon5:c.948delT:p.I31
6fs 
 
Not in 
variant 
server - 
**** 
ZCWPW2 3 frameshift deletion 
ZCWPW2:NM_001040432:exon6:c.684_6
88del:p.228_230del, 
Not in 
variant 
server - 
** 
SENP3 17 
Non-frameshift 
deletion 
SENP3:NM_015670:exon2:c.254_256del:
p.85_86del 
Not in 
variant 
server - 
** 
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Gene  Biological 
preservati
on 
Known interactions  Candidate 
score  
ESR2 Yes Oestrogen receptor beta (ERbeta), isoform of oestrogen receptor (ER 
alpha). DNA binding domain within protein, multiple DNA binding sites 
via oestrongen response elements (ERE) including upstream of the 
RET gene. Ligand activated by oestrogen. Implicated in breast and 
thyroid cancers. Association with RET proto-oncogene in breast 
cancers refractory to oestrogen modulation (Stine et al., 2011).   
***** 
MED17 Yes Loss of MED17 implicated in progression of prostate cancer due to 
abnormal androgen signalling pathways (Vijayvargia, May and 
Fondell, 2007). No known thyroid/neural crest interactions. 
** 
FOLR3 Yes Folate receptors overexpressed in ovarian cancer (Yuan et al., 2009). 
Not implicated in thyroid disease.  
** 
TTC3 Yes Ubiquitin protein ligase. Degredation of phosphor Akt. May play role in 
neuronal differentiation (Berto et al., 2014). Not implicated in thyroid 
disease.  
** 
NCKIPSD Yes Located at the nucleus, protein produce plays a role in signal 
transduction. Implication in leukaemia (Sano, 2001).   
** 
ZCWPW2 Yes Zinc finger protein, implicated in cellular structural properties (Ilagan et 
al., 2014). Not implicated in thyroid of neural crest abnormalities.  
*** 
SENP3 Yes SUMO2/3 protease. Important role in post-translation protein 
modification. Implicated in many cancers including gastric and oral 
(Ren et al., 2014). No report thyroid/neural crest interactions. 
*** 
Table 29. Targeted candidate analysis based on biological information excluding de-
novo paradigm. The 7 alterations identified as most likely to be disease causing are 
further analyses here for potential biologically relevant interaction.    
 
5.3.4 Identified mutations and rational for taking forwards 
Based on the above analysis, mutations with the highest scores were further 
evaluated by capillary sequencing to ensure they were true positives. 
Confirmation of the ESR2 mutation (c.948delT) and ZCWPW2 (c.648_688del) 
along with the other deletions were confirmed by capillary sequencing (Figure 
41/42). The SENP3 in frame deletion could not be confirmed by capillary 
sequencing and as such discarded from further analysis.   
      
 
Figure 39. ESR2 c.948delT reverse 
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Figure 40. ESR2 c.948delT forwards 
 
      
 
Figure 41. ZCWPW2 c.648_688del reverse 
 
Figure 42. ZCWPW2 c.648_688del forwards  
 
5.3.4 ESR2 and ZCWPW2: Biological assessment  
The ESR2 gene encodes the trans-membrane nuclear receptor oestrogen 
receptor beta (ERβ). ERβ along with its isoform ERα are part of a superfamily 
of transmembrane and cytoplasmic receptors that regulate cellular 
transcription via complex intracellular signalling. ERβ is expressed in thyroid 
tissue as well as breast and prostate. Oestrogen receptors (ER) bind17beta-
estradiol or related ligands which lead to the formation of ER homo- or hetero-
dimers that interact with specific DNA sequences called oestrogen response 
elements (ERE) to activate transcription of specific genes. Recently, ERE 
were detected on the RET gene promoter and it was shown ERα was able to 
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regulate RET transcription (Zhao et al., 2007).  ERβ is thought to regulate the 
response of ERα and in this way may act directly as tumour suppressor gene, 
although the mutated form could also act as a proto-oncogene by binding 
directly to RET and leading to upregulation (Zhao et al., 2007).  Further, the 
RET tyrosine kinase has been implicated in oestrogen independent breast 
cancer and those resistant to tamoxifen (Stine et al., 2011). 
 
The ZCWPW2 gene encodes a zinc finger, CW type, with a PWWP domain. 
Zinc finger proteins bind DNA and RNA and act as stabilisers. They are 
extremely common in higher animals (found exclusively in vertebrates) and 
can be classified based on their structure and binding properties (Perry and 
Zhao, 2003). No phenotypic presentation of abnormalities in this gene has 
been described and its in vivo function is unknown. In terms of biological 
plausibility ESR2 gene alterations seem more plausible than ZCWPW2 and it 
is for this reason it will be taken forwards for further investigation.  	
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5.4 Discussion  	
5.4.1 WES: Selecting mutations for in-vitro studies 
WES has been successful within the context of this disease, generating a high 
level of fidelity (depth of base reading) and significant exome cover. By 
adopting a multi hypothesis approach to WES mutation analysis it has been 
possible to successfully reduce the number of candidate mutations to a 
workable group. Although this approach has been used before in the context 
of MTC, to date no causative mutations other than low frequency RET 
mutation have been discovered (Qi et al., 2011).  The two mutations that 
scored highest in the bioinformatics analysis and were confirmed through 
capillary sequencing were ESR2 and ZCWPW2. As a biologically preserved, 
frameshift mutation in a relevant pathway, the c. 948delT ESR2 mutation is 
clearly the standout finding from WES. It was not possible however, to confirm 
the presence of SENP3 by capillary sequencing. Based on the stand out 
qualities of the ESR2 mutation we opted not to pursue the other non-
synonymous mutations identified by the searches presented here.  
 
Although an appropriate tool in the context of this study, WES is not without 
limitations even prior to the application of a bioinformatics approach to 
mutation filtration. As discussed, confining mutation searches to the exome 
alone may miss the mutation altogether (likely in 15% of cases) (Mamanova 
et al., 2010). The definition of the ‘exome’ has clear implications and although 
consensus on many gene loci have been reached, there are significant 
differences between sequencing platforms (Kim D Pruitt et al., 2009). 
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Furthermore, within platform considerations such as target regions not well 
covered by the sequencing technology, clearly has the potential to falsely 
eliminate target mutations prior to application of bioinformatics approaches 
(Biesecker, Shianna and Mullikin, 2011b). These points considered, WES is 
the most applicable methodology to use within this study.   
 
An incomplete understanding of the biology of the disease under investigation 
represents a potential problem. An attempt has been made here to perform 
multiple search strategies of the same dataset under differing criteria to reach 
a ‘consensus’ search that is inclusive of the mutations that require further 
interrogation without including so many as to be impractically workable. Other 
authors use similar approaches, applying phenotypic and heredity 
characteristics into a bioinformatics based search approach (Comino-Méndez 
et al., 2011), (Robinson, Krawitz and Mundlos, 2011). The first consideration 
is that of commonality. The assumption that all members of a cohort that 
phenotypically present with disease carry the mutation and that those 
unaffected do not, was made initially. Ideally, in familial studies, the most 
distantly related members of the same family would be chosen for WES to 
increase the likelihood of mutations common to both or multiple individuals 
are more likely to be disease causing (signal) and reduce the number of non-
relevant mutations (noise) (Figure 37) (Michael J. Bamshad et al., 2011). This 
is less easy to achieve in small families such as the one presented here. The 
risk with commonality assumptions is that mutations may not be fully 
penetrant or, at least when sampled, individuals did not have disease specific 
signs or symptoms (Summerer, 2009). In these data presented here, the 
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novel hypothesis was rejected, indicating that one of the proband’s parents 
was a carrier of all mutations deemed significant.  
 
In relation to RET mutations, it is estimated that penetrance is in the region of 
80% but worth bearing in mind the carrier status of RET sequence alterations 
in the general population is as high as 10% (Frank-Raue et al., 2011). Further, 
commonality (individuals with the same phenotype sharing the same 
alteration) is an important factor when considering multiple individuals from 
differing pedigrees, although less of a problem when sampling multiple 
individuals from the same pedigree, as modifying factors from the expression 
of different genes would likely be less prevalent (Figure 36).  
The second factor to consider is presumed mode of mutation transmission. 
Typically, diseases of autosomal dominant pattern of inheritance present with 
multiple affected individual within a family by vertical presentation, such as the 
one observed in our index family (Newman et al., 1988). Autosomal recessive 
disorders on the other hand present with a pedigree where phenotype is seen 
in a horizontal pattern (Eng et al., 1996). Furthermore, if the trait is dominant 
then one would expect approximately 50% of an affected individual’s offspring 
to be affected rather than 1 in 4 for recessive traits. In rare disease, 
autosomal dominant patterns of inheritance are more common from a 
heterozygous mutation. Assuming a dominant pattern of inheritance allows 
removal of homozygous mutations from datasets and therefore further 
analysis (Michael J. Bamshad et al., 2011). 
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The third assumption is that a mutation is derived do-novo. It is understood 
that a large proportion of the heritable disease encountered clinically cannot 
be explained by data accrued from population based genomic studies such as 
genome wide association studies (GWAS) (Stringer et al., 2011). It is 
therefore postulated the shortfall between what is predicted and observed is 
made up from de novo mutations acquired at meiosis through replication 
fidelity errors in potentially tumorigenic genes, each individually too rare to be 
detected by GWAS but having a large effect on disease prevalence (Ryoo 
and Lee, 2014) (Manolio et al., 2009). Further, mutation ‘novelty’ should be 
assumed in bioinformatics approaches in gene mutation discovery as non-
novel mutations, that is, those previously described in other forms of disease 
and presented on the various mutation servers, would presumably have 
already been linked to MTC if mutations were found to be causative (1000 
Genomes Project Consortium et al., 2010). Removing all SNPs that are 
previously described in SNP databases further reduces the number of 
mutations that can be excluded.   
 
Further assumptions were made based on the likely effects that a mutation 
would have on the transcription process to mRNA and ultimately the protein 
product. Synonymous point mutations (leading to a change in the coding DNA 
a single point but, although a different codon is transcribed, the same amino 
acid is produced) were excluded. Non-synonymous mutations were included 
although the predicted effect of this type of single base mutations is extremely 
variable. Modelling through online tools (SIFT and Polyphen) was performed 
in these situations to predict potentially damaging effects (Adzhubei, Jordan 
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and Sunyaev, 2013). The mutations most likely to alter protein structure are 
those where is either a significant change in the code due to deletions or 
insertions or where a stop codon is either lost or gained (Lengauer, Kinzler 
and Vogelstein, 1998). Deletions and insertions can be well tolerated if they 
lead to in-frame change and loss or gain of a single amino acid coding region. 
Where insertions or deletions are out of frame however, this can lead to 
truncation or elongation of a transcriptional region and therefore protein 
(Vogelstein and Kinzler, 2004). It is to these mutations special attention was 
given when identifying potential candidates.  
 
5.4.2 Exome data and mutational analysis  
ESR 2, encodes oestrogen receptor beta (ERβ), consisting of a 9 coding exon 
gene with multiple isoforms found on chromosome 14. It was discovered in 
1996 using degraded primers in studies of ERα with which it shares significant 
homology, particularly in its DNA binding domain. The most common two 
identified isoforms of ESR2; isoform a (wildtype, 530αα) and isoform b (496 
αα), differ in exon 9 coding (ligand binding domain). The c.948delT frameshift 
deletion leads to a coding of a further 26αα chain before a stop codon is 
reached (αα position 330). The mutation is predicted to affect the AF2, ligand 
binding domain indicating the possibility of a protein that degrades due to 
nonsense mediated decay or one that functions without the ligand binding 
capabilities.  
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Figure 43. ER homology 
 
ERα and ERβ form homo and heterodimers on ligand binding with oestrogen 
(E2) and its analogues. Once dimerised by ligand, ERs act via classical 
pathways, binding to specific DNA sequences known as oestrogen response 
elements (EREs), to activate transcription specific genes (Ogawa et al., 
1998). By altering chromatin structure and up-regulating gene expression, ER 
bound EREs ultimately lead to cellular growth and differentiation. EREs have 
been identified in the upstream regions of many genes, and recently, EREs 
have been detected on the RET gene promoter. It has been shown that ligand 
bound ERs[7] regulate RET transcription and thus cellular proliferation (Zhao 
et al., 2007). 
 
ERα, encoded by the ESR1 gene, was the first ER to be discovered (1986) 
and studied in great detail in the context of breast cancer where it forms part 
of the prognostic work up of breast tumours and a marker, as well as direct 
target, for oestrogen modulation therapy most commonly in the form of 
selective oestrogen receptor modulators (SERMS e.g. Tamoxifen) (Clemons, 
Danson and Howell, 2002). ERs contain the structural, functional domains A-
F. The A/B-domain contains the activation function 1 (AF-1), which is 
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hormone/ligand-independent. The C-domain contains the DNA-binding 
domain, with the hinge region in the D-domain having nuclear localization 
sequences that interact with AP-1. The E/F-domain is the ligand-binding 
domain with ligand-dependent activation function, AF-2 (Burns and Korach, 
2010). 
 
 ERβ, has been proposed as a tumour suppressor gene and in vivo is thought 
to exhibit a dominant negative effect, inhibiting the transcriptional up-
regulation of ERα, thus inhibiting the physiological response of oestrogen. 
Further, ERβ has been shown to repress c-myc, cyclin D1 and cyclin A and to 
increase the expression of p21waf1/cip1 and p27kip1 causing a cell cycle 
arrest of MCF-7 cells in G2 phase (Paruthiyil et al., 2004). ERβ is expressed 
ubiquitously throughout the body including thyroid tissue as well as breast, 
prostate, colon and brain (Taylor and Al-Azzawi, 2000). Further, ERβ has 
been shown to be expressed in both thyroid follicular and parafollicular C-
Cells whereas ERα is not expressed at all (Bléchet et al., 2007). Conversely, 
in MTC, ERα is reported in as many as 90% of tumours with expression of 
ERβ more variable, typically around 70% but often much lower (Taylor and Al-
Azzawi, 2000). I propose that the down regulation of ERβ and possible up-
regulation and unopposed action of ERα are important events in C-cell 
proliferation and could potentially lead to malignant predisposition via the 
intermediary CCH. It follows that such a change could be oestrogen mediated 
and involve up-regulation the RET pathway.  
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Figure 44. ESR 1 and 2 protein products (ERα and ERβ) on ligand activation bind to 
oestrogen response elements (EREs) one of which has recently been discovered in the 
RET promoter region. It is postulated that the c.948delT mutation leads to a null or 
attenuated protein product, reducing the inhibition of ERα induced RET up-regulation. 
 
The potential link between oestrogen signalling via ERs in thyroid disease and 
thyroid cancer has recently been suggested (Rajoria et al., 2012). The 
concept is however not novel, with studies as early as 1988 demonstrating in 
vitro TT cells (MTC cell line) proliferation in response to oestrogen and growth 
inhibition in response to tamoxifen (Yang, Pearson and Samaan, 1988). 
Oestrogen has been shown to mediate cellular proliferation via ERs in other 
thyroid cancer cell lines with ligand bound ERβ responses via EREs typically 
leading to decreased proliferation on MTT assays (Zeng et al., 2007). 
Furthermore, an anti-oestrogen therapy has been proposed as a treatment for 
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thyroid malignancies, although to date no clinical trials have been undertaken 
(Rajoria et al., 2012). Based on sequencing results and these biological 
interactions, we believe the c.948delT mutation of ESR2 to be the most 
appropriate candidate gene to take forwards for further investigative functional 
work.  
 
5.4.3 Proposed experiments based on WES results  
Aims  
• To assess the wider cohort of familial and sporadic disease for the 
presence of ESR2 mutations  
• To model ESR2 mutation in vitro in appropriate cell lines 
• To demonstrate the ESR2 c.948delT mutants lead to null proteins 
• To demonstrate the expression of mutant ERβ leads to up regulation of 
the RET pathway.  
• To demonstrate the effect of specific oestrogen receptor antagonists on 
both proliferation and on RET pathway up regulation 
• To establish ERβ and ERα immunostaining patterns in familial and 
sporadic disease  
 
To assess which cell lines are most appropriate for use within these 
experiments, the following cell lines were cultured to extract protein and test 
ERα and ERβ positivity by western blotting.  
 
MCF 7:  Breast cancer derived cells expressing both ERα and ERβ  
T47D:  Breast cancer derived cells that express neither ERα nor ERβ  
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TT cells: MTC derived cells, ER positivity to be determined 
 
Although MCF7 and T47D are breast rather than thyroid cell lines, we believe 
they may be good to use as preliminary models both due to their expression 
characteristics with regard to ERs and also as they are easily transfected and 
grow rapidly. TT cells are the only MTC model and are derived from the 
metastasis of a patient with disseminated disease and a known RET mutation 
(C634W: MEN2A). This may confound our assays of RET and RET pathway 
in this line although as the only in vitro model of MTC we feel its use is 
justified.   
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Chapter 6.   
 
ESR2 sequencing of familial and sporadic MTC  
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6.1 Introduction  	
Having identified a candidate mutation from WES, and confirmed it through 
capillary sequencing, the next step was to confirm the presence of c. 948delT 
ESR2 mutations in the family and wider cohort of sporadic patients recruited 
with MTC. The primary question is whether the mutation segregates within the 
family (and also to possibly assess penetrance). The second question was to 
examine whether further mutations in germline and tumours were present in 
the remaining ESR2 exons. Clearly, when dealing with a possible disease 
susceptibility mutation, a complete lack of segregation within the family would 
indicate reconsideration of the identified candidate genes or the consideration 
of complex penetrance issues.  
 
As discussed, one hypothesis regarding the biological behaviour of ERβ is 
that it acts as a tumour suppressor. As a heterozygous mutation (c. 948delT 
ESR2), and if adopting a classical theory of tumour suppressor genes, one 
would expect a second hit in the same gene to confirm cancer predisposition 
(Knudson, 2002). The second hit could be present in either germline or, more 
likely, in somatic DNA and as such both should be examined for the presence 
of mutations throughout the ESR2 gene. If no second hit was identified, it is 
possible that the c. 948delT ESR2 mutation is still the driver mutation for MTC 
predisposition in the family but that a haploinsufficient or ‘mutator’ phenotype 
model is more likely (Loeb, 1991). It is possible however, that no other 
mutations will be identified and again, in this case we would have to consider 
returning to our list of candidate genes to explore other possibilities.    
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Understanding the prevalence of ESR2 mutations in the wider cohort of both 
germline and somatic DNA would insight into the comparative mutation 
profiles and there relative frequencies. Finding additional mutations in the 
wider cohort would also add weight to our theories regarding ESR2 c. 948delT 
driven MTC predisposition and the relevance of ESR2 mutations in sporadic 
disease. Again, it has to be accepted at this stage that, as a potential 
causative mutation in a rare family phenotype, there may be very few 
germline or sporadic mutations of the ESR2 gene. If this is the case then 
decisions regarding the on-going functional work will need to be made.  
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6.2 Materials and methods  	
6.2.1 Histology and tumour blocks 
Histological specimens were obtained from all members of the family who had 
undergone thyroid surgery, where available. Newly cut and slides were cut 
from tumour blocks as needed. Histological classification and examination of 
slides were performed independently and with the examiner (RB) blinded to 
the clinical information.  All histological classifications were cross-referenced 
with original histological diagnosis and where there was disparity, secondary 
checks and a second reviewer examined the slides. In two cases there was a 
change in the eventual pathological diagnosis. In the original examination of 
the prophylactic thyroidectomy specimens from two of the offspring of the 
proband, one had been classified as CCH but was reclassified normal and 
one normal case classified was reclassified CCH. In the original examination 
of specimens, calcitonin staining had not been performed, which accounted 
for the discrepancy.  
 
6.2.2 PCR and sequencing  
PCR amplification of individual exonic regions of the ESR2 gene in germline 
and somatic DNA samples was performed for all patients using methods as 
previously described for RET exonic sequencing. Again, primer pairs were 
designed for each exonic region using Primer 3 software as previously 
described. Where PCR bands were not clearly identified using these methods 
primers were redesigned.  
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Oligonucleotide Sequence Redesign needed 
ESR2 Exon 1 Forwards GCGCTTACCTCGCTTCAGT - 
ESR2 Exon 1 Reverse ACAGAAAGGCGCTTCTGAAC - 
ESR2 Exon 2 Forwards 
 
TTCTCACCATCCCTCACTCA TTTTTGTCCTTGAAGAAGCCTTA 
ESR2 Exon 2 Reverse GTGTCAGCGGCTGTGATAAG - 
ESR2 Exon 3 Forwards CCCCACAGACCTGACTTCTC - 
ESR2 Exon 3 Reverse GAGCAAGACCAGCAGTAGCA - 
ESR2 Exon 4 Forwards CAAACTGCAAACTCGTGCTC CAAACTGCAAACTCGTGCTC 
ESR2 Exon 4 Reverse ACACTGGGTAGACCACAGCA GACCGAGAAACGAACTGTGG 
ESR2 Exon 5 Forwards ACTGACCAACGCCCTCTG GGACGTGCAGCATTCTAAGG 
ESR2 Exon 5 Reverse AAGAGCGAGCACCTCATTTC - 
ESR2 Exon 6 Forwards AGAGCAGCTTGGTGGTCATT ACATGAGGAAGCAGCCAGAG 
ESR2 Exon 6 Reverse CCCCAGACAGGCAATAGGTA GTCACCTGCCTCCCTGTG 
ESR2 Exon 7 Forwards AGCTGCCTGGCTAAGGTGT TACCCTCAGGCCATTACAGG 
ESR2 Exon 7 Reverse AGGCCCAGGCTCCAGAAG GCTTTTCTCAAAGGGCAGGA 
ESR2 Exon 8 Forwards CCTGTGACCCTGCTTGTCT - 
ESR2 Exon 8 Reverse AGACCTGGAGCAGGGAGAG - 
ESR2 Exon 9 Forwards GATCTGCCTAGGAGGTGGTG GATCTGCCTAGGAGGTGGTG 
ESR2 Exon 9 Reverse GTTCCCATGCCCTGATTAAA TCTCCTACCTGTTCCCATG 
Table 30. Oligonucleotide primer designed for the sequencing of ESR2   
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6.3 Results  	
6.3.1 Germline mutations  
6.3.1.1 The ESR2 c. 948delT mutation segregates in the family to 
individuals with disease proven by histology  
All cases of histologically confirmed CCH and MTC, after review were found 
to have germline mutations in the ESR2 gene corresponding to the c. 948delT 
ESR2 mutation. In addition, the father of the proband also had the c. 948delT 
ESR2 mutation but has not developed MTC (Figure 46). Calcitonin testing 
showed elevated results but based on this alone and in the absence of RET 
mutation, no further investigation or treatment was carried out.   
 
 
Figure 45. Sequencing confirmation of individuals carrying the germline c. 948delT 
mutation ESR2 confirmed by sequencing  
 
6.3.1.2 No germline ESR2 mutations were found in other recruited 
families 
ESR2 sequencing was carried out on 12 individuals across the two additional 
families shown in Figure 22 (page 91). Neither the c. 948delT ESR2 mutation 
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nor any other mutation in the ESR2 gene has been identified in either of the 
two families for which we had germline DNA available at the time of the study 
(Figure 22, page 90, families recruited to the study in collaboration with MR, 
Madrid). The more recently recruited families are awaiting testing but these 
results will be reported elsewhere.  
6.3.1.3 Germline ESR2 mutations in the wider cohort  
 A single novel germline alteration (ESR2 c.800 C>G, p. V128L) has been 
identified in a patient with young onset sporadic disease. At the time of 
writing, this alteration has not been reported in SNP databases. Whether this 
is a novel mutation or rare SNP is not clear but given its context within 
patients with young onset sporadic disease, warrants further examination. 
Modelling this alteration in SIFT and Polyphen suggests that this alteration is 
well tolerated.  
	
Figure 46. ESR2 Exon 3 forward c. 800 C>G p. V128L 
	
Figure 47. ESR2 Exon 3 reverse c. 800 C>G p. V128L 
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Figure 48. ESR 2 Exon 3 Normal sequence 
6.3.2 Somatic mutations  
Somatic alterations of the ESR2 gene were identified in DNA extracted from 
two tumours from patients from Sydney within the splice site of Exon 9 c. 917 
T>C p. L306S (Figures 50-52). 
	
Figure 49. Splice site exon 9 forwards c. 917 T>C p. L306S  
	
Figure 50. Splice site exon 9 reverse c. 917 T>C p. L306S 
 
Figure 51. Exon 9 normal  
 
6.3.2.2 No further germline ESR2 mutations been discovered to date 
In all, 53 germline samples of DNA and 24 samples of somatically derived 
DNA were analysed for ESR2 alterations. Of the germline samples, 36 had 
apparently sporadic MTC, with 12 familial MTC positive disease (individuals 
with histologically confirmed CCH/MTC from three families) and 5 familial 
samples with no clinical evidence of disease (unaffected members of the 
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index family). In all, novel alterations were identified in 7/54 germline DNA 
samples (c.948delT in six members of the index family and p.V128L in one 
young onset sporadic MTC) and 2/24 tumour samples (p. L306S in two 
Tumours from Sydney).  
Patient type  N= Germline ESR2 
alteration 
Somatic 
alteration  
Familial Non-
RET CCH/MTC 
12 5/12 - 
Familial non-
RET (No clinical 
phenotype) 
5 1/5 - 
Apparently 
sporadic Non-
RET MTC 
36 1/36 0/12 
Somatically 
derived DNA  
24 - 2/24 
Table 31. Identified ESR2 alterations in familial and sporadic MTC recruited to the 
study.   
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6.4 Discussion  	
The fact that the disease phenotype and c. 948delT mutation segregate within 
the family and correlate with histology is a positive finding adding weight to 
the hypothesis that ESR2 mutations predispose to CCH/MTC. The presence 
of a mutation within, as far as can be ascertained, an unaffected family 
member is potentially problematic. Several explanations may exist. Firstly the 
mutation is incompletely penetrant and at that generational level there exist 
modifying genetic influences that abrogate the effects of the mutation, 
possibly by epigenetic events (intergenerational gene silencing) (Harper, 
2005), (Orozco et al., 2014). RET mutations themselves are estimated to be 
around 80% penetrant and as a novel mutation it is impossible to predict what 
the penetrance might be (Frank-Raue et al., 2011). It is unlikely to be 100%. 
Secondly, we assume that CCH is always a premalignant condition and that 
ultimately the children who underwent thyroidectomy prophylactically and 
were found to have CCH would have gone on at some point to develop MTC. 
This is not necessarily the case and we do not know to what extent if any 
environmental factors have played a role in the development of MTC in the 
proband e.g. second hit or other epigenetic event. It is worth noting that the 
proband’s brother (identical twin) had CCH only with no evidence of MTC on 
histology. Thirdly, the father of the proband had had an elevated calcitonin 
following pentagastrin stimulation so it is entirely possible that he too has 
CCH on histological grounds although we will not know for sure. Based on 
these findings within the family, we feel it is reasonable to take forward ESR2 
c. 948delT for in vitro interrogation.     
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Finding a novel alteration (c.800 C>G p. V128L) in the germline of a patient 
with young onset disease is also potentially interesting and adds weight to the 
theory that ESR2 mutations are important in MTC tumourigenesis. Taken in 
isolation this could be a rare SNP and have no relevance to MTC 
predisposition. Indeed the modelling by SIFT and Polyphen-2 data-bases 
would predict that Valine to Leucine residue changes are not likely to be 
detrimental (Adzhubei, Jordan and Sunyaev, 2013). However, the patient is 
young and the mutation is in the germline rather than tumour and it is in a 
highly conserved region of the exome. As seen from the wider cohort, several 
SNPs are highly prevalent, but this one is neither prevalent in our sample nor 
when searching the wider database. Furthermore, modelling databases such 
as Polyphen 2 are modelled on sequence and protein property algorithms and 
have an inherent false negative rate (Adzhubei, Jordan and Sunyaev, 2013).  
Single residues suspected of being important cannot be truly predicted using 
bioinformatics databases but rather need to be scrutinised in the laboratory. 
Within the context of this study, and with the clinical features, it was deemed 
sensible to model this mutation and take it forward for further investigation.  
 
It is harder to establish the possible effects of the splice site mutation in the 
somatic DNA of the patients from Sydney. Again, it is a novel mutation but 
cannot easily be modelled in vitro. To this end I have excluded it from further 
functional work but may revisit at a later date depending on the functional 
results.  
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In total, I have identified three novel mutation in the ESR2 gene in RET 
negative patients with MTC. In the absence of other strong candidates I feel 
that this is sufficient evidence to explore ESR2 functionally to attempt to 
unpick the biochemical pathways. The fact I have not identified further 
mutations may be representative of inappropriate candidate gene selection. A 
further possibility is that, as discussed earlier in this report, candidate genes 
other than RET are likely to exist in low frequencies. Access to a wider cohort, 
particularly of sporadic patients with young onset disease is likely to have 
significant impact. I am however obliged to progress with the project in the 
most appropriate way and accept that some of the assumptions I have made 
can only be tested by in vitro functional evaluation.  
  
	 	 	
	 	 	 	154	
Chapter 7.   
 
Functional studies  
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7.1 Introduction  	
The functional work presented here has two main aims. First is to link, through 
cellular modelling, the interactions between ESR2 mutants and proliferation 
pathways including RET at the level of mRNA and protein expression. Second 
is to link ESR2 mutations to the index family and sporadic cohort. Having 
agreed to move forwards with ESR2 as a candidate predisposition gene, 
plasmid vectors were created containing ESR1 (Wild type oestrogen receptor 
alpha: WT ERα), ESR2 (in two common isoforms WT ERβa and WT ERβb), 
and ESR2 c. 948delT and ESR2c.800 C>G p.V128L mutations for in vitro 
experiments (see Chapter 2). Finally, in the study of hormone receptors it is 
clearly important to unpick some of the oestrogenic effects that may influence 
target gene expression, as the ligand driver of receptor binding and 
downstream up-regulation, is an important consideration and has been 
included in the analysis here.  
 
The primary hypotheses are that: 
• Identified mutations of the ESR2 gene lead to null or attenuated ERβ 
proteins  
• That ERβ mutants lead to cellular dysregulation and predispose to 
proliferation compared with wild type WT[8]  and thus potentially to 
malignant change  
• As a tumour suppressor gene, ESR 2 null mutants lead to loss of 
inhibition of ESR 1 driven up-regulation 
• That a haplo-insufficient model of tumour progression is present in this 
family leading to cancer predisposition  
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• That cellular deregulation is driven by alteration in the RET pathway.   
 
7.1.1 Cell lines  
The choice of a suitable model is clearly important. There are a number of key 
considerations when considering MTC and the options that are available. 
Human derived MTC cell lines are available, the most readily used being the 
Human TT cell line although others such as the MTC-SK cell line have been 
developed, they are less widely used (LCG Standards, USA (Anon, n.d.)). The 
TT cell lines were established from a needle biopsy from a 77 year old 
Caucasian female with aggressive, but presumably sporadic (based on age at 
presentation) form of the disease (Berger et al., 1984). The cells line was 
subsequently found to harbour the codon 643 cysteine to tryptophan (C>T) 
missense mutation most commonly associated with the MEN 2a (Carlomagno 
et al., 1995). This has significant implications for this study as we are 
essentially examining biochemical pathways important in cancer 
predisposition in patients without RET mutations. As one of our key outcomes 
in trying to link ERβ expression to RET tyrosine kinase expression, choosing 
a model with endogenous, abnormal RET expression is problematic. 
Furthermore, many authors report significant challenges in transient 
transfection of TT cell in culture due to their relatively slow growth (doubling 
time 83 hours) and difficulty establishing, non-adenoviral vector transfection 
(Behr et al., 1997). However, as most studies in MTC have utilised this cell 
line we believe that an attempt to include TT cells in a battery of cell lines 
would be prudent, even if we would not pursue this if difficulties were 
encountered.   
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Although primary culture of malignant cells derived from MTC has been 
reported, primary culture of C cells has not and would have a number of 
technical issues. The position of C cells within the thyroid gland and their 
paucity in normal tissue, render cellular isolation difficult and the likelihood of 
contamination with other cellular components of the thyroid gland including 
thyrocytes and lymphatic components is high (ROOS et al., 1975). Primary 
cell culture of C cells was considered in the context of this study but was 
beyond what was achievable in the allotted time frame. Primary culture of C 
cells would be the ideal model for the experiments described here, however, 
and as such should be considered in the further planned work section of this 
report.        
 
With these issues in mind, in addition to TT cells, the following cell lines were 
chosen for culture preparation and attempted in vitro experimentation.  
 
7.1.2 MCF 7  
MCF 7 are adenocarcinoma of the breast derived from cellular material taken 
from metastatic pleural effusion of a 69 year old Caucasian female (Soule et 
al., 1973). MCF 7 cells are widely used in breast cancer as well as generic 
cancer biology and widely used in the study of oestrogen and androgen 
signalling responses and oestrogen receptor studies. MCF 7 cells, in addition 
to normal breast tissue and other breast tumours, express both ERα and ERβ 
in varying amounts (Vladusic et al., 2000). MCF 7 cells readily transfect and 
rapidly divide, making them an ideal starting point for protein and mRNA work 
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and for our planned work with oestrogen signalling and pathway upregulation. 
The interaction between these two receptor isoforms in MCF 7 cells is thought 
to be important in cellular proliferation, with ERβ acting to inhibit growth in a 
ligand dependent and independent manner (Treeck et al., 2010) (Paruthiyil et 
al., 2004). Endogenous expression of ERα and ERβ is a limitation of this cell 
line, and up regulation in these already activated pathways by transient and 
stable transfection, will have to be measured over and above endogenous 
expression.  
 
7.1.3 T47D 
The T47D cell line is another breast cell line and like the MCF 7 cell line, is 
derived from a malignant pleural effusion and variably expresses ERα and 
ERβ (Lu et al., 2005). T47D cells are again readily transfectable and have a 
rapid doubling time, making them a suitable comparator for the MCF7 cell 
line. An advantage of the T47D cell line over that of MCF 7 is the absence of 
the RET/PTC rearrangement, with the primary expression characteristics 
being the WNT7B oncogene.  
 
7.1.4 mRNA expression  
The measurement of target gene expression by measuring mRNA is an 
established technique in experimental and diagnostic fields and has the ability 
to provide quantitative data at the level of gene expression from a very small 
number of cells. Ultimately, measuring mRNA expression is a tool to measure 
the decision-making within cells under certain conditions and allow 
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assessment of a multitude of parameters regarding cellular differentiation and 
proliferation at the same time (Zamorano, Mahesh and Brann, 1996). Within 
the context of this study, I am more interested in the level of functional protein 
produced in the context of transient manipulation of gene expression. 
However, mRNA expression adds valuable information to support these 
hypotheses as well as allowing a more detailed investigation of the more 
subtle interaction between the genes of interest and down-stream pathways. 
Clearly, taken on it is own, the quantification of mRNA expression following 
transient transfection does not establish a direct link between genes of 
interest and cellular behaviours as multiple steps following gene transcription 
will dictate whether functional proteins will be produced. mRNA expression 
data does have the potential, however, to add weight to some of the theories 
regarding the interactions between genes and to the extent that these 
interactions are ligand driven (Bustin, 2000).  
 
Reverse transcription polymerase chain reaction (RT-PCR) can involve either 
a one or two step technique and when combined with Taqman chemistry, can 
give reliable real time information regarding mRNA expression. The 
fundamentals of the procedure involve the creation of a cDNA library from 
RNA extracted under various experimental conditions prior to conventional 
PCR in combination with a labelled probe. In this case, specifically designed 
Taqman probes measuring (Applied Biosystems, Paisley, UK[9]). Reverse 
transcription was catalysed using avian myeloblastic virus reverse 
transcriptase (AVM-RT: Applied Biosystems; Paisley, UK) which has higher 
fidelity,reducing issues with RNA secondary structure than other reverse 
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transcriptases (Freeman, Vrana and Vrana, 1996). As cDNA libraries are 
much more stable they can be stored at -20 ̊C and revisited as needed.   
 
The Taqman assays for ERα, ERβ and RET were obtained and used as per 
manufacturers guidelines (Invitrogen; Paisley, UK). The assays consist of a 
fluorescence labelled dye and a quencher on either end of probes designed 
specifically to the ‘5 end of the amplicon (Holland et al., 1991). Primers are 
designed for either end of the amplicon on separate exons. During thermal 
cycling, taq polymerase reconstitutes the amplicon. As the fluorescent probes 
have a lower affinity than polymerisation, the probe is displaced and 
hydrolysed, first at the fluorescence end and then at the quencher end of the 
probe (Bustin, 2000). As the dye and quencher are separated the 
fluorescence intensity can be measured and is directly proportional to the 
number of molecules that bound probes during the cycle (Bustin, 2000).  
Fluorescence intensity machinery is specifically designed to perform thermal 
cycling as well as fluorescence detection and quantification. As the PCR 
amplification is very sensitive at amplifying small quantities, contamination 
remains a key issue in setting up experiments. The single analyser and cycler 
set up, allowing reactions to take place in a single sealed well of a 96 well 
plate without the need to potentially introduce contamination goes some way 
to ameliorating this. (Bustin, 2000).    
 
7.1.5 Immunohistochemistry 
It is important within the context of a clinical based study such as this to make 
an attempt to tie back the findings in the laboratory with the clinical 
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parameters and observation with blood and tissue samples collected so far. 
Immunohistochemistry is a technique that, used in isolation, can have 
considerable issues with regard to establishing scientific basis of diseases 
(Tavangar et al., 2007). It is, however, a useful technique in some situations 
and can provide valuable corroborative evidence regarding causative links. 
The major limitation to the use of immunohistochemistry within the context of 
this study is the reliability (sensitivity and specificity) of the staining techniques 
in verifying true positives and negatives particularly in the context of historical 
blocks and slides. Particular issues arise when using staining techniques and 
looking for protein expression beyond that which is used in the diagnostic 
setting and in addition, using antibodies that are not optimised for a specific 
tissue .  
 
With respect to the tumour library available for this project, the most 
interesting results would be to look at the ERβ characteristics between family 
members with a known ERβ mutation and the wider cohort of patients with 
MTC, as well as looking specifically at RET expression levels in relation to 
this. Neither RET nor ERβ staining is optimised for use within the clinical 
setting and as such, challenges exist in extraction of meaningful and 
comparable results.  	  
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7.2 Methods  	
7.2.1 Cell culture  
Cells were maintained and passaged as described in Chapter 2.  
 
7.2.2. Site directed mutagenesis 
Primers were designed as previously described to induce the two ESR2 
mutations identified within the cohort. PrimerX software was used to model 
the identified mutations (web based SDM primer designing tool; 
bioinformatics.org, USA) and optimised using for melting temperature and GC 
content to improve binding capability using the following equations.  
Tm = 81.5 + 0.41(%GC) – (675/N) 
Tm = 81.5 + 0.41(%GC) – (675/N) - %mismatch  
Primers were purified using polyacrylamide electrophoresis (PAGE) to 
improve fidelity prior to use.  
Table 32. Site directed mutagenesis primer design  	  
Primer 
Name  
Sequence Melting 
Temp 
°C         
% GC 
content  
Flankin
g 
region 
Mutatio
n 
Purification 
type 
948delT 
forward 
GGCCAAGAAGAT
CCCGGCTTTGTG
G 
77.8 60.0 12bp Single 
base 
deletion 
PAGE 
948delT 
reverse 
CCACAAAGCCGG
GATCTTCTTGGC
C 
77.8 60.0 12bp Single 
base 
deletion 
PAGE 
V128L 
forward 
GACACTGAAAAG
GAAGCTTAGTGG
GAACCGTTG 
77.7         48.5 16bp Single 
base 
substitut
ion  
PAGE 
V128L 
reverse 
CAACGGTTCCCA
CTAAGCTTCCTTT
TCAGTGTC 
77.7         48.5 16bp Single 
base 
substitut
ion 
PAGE 
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7.3 Results  	
7.3.1 MCF 7 cells were the most reliable cell type for ER receptor 
experiments  
After multiple attempts and obtaining cells from multiple sources we were 
unable to establish TT cells (MTC cells harbouring RET c. C643T), in a stable 
condition to undergo transfection. Owing to time, the TT cell line was 
eventually abandoned. Significant Issues with T47D and Hela cell models 
were encountered in establishing stable expression of wild type ERβ following 
transfection (data not shown). Although endogenous ERα/ 
ERβ were not detected in any of the cell lines, WT transfection in MCF7 
showed consistently detectable up-regulation following transfection and as 
such form the backbone for the protein and mRNA work shown here.  
 
7.3.2 Myc Expression of c. 948delT ESR2 mutation confirms a null 
protein using N terminal tagged plasmid in MCF 7 cells  
Initially, C terminal tagged plasmids were used to transiently transfect MCF7 
cell lines in stable culture. As the c.948delT mutation would be predicted to 
produce a truncated protein, non-detection of the C terminal tag would be 
expected and as such further vectors were established with N terminal tags. 
Figure 53. shows transfection with vector only control, ERα WT, ERβ WT, p. 
V128L and c. 948delT over time. Maximum protein expression was seen at 24 
hours. No expression of c. 948delT is seen at any point following transfection 
with C terminal and N terminal tagged plasmids. Expression of the p. V128L 
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mutation appears attenuated compared with wild type. Beta actin is shown 
separately and displays no disparity in terms of protein quantities. Data shown 
here was repeated in triplicate with both types of plasmid backbone.  
 
Under the same transfection conditions and again using myc N-terminal 
tagged plasmids, immunofluorescence demonstrates nuclear localisation of 
WT ERβ (Figure 54). Significant proportions of cells expressed ERβ following 
transfection indicating a high rate of transfection success when cross 
referenced with non-specific nuclear staining (4',6-diamidino-2-phenylindole 
DAPI: Life Technologies, Paisley, UK). A notable decrease in response was 
noted with ESR2 p. V128L mutations, with no MYC expression was seen in 
MCF 7 cells Transfected with ESR2 c. 948delT mutations (Figure 54).  
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Figure 52. Western blot showing Myc tag primary antibody with secondary mouse 
conjugated antibody following 12, 24 and 48 hour transient transfection pCMV6-AN 
Myc tagged vectors (N terminal tagged). In this experiment wild type ERα and wild type 
ERβ and the myc tagged protein products are readily detectable when compared to 
vector only control (lanes 2 and 3). When transfecting plasmids that are mutated to 
mimic the identified mutation, p. V128L (lanes 4,) attenuated myc tagged protein 
product can be seen compared to wild type ERβ. When transfecting plasmids that are 
mutated to mimic the identified mutation c.948delT (lane 5), no myc tagged protein 
product is detectable (comparable to vector only: lane 1).  
 
 
 
Figure 53. Immunofluorescence. When myc tagged, wild type ERβ is transfected, the 
protein product can be readily detected at the nucleus of successfully transfected cells 
DAPI 
		Myc Vector	only ERβ WT p.	V128L c.	948delT 
N	=	3	
1 				2									3									4										5							VO							ERα					ERβ			p.V128L	c.948Tdel 
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compared to vector only (upper panels 1 and 2). The corresponding nucleus of all cells 
in each field of are shown by DAPI staining (lower panels). When transfecting plasmids 
that are mutated to mimic the identified mutation, p. V128L, Myc tagged protein 
product is detected with less frequency than wild type ERβ (upper panels 2 and 3). 
When transfecting plasmids that are mutated to mimic the identified mutation 
c.948delT, no myc-tagged protein product can be seen.  
 
 
7.3.3 RET is over expressed in MCF 7 cells transiently transfected with c. 
948delT mutants and to a lesser extent p. V128L mutants compared to 
wild type.  
RET protein expression was not detectable in protein extracted from MCF7 or 
T47D cells in culture (data not shown). RET protein expression was not 
detected in MCF 7 cells after 24 hour transient transfection with vector only 
pCMV AN Myc tagged plasmids, or when transfected with different isoforms of 
wild type ERβ. Significant up-regulation of RET was observed with 
transfection of the ESR2 p.V128L alteration and to a greater extent the ESR2 
c. 948delT mutation. Again, maximal expression was demonstrated 24 hours 
post transient transfection. Figure 55 demonstrates RET expression after 24 
hours transient transfection with wild type and mutant ERβ. Experiments were 
reproduced in triplicate.   
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Figure 54. Western blot showing RET protein expression in MCF 7 cells after 24 hour 
transient transfection with pCMV AN Myc tagged plasmids. Here, transfections with 
wild type ERβ in its two most common isoforms (wild type 1 and 2: WT1, WT2), lead to 
no detectable increase in RET protein product. When transfecting plasmids that are 
mutated to mimic the identified mutation, p. V128L, RET protein is more readily 
detectable than wild type or vector only transfection (lane 5 vs. lanes 2 and 3).  When 
transfecting plasmids that are mutated to mimic the identified mutation, c.948delT, a 
significant increase in RET protein product is seen compared to wild type ERβ or 
vector only transfection (Lane 4 vs. lanes 2 and 3).    	
7.3.4 RET mRNA is overexpressed in MCF7 cells transiently transfected 
with c. 948delT mutations, in the presence and absence of oestrogen 
Following 24 hour transient transfection, MCF cells were treated with either 
oestrogen or ethanol control. In terms of RET mRNA fold change, greatest 
effects were seen between 24 and 48 hours post oestrogen treatment (data 
not shown). Significant RET mRNA fold changes were demonstrated when 
transfecting ERα treated with oestrogen vs. control (Figure 56). No changes 
were seen when ERα and ERβ constructs were co-transfected with or without 
oestrogen. Co-transfection with ERα and ESR2 c. 948delT mutants showed a 
2 fold change in mRNA expression over ERα - ERβ WT co-transfection. The 
fold change is consistent with 50% ERα alone transfection suggesting loss of 
the inhibitory effect of WT ERβ.  
RET 
Beta	actin 
VO					WT1						WT2								c.948delT					p.V128L 
n	=	3 
160Kd 
45Kd 
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Figure 55. RET mRNA expression in MCF 7 cells initially transiently co-transfected with 
combinations of AN-myc-tagged plasmids containing, vector only, ERα and ERβ WT 
and the ERβ c. 948delT mutant construct. When ERα is transfected alone in the 
presence of oestrogen, a four fold up regulation of RET mRNA is seen. When ERβ is 
transfected alone or with ERα, no increase in RET mRNA is detected with or without 
oestrogen suggesting an inhibitory role for ERβ.  When ERα and ERβ c. 948delT are 
co-transfected there is a two fold increase in RET mRNA production suggesting loss of 
the inhibitory role of ERβ.  
 
7.3.5 Calcitonin staining is not detected in normal thyroid tissue but can 
be easily seen in CCH and MTC  
Calcitonin staining was performed on all members of the index family and all 
available tumour normal blocks for patients with sporadic disease. Calcitonin 
staining was not evident in normal thyroid tissue taken from the unaffected 
side of patients with sporadic disease (0/18 samples). Three offspring of the 
index family displayed evidence of CCH on a background of normal thyroid 
0	1	
2	3	
4	5	
6	
Fold	Ch
ange		
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tissue (figure 57, left panel). All cases of sporadic MTC stained avidly 
calcitonin positive (figure 57, right panel).  
     
Figure 56. Hematoxylin and Eosin (H and E) staining of normal thyroid tissue showing 
arrangements of thyrocyte around follicles of thyroglobulin (left panel). Calcitonin 
staining of normal thyroid tissue taken from the unaffected side of a patient with MTC 
(right panel).  
     
Figure 57. Calcitonin staining in CCH  (left panel) and MTC (right panel).   
7.3.6 ERβ is ubiquitously expressed in normal thyroid tissue 
     
Figure 58. H and E staining of normal thyroid tissue (left) showing thyrocytes (blue 
staining) arranged in functional units around colloid (pink staining). ERβ staining of 
normal thyroid tissue demonstrating ERβ expression in normal thyrocytes.  
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7.3.7 ERβ Is lost in tumours in carriers of c. 948delT mutation  
ERβ expression was seen in 18/18 sporadic MTCs with no germline ESR2 
mutation (Figure 61, left panel). By comparison, significant ERβ under-
expression was observed in MTC tumour carrying germline ESR2 c. 948delT 
mutation (right panel).  
 
     
Figure 59. ERβ staining in MTC (left) showing dense staining in malignant cells of C 
cell origin. Right panel from tumour of patient carrying c.948delT mutation showing 
significant under-expression.  		
7.3.8 RET is overexpressed in carriers of ESR2 c. 948delT mutation  
As part of the initial clinical work-up, RET staining was performed on 
members of the index family. RET over expression has clearly been identified 
in C cells and MTC in family members subsequently found to carry the ESR2 
c.948delT mutation (Figure 61.) when compared with normal and positive 
controls (Figure 62.).   
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Figure 60. Right panel showing calcitonin staining in familial c.948delT with RET 
staining (left panel) from the same family member 
7.3.9 RET expression could not be determined in MTC or normal thyroid 
tissue in the wider cohort   
RET staining is not routinely performed by the UHB laboratories. RET staining 
was carried out as per manufacturers guidelines but no staining could be 
demonstrated in either normal thyroid, CCH or MTC (Figure 62). The positive 
control (small bowel) as recommended by the manufacturers, shows little 
positive staining (enteric nervous system only shows positive staining). 
Multiple antibody titrations were performed without establishing positive 
staining. The slides have subsequently been sent to a laboratory specialising 
in RET biology although these data were not available at the time of writing.  
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Figure 61. RET staining in positive and negative controls as well as CCH and MTC with 
and without mutations.  	 	
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7.4 Discussion  	
Through protein analysis by western blotting two of the main hypotheses were 
tested. Firstly, that the c. 948delT mutation produces a null protein and 
secondly, that transient transfection of the two identified mutations (ESR2 c. 
948delT and p.V128L) leads to up regulation of RET protein when compared 
with wild type transfection and vector only. The question of whether a null or 
truncated protein would be produced by our deletion is clearly of great 
importance to the project as a whole as it provides some evidence of the 
potential interactions that underpin tumour predisposition within the index 
family. The null protein hypothesis is supported by the western blotting and 
immunofluorescence results, although these results have to be taken within 
the context of a single cell line. This is clearly a limitation, and time constraints 
were the reasoning that evidence from additional cell lines was not sought. 
Further corroborative work with these issues in mind is currently underway. 
Further support to the null hypothesis is gained, however, from the 
immunohistochemistry results. The fact that all normal thyroid and sporadic 
MTC tumours stain avidly for ERβ except for those harbouring the ESR2 c. 
948delT mutation is significant, both from a point of adding weight to our null 
protein hypothesis but in addition, linking in vitro findings back to the index 
family.  
 
If we are to assume that the ESR2 c. 948delT mutation is indeed the single 
mutation that gives C cells a selective proliferative advantage then it is clearly 
important to understand the nature of this interaction at the level of the 
protein. The suggestion from the results presented here is that no protein is 
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produced or that the protein product is so unstable that it is rapidly degraded 
by the cellular mechanism of abnormal protein degradation or, more likely 
based on these data, nonsense mediated mRNA decay (Chang, Imam and 
Wilkinson, 2007). No demonstrable myc signal was detected when attached 
to the N terminal end of the protein product of the ESR2 c. 948delT mutant, 
even at the shortest time interval either by immunofluorescence or by mRNA 
estimation. Nonsense mediated decay is a cellular mechanism by which 
abnormal truncated mRNA is removed prior to transcription[10] to prevent the 
potential damaging effects of a truncated protein which may harbour a gain of 
function (Anczuków et al., 2008). Whether nonsense mediated decay 
prevents any protein being made, however, is open to debate and has shown 
to be mutation specific in both BRCA1/2 and TP53 mutations (Anczuków et 
al., 2008), (Perrin-Vidoz et al., 2002). The possibility remains therefore, that 
the ESR2 c. 948delT mutation still produces a protein product modified in 
such a way as to be undetectable by the methods employed here.  
 
The immunohistochemistry results suggests that the model of disease 
predisposition is one of haplo-insuficiency, whereby expression of the ESR2 
c. 948delT mutation in target tissues results in a 50% reduction in the quantity 
of functional ERβ (Figure 61) (Paratore et al., 2002). In the haplo-insufficiency 
model, WT ERβ acts as tumour suppressor gene, possibly by inhibiting the 
proliferative effects of ERα, and that reducing the dose of its suppressor 
activity is enough to give tissue harbouring the mutation a selective 
advantage. Halpo-insufficiency has been implicated in many diseases and 
goes some way to explaining the additional disease burden not solely 
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explained by the two hit hypothesis (Knudson et al., 1976)(Meng et al., 1998). 
As ERβ is ubiquitously expressed in human tissues this hypothesis would 
have to support the notion that C cells or tissues of neural crest origin are 
uniquely sensitive to the suppressor effect the ERβ has on the RET pathway 
(as other tumours have not been seen do date within the index family). This is 
of course potentially the case as patients with germline RET mutations (MEN 
2 syndromes) only develop tumours in tissues of neural crest origin and not in 
other tissues (Mulligan et al., 1993).  
 
With regard to ERα and RET immunohistochemistry, no staining was seen in 
MTC with or without mutations performed as part of this project. It is 
somewhat surprising that no ERα was seen in any of the examined tumour of 
normal slides as expression has been variably reported in MTC, normal 
thyroid tissue and thyroid cancer (Yang, Pearson and Samaan, 1988), (Zeng 
et al., 2007), (Kumar, Klinge and Goldstein, 2010). To support the hypothesis 
that proliferation in C cells harbouring the ESR2 c. 948delT mutation was 
driven by unopposed ERα, it would be expected that up-regulation of ERα 
would be seen in the index family compared to sporadic MTC tumours. 
Clearly, as it was not possible to demonstrate ERα expression in any of the 
examined slides, this is not possible. This could of course indicate that ERα is 
not up-regulated nor involved in the progression of MTC. However, the ERα 
antibodies used here have been optimised by the histopathology lab at the 
QEH as they are widely used as markers for diagnostic purposes in breast 
cancer where ERα is abundant (as seen in Figure 61. positive control). It is 
possible that the protocol used was not sensitive enough to detect the lower 
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levels expected in thyroid tissue. Regarding RET, it is suspected that there 
may be issues with the supplied antibody (again, not used in current 
diagnostics) as evidenced by weak staining in the positive control, as it would 
certainly be expected that RET overexpression in would be demonstrated in 
some if not all MTC (Eng et al., 1998). Analysis of the historical slides from 
the index family however, clearly indicates that RET is overexpressed in 
tumours and C Cells within the thyroid tissue of those harbouring germline 
ESR2 c.948delT mutation. This is clear evidence that the disease is driven 
through the RET pathway, and supports the hypothesis that mutations in the 
oestrogen pathway could lead to RET dysregulation. Further comparative 
evidence from the wider cohort is needed here and, as discussed, further 
slides have been sent to another group for verification. Results are awaited 
(data not available at time of writing).         
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Chapter 8.  
 
Final conclusions and future directions  
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8.1 Conclusions 	
MTC is an aggressive disease with poor outcome and limited treatment 
options (Kloos et al., 2009). For those with advanced disease, there are few 
adjuvant treatments and MTC remains primarily a surgical disease (Perros, 
2007). As seen in this cohort and in the wider literature, advanced disease at 
presentation is extremely common (Roman, Lin and Sosa, 2006). Although 
RET testing is in routine use, the majority (75%) of patients are RET negative 
and, as such unable to benefit from screening tests (Frank-Raue et al., 2011). 
There remains a need for better understanding of the genetic and epigenetic 
events predisposing to the development of MTC. I hope in this project I have 
gone some way to addressing this need. Although further corroborative 
evidence is needed, the identification of constitutional ESR2 mutations as 
MTC predisposing represents a major breakthrough and has potential to 
translate directly to patients by way of a simple clinical genetic test. With 
regard to the index family, this has direct implications for future generations. 
Furthermore, elucidation of the cellular events leading to MTC may also open 
avenues for targeted drug therapy within both the index family and in the 
wider sporadic cohort.    
 
8.2 Oestrogens and thyroid cancer 	
There has been a longstanding link between oestrogens and well-
differentiated thyroid cancer, although no specific links to MTC. Clinically, well 
differentiated thyroid cancers most commonly occur in pre-menopausal 
women with a lower incidence in men and post-menopausal women (Santin 
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and Furlanetto, 2011).  In vitro, oestrogen receptors have been shown to be 
overexpressed in well differentiated thyroid cancer and proliferation is induced 
in thyroid cell lines exposed to oestrogen receptor binding ligands (Kumar, 
Klinge and Goldstein, 2010). Furthermore, ERβ has been shown to be 
overexpressed and ERα underexpressed in both CCH and MTC (Bléchet et 
al., 2007). Oestrogen receptor positivity, has been proposed as a possible 
prognostic marker in well differentiated thyroid cancers although to date, 
these findings have not be translated to routine clinical practice (Magri et al., 
2012).  
 
8.3 ERβ and ERα 	
Oestrogens, acting as ligands and binding to oestrogen receptors, are critical 
in the development of many different tissue types and have been implicated in 
many human malignancies including cancers of the breast and prostate. 
Although postulated as important in thyroid disease and thyroid cancer, their 
exact role is unknown. ERα and ERβ are part of the nuclear receptor 
superfamily of ligand-regulated transcription factors, regulating gene 
expression through DNA response elements (Zhao et al., 2007). There are 
classical methods of oestrogen signalling where oestrogen receptors dimerise 
and bind oestrogen response elements (EREs) that have specific regions for 
DNA binding and effect chromatin structure, DNA transcription and RNA 
recruitment. ERs also signal through non-classical, ligand-independent means 
with similar effects. ERα and ERβ are thought to work synergistically and it is 
the ratio of their expression that determines the overall effect on cellular 
transcription. With the discovery of EREs in the RET promoter pathway, it 
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follows that, a major disruption in the structure of ERβ, such as could be 
caused by a ESR2 c. 948delT mutation, could lead to a significant alteration in 
the transcriptional properties of the cell and therefore predispose to malignant 
change. This hypothesis is supported by the functional work and 
immunohistochemical analysis presented here.  
 
8.4 Sporadic MTC 	
Conformation of abnormalities of the ESR2 gene in somatically derived DNA, 
represents a significant finding and potentially opens new avenues in 
understanding of MTC and its pathogenesis. In the future, it may and open 
potential for new therapeutic targets. If the mutated ERβ protein acts by 
exerting a dominant negative effect, that is, forms a non-functioning protein 
that does not inhibit ERα, it follows that drugs which inhibit ERα may reduce 
the proliferative effects associated with oestrogen stimulation. ERα is 
prevalent in many breast cancers and the sensitivity of breast cancers to 
oestrogen is a major marker of prognosis, in part due to the presence of the 
oestrogen receptor as a marker of differentiation, but also for its use as a drug 
target. Selective oestrogen receptor antagonists (SERMS), such as tamoxifen 
have been used successfully to treat oestrogen sensitive breast cancers for 
many years. If some thyroid cancers are oestrogen sensitive then it may be 
that such therapies may be useful in the treatment of MTC or well 
differentiated thyroid cancer. Indeed, tamoxifen has been shown to inhibit 
cellular proliferation in MTC cancer cell lines (Yang, Pearson and Samaan, 
1988) (Weber et al., 1990).   
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8.5 Limitations  	
As with all studies of rare disease, access to cohorts of patients and tissue for 
analysis is always challenging. Although there were significant successes in 
recruitment, this project is still relatively small, particularly when performing 
analysis sub groups such as RET negative families and sporadic disease with 
young onset. These issues were always going to be potentially problematic 
and are particular to inception studies such as this, rather than adjuncts to 
larger studies where significant numbers of patients have already been 
recruited. The main effect in a small cohort size such as this is the confidence 
with which identified mutations can be taken forward to functional studies. We 
would obviously have liked to have more certainty at the start of the project 
regarding the suitability of ESR2 c. 948delT as a disease causing mutation 
rather than an incidental finding by, for example, identifying convincing ESR2 
mutations in other families. It is obviously a big step both financially and with 
regard to time investment to begin functional work. The other issue faced here 
with an inception project is ultimately the amount of time and resources spent 
on the gathering of data and recruitment and the knock on effect to the 
functional work towards the end of the project. With further funding secured to 
take the project forwards, we hope that the groundwork has been completed 
and the project will gain future successes.      
 
It is possible still that candidate mutations other than ESR2 c. 948delT 
identified by WES were MTC predisposing. Alternatively, and I believe more 
likely, is that this is a unique finding within this family. Indeed, genome wide 
association studies suggest that there is a significant proportion of heritable 
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disease not accounted for and rare or unique mutations may go some way to 
explaining this disparity (Ng et al., 2009). The functional work presented here, 
however, does support the hypotheses that the correct mutation was 
identified. It may be that either through wider recruitment or through 
collaboration with other teams it is possible to confirm the uniqueness or 
otherwise of this mutation in familial non-RET MTC. Ultimately the on-going 
functional work will unpick the relationships with more certainty.  
 
The functional work shows that mutations of the ESR2 gene lead to 
dysregulation of the oestrogen-signalling pathway and ultimately to RET 
pathway up-regulation and a cellular proliferative advantage. The aim was to 
show this effect in as many possible ways and proposals for future 
experiments are outlined in the following section. Further evidence from these 
additional proposed experiments should strengthen our hypotheses prior to 
moving forward to treatment-based experiments.  
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8.6 Future directions   	
8.6.1 ESR2 mutations as diagnostic test  
Detection of the ESR2 c. 948delT mutation could form part of the diagnostic 
work up for patients with non-RET MTC. This of course would require 
acceptance and peer review of this work, and this is currently underway. It 
would be expected however that, based on our tested cohort and mutation 
databases, constitutional ESR2 mutations are rare and only likely to account 
for small numbers of patients overall with MTC.  
 
8.6.2 Further exome sequencing using the existing cohort and newly 
recruited families  
The findings presented here support the theory that much of the heritable 
disease seen in clinical scenarios is explained by mutations with low 
frequency, possibly in single families. As demonstrated, exome sequencing 
with reference back to the patient specific data and to a larger cohort of 
patient may be the ideal tool for this. Using the additional families identified 
here as a starting point for further exome sequence analysis is warranted. 
having established a method that has generated results and having reference 
cohort to refer to, will significantly reduce the time and effort required to invest 
in this in the future.    
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8.6.3 Examination of ERβ isoforms  
Some of the complexity encountered in this project may be explainable[11] by 
the nature and function of the isoform of ERβ and the relative paucity of data 
to distinguish specific roles of each individual isoform. Ultimately, we do not 
have complete knowledge of the differing role and to what extent function of 
each specific isoform is modulated by local factors in the environment.  
 
8.6.4 Sequencing of ESR1  
Although it is postulated that it was the interaction between ERα and ERβ that 
most likely would explain up-regulation of the RET pathway in this family, we 
have not been able to show that definitively, either in the staining 
characteristics of the immunohistochemical slides, or in the mRNA studies. 
There are many possible reasons for this, as explained in Chapter 7. It would 
be interesting to see whether germline or somatic mutations in ESR 1 play a 
role in MTC predisposition, but further sequencing was beyond the scope of 
this study.   
 
8.6.5 Verification of null protein hypothesis in further cell lines and 
knockdown with siRNA 
Proving that the same mechanism of RET pathway up regulation and cellular 
proliferation can be induced by multiple models is important and, although 
beyond the scope of the work presented here, will be a major feature of the 
on-going work on this project and form part of the presentation for peer 
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review. Establishing that a siRNA knock down model of ERβ leads to up-
regulation and cellular proliferation would add weight to the results already 
obtained that the null protein model that we predict from the ESR2 c. 948delT 
mutation leads to proliferation.   
 
8.6.6 Verification of downstream activators other than RET 
The hypothesis, based on the presentation and phenotype of the family is that 
the mutation predisposing to disease is most likely to lead to up-regulation of 
the existing pathway, and indirectly influence the expression of RET via 
another mechanism. The ER pathway, with upstream binding to the RET gene 
is a perfect example of this. It remains possible, however, that mutations of 
ESR2 lead to cellular proliferation and differentiation through RET 
independent pathways, and that examination of downstream effectors other 
than RET would aid in understanding of the mechanics of cancer 
predisposition. Again, this will form a part of the on-going studies.   
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8.7 Overall conclusion  	
I believe that this project has achieved three outcomes. Firstly, through project 
advertisement, presentations and the establishment of collaborative teams 
both within and without the UK, I have raised awareness of some of the 
issues within the field of MTC, both in familial and the often overlooked 
sporadic disease, stimulating interest in future research and collaboration. 
Establishing a cohort of patients with sporadic disease has aided directly in 
this project, but will also hopefully serve as resource reservoir for future 
projects. The additional families recruited towards the end of the project will 
enable expansion of the research, and has already attracted further funding.  
 
Secondly, using next generation sequencing techniques, I have established a 
method for novel cancer gene mutation discovery in the context of MTC, 
something not achieved since the discovery of the disease causing RET gene 
mutations in MEN 2a/b in the early 1990s (Eng et al., 1995) (Eng et al., 1994). 
Although WES has been used in the context of MTC, no non-RET mutations 
have been identified to date and as such no novel pathways that might be 
exploited therapeutically (Qi et al., 2011).  
 
Finally, by identifying ESR2 mutations as potentially predisposing in familial 
MTC and sporadic disease, I have provided evidence that disease 
predisposition is driven through up-regulation of the RET pathway. Further 
work is required to fully unpick the molecular pathways here but we believe 
this project provides a platform on which to base future studies.     
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Molecular genetic investigation of familial non-RET medullary 
thyroid carcinoma (MTC)
Smith JA,  Maher ER, Woodward ER, Watkinson JC.  Institute of Biomedical Research, University of Birmingham  
Background 
Medullary Thyroid Cancer MTC is an aggressive disease associated with poor outcomes 
It accounts for between 5 and 10% of thyroid cancer in the UK
Survival is linked to disease stage at presentation 
As a rare cancer both the British and American Thyroid Associations recommend management in multi disciplinary 
teams 
25% of MTC is accounted for by MEN 2 with RET mutation
With routine RET testing there are a significant proportion of apparently familial MTC who test RET negative 
These individuals could harbour other genetic abnormalities as yet undetermined that could also have significant 
implication for apparently sporadic cases of MTC
Key references 
American Thyroid Association: Professional Guidelines. Accessed on 18/06/10 at:  HYPERLINK  HYPERLINK "http://www.thyroidguidelines.org/medullary/resultssa" http://www.thyroidguidelines.org/medullary/resultssa
British Thyroid association: Guidelines for the management of thyroid cancer second edition 2007. Accessed on 18/06/10 at HYPERLINK  HYPERLINK "http://www.british-thyroid-association.org" http://www.british-thyroid-association.org 
Choi M, SCholl U, Ji W, Liu T et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. PNAS 2009; 10: 19096-101
Cooper DS, Doherty GM, Haugen BR, Kloos RT et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Accessed 18/06/2010 at HYPERLINK http:// HYPERLINK "http://www.thyroid.org/professionals/.../" www.thyroid.org/professionals/.../ATA_Guidelines_DTC_2009.pdf
Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2(7): 851-6.
Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Clin Endocrinol (Oxf) 1995; 43(1): 123-7.
Methods 
Using our identified RET negative pedigree we will perform:
! whole exome sequencing to identify candidate genes for further investigation
! copy number array analysis to exclude genomic deletions/amplifications
Recruitment of further RET negative MTC families both nationally and internationally to verify our results
Aims 
To identify novel MTC predisposing genes and to assess their contribution to familial and sporadic MTC 
tumourogenesis.
Type to enter text
Contributors 
This project is going ahead with kind sponsorship from Get-A-Head and The University Hospital Birmingham Charitable funds 
We need your help with recruitment! 
We are looking for:
RET negative- 
! !
! Apparently sporadic cases of MTC developing before the 
! age of 40
! Any familial case of C cell hyperplasia/MTC 
!
RET positive /negative fresh frozen MTC samples (ideally) or paraffin 
blocks
How to refer patients/for more information regarding the study 
Please refer any suitable patient using a standard hospital letter to Joel 
Smith C/O Emma Woodward at:
!
! Clinical Genetics Unit
" Birmingham Women's NHS Foundation Trust 
 Mindelsohn Way, 
 Edgbaston, Birmingham B15 2TG 
 Email: e.r.woodward@bham.ac.uk
 Tel: 01216272630
What will happen to enrolled patients:
! Patients consenting to be involved in the study will have blood taken             
! for RET testing 
! Pathological specimens will be requested for re examination
! Contact tracing may take place 
Figure 3. Total thyroidectomy specimen 
medullary thyroid cancer 
Figure 4/5 Ultrasound and computed tomographic images of MTC
Figure 1/2. Histological preparations dem-
onstrating medullary thyroid caner
